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1. Introduction  
1.1. The phenomenon of preconditioning 
Preconditioning describes the phenomenon of small doses of noxious stimuli 
inducing tolerance towards future injury. In 1943, Richard L. Noble was the first who 
described that short periods of global hypoxia protect the entire mammalian organism 
and preserves brain energy metabolism during longer periods of hypoxia (Noble, 
1943). The term “preconditioning” was introduced in 1964 (Janoff, 1964), and until 
today researchers investigate this important concept and the underlying complex 
mechanisms that mediate cell survival and increase life expectancy.  
Tolerance induced by preconditioning occurs by ischemia, low doses of endotoxins, 
and hypoxia (Cadet and Krasnova, 2009). The tolerance can occur within minutes 
after the stimulus (rapid preconditioning) involving cellular changes which influence 
enzymes, secondary messengers, and ion channels. Moreover, the tolerance can be 
developed after several hours (late preconditioning) (Correia et al., 2010). This late 
phenomenon of preconditioning is characterized by altered gene expression and de 
novo protein synthesis (Barone et al., 1998;Gidday, 2006;Kirino, 2002).  
However, the exact mechanisms leading to the induction and maintenance of 
tolerance towards later injury remain largely unknown. Most researchers agree that 
there is not just one mechanism that is exclusively responsible for preconditioning 
effects. More likely, the phenomenon of preconditioning requires a concerted action 
of different cellular and molecular mechanisms (Dirnagl and Meisel, 2008) which are 
in the focus of this thesis in model systems of neural cell death. 
 
At the molecular level, many mechanisms for preconditioning are described and a lot 
of them apparently converge at mitochondria. The most prominent mechanisms 
involve slight increase in reactive oxygen species (ROS) production, opening of 
mitoKATP channels, upregulation of uncoupling proteins, and stabilization of the 
transcription factor hypoxia-inducible factor 1 (HIF-1). 
The mitochondria are major sources of ROS, and especially the respiratory chain 
complexes I and III are considered as the primary sites of ROS production and 
release (Zhang and Gutterman, 2007). Multiple studies demonstrated that slight 
increases in ROS levels mediated brain tolerance in paradigms of preconditioning 
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(Dirnagl et al., 2009;Dirnagl and Meisel, 2008;Ravati et al., 2000;Ravati et al., 2001). 
Such ROS-mediated preconditioning can be abolished through radical scavengers 
(Ravati et al., 2000). It was further shown that moderate increases in ROS levels 
were followed by the activation of the transcription factor nuclear factor-kappa B  
(NF-B) and a subsequent increase in NF-B-regulated gene expression, such as 
manganese superoxide dismutase (MnSOD) (Ravati et al., 2001). Furthermore, an 
increase in ROS induced by H2O2 mediated neuroprotection, thereby blocking the 
loss of mitochondrial membrane potential (MMP, ΔΨm) and leading to an increase in 
expression levels of the pro-survival protein Bcl-2 (Tang et al., 2005).  
In addition, a connection between ROS levels and mitoKATP channels was 
demonstrated since antagonists of mitoKATP channels were able to block 
preconditioning effects whereas mitoKATP channel openers, such as diazoxide, 
mediated neuroprotective effects (Simerabet et al., 2008). MitoKATP channel 
expression in brain mitochondria is up to seven times higher compared to liver or 
heart mitochondria (Bajgar et al., 2001). This reflects the particular importance of 
mitochondria for the regulation of neuronal function and survival. Preconditioning by 
mitoKATP channel openers is linked to mitochondrial depolarization and PKC 
activation which prevents free radical production during neuronal stress (Kis et al., 
2004).  
Recently, it was shown that inhibition of mitochondrial complex I by NS1619 induces 
neuronal protection by preconditioning in rat cortical neurons, thereby increasing 
ROS production and mitochondrial depolarization (Gaspar et al., 2008;Gaspar et al., 
2009). Moreover, NS1619 decreased the Ca2+ influx through glutamate receptors and 
increased the activity of superoxide dismutase (SOD) (Gaspar et al., 2009). Thus, 
mitochondrial ROS apparently play a critical role in mediating preconditioning to the 
brain. 
An important protein that is regulated by ROS is the uncoupling protein 2 (UCP 2) 
(Echtay and Brand, 2007). UCP 2 is located in the inner mitochondrial membrane 
and highly expressed in brain neurons (Brand and Esteves, 2005;Duval et al., 2002) 
where it can uncouple the electron transport from ATP synthesis, thereby regulating 
the energy balance (Kim-Han and Dugan, 2005) of the cell. In vitro and in vivo 
experiments demonstrate that an upregulation of UCP 2 mediates neuroprotective 
effects via preconditioning in response to various cellular stresses (Diano et al., 
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2003) which is triggered by enzymes, such as adenosine 5’-monophosphate-
activated protein kinase (AMPK)  (Xie et al., 2008). Further, it was shown that UCP 2 
overexpression in mice prevented neuronal death after stroke and brain traumata by 
mild uncoupling (Mattiasson et al., 2003). 
Another key player in developing brain tolerance is HIF-1. Mitochondria and 
mitochondrial ROS are critical regulators of HIF-1α, a subunit of HIF-1 involved in 
angiogenesis, cell metabolism, apoptosis, and cell survival. Under hypoxic conditions 
HIF-1α is stabilized by the inhibition of prolyl-hydroxylase enzymes that initiate the 
cascade of HIF-1α degradation under normal conditions. Mitochondrial ROS inhibit 
the activity of these enzymes, thereby promoting the stabilization of HIF-1α. This 
crosstalk between mitochondrial ROS and HIF-1α has been suggested to be 
responsible for neuroprotection mediated by preconditioning (Correia and Moreira, 
2010). In fact, it is demonstrated that hypoxic preconditioning is associated with an 
increase in ROS and a subsequent induction of HIF-1 and its downstream gene 
erythropoietin (Liu et al., 2005).  
All these findings suggest a central role of mitochondria in the regulation of neural 
survival mediated by preconditioning effects in the brain. The first part of this thesis 
investigates mechanisms of mitochondrial preconditioning caused by the regulation 
of mitochondrial complex proteins in a murine neural cell line of hippocampal origin. 
 
Another important aspect in preconditioning is modulation at the cellular level by an 
interaction between neighboring cells. Such cell-cell communication occurs e.g. 
through the formation of gap junctions by apposition of two hemichannels, also 
named connexins, which link two cells across an extracellular space of about 2-4 nm. 
Through these gap junctions a rapid and direct communication between the 
cytoplasm of neighboring cells is possible, and molecules up to 1 kDa can diffuse 
between the cells (Bloomfield and Volgyi, 2009). It has been shown that controlled 
hypoxic preconditioning increases connexin 43 (cx43) expression in neural stem cells 
(NSCs) which is essential for many of the functional and beneficial interactions after 
NSC engraftment between grafted cells and host cells (Jäderstad et al., 2010). An 
increase in cx43 hemichannels results in ATP release that is hydrolized to 
adenosine, a potent neuroprotective molecule (Lin et al., 2008).  
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In addition, it has been demonstrated that glial cells drive a preconditioning-induced 
protection of the blood brain barrier (BBB) (Gesuete et al., 2011). The main 
components of the BBB are endothelial cells of the cerebral microvasculature, which 
are closely associated with astrocyte endfeet, pericytes, and microglia. This 
association plays an important role for the maintenance of the central nervous 
system (CNS) microenvironment (Deli et al., 2005). Ischemic preconditioning has 
been shown to attenuate disruption of the BBB and brain edema in models of 
ischemic brain injury (Hua et al., 2008;Masada et al., 2001). Gesuete et al. 
demonstrated that astrocytes are major mediators of the observed protective 
phenotype assumed by BBB protection after preconditioning (Gesuete et al., 2011). 
A further proof for preconditioning effects mediated at the cellular level was reported 
after heat shock preconditioning. Thermal stress induces glial cells to produce heat 
shock protein (HSP) 70, which is then transported to the adjacent axonal process 
(Masada et al., 2001). Such a cell-cell transfer provides a mechanism for fast delivery 
of neuroprotective substances during stress situations (Brown, 2007). The fact, that 
glial cells release HSP 70 and neurons can take up HSP 70 resulting in greater 
tolerance to cell death induced by chemical substances or trophic factor withdrawal 
was further confirmed in tissue culture experiments (Guzhova et al., 2001).  
Such intercellular interactions mediated by preconditioning can be mimicked by the 
generation of so called conditioned media (CM). Medium from cells cultivated under 
slightly stressful conditions can be used in other model systems of lethal neuronal 
stress to mediate neuroprotective effects. For example, CM generated from human 
adipose stem cells under mild hypoxic conditions shows beneficial therapeutic effects 
in an in vivo rat model of stroke (Cho et al., 2012). Thus, CM offers new therapeutic 
potential to use fundamental self-protecting processes of organisms for the treatment 
of neurological disorders.  
The second part of this thesis investigates the neuroprotective effects of CM 
generated from neural progenitor cells (NPCs) that undergo cell death induced by 
growth factor withdrawal in a model system of hippocampal HT-22 neurons that are 
exposed to lethal glutamate concentrations combined with growth factor deprived 
media.  
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1.2. Neuronal cell death 
Acute brain injury and neurodegenerative diseases, such as Parkinson’s disease 
(PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and amyotrophic lateral 
sclerosis (ALS) are characterized by progressive dysfunction and death of neurons 
leading to the severe neurological impairments characterizing these diseases (Kim 
and de Vellis, 2009). Although recent advances have improved the management of 
these diseases there is no curative therapy available. The current treatments are 
mostly symptomatic and often successful for a limited time only since most of these 
diseases are progressive in their development. Further, long-term medication is often 
accelerated to high doses leading to severe side effects (Kim and de Vellis, 
2009;Lang and Lozano, 1998a;Lang and Lozano, 1998b;Marshall, 1994). Thus, it is 
very important to understand the mechanisms causing neuronal cell death that 
underlie progressive loss of brain function in neurodegenerative diseases or after 
acute brain injuries.  
The two major forms to classify neuronal cell death in pathological contexts are 
necrosis and apoptosis. In the last few years several additional classifications of 
neuronal cell death have been introduced based on biochemical and functional 
considerations, such as regulated necrosis and authophagy (Galluzzi et al., 2012). All 
these forms of neuronal cell death are described in neurodegenerative diseases and 
acute brain injuries. 
The typical characteristics of necrosis are mitochondrial swelling, depletion of ATP, 
massive calcium influx, and deregulation of the intracellular ion homeostasis. In later 
stages, hallmarks of necrosis are cell swelling, membrane lysis, and inflammatory 
processes (Majno and Joris, 1995). Necrotic cell death is described for several 
neurodegenerative diseases and for vascular-occlusive diseases, but it has also 
been suggested to contribute to embryonic development (Yuan et al., 2003;Zong and 
Thompson, 2006). In contrast to classic necrosis, which is described to occur 
accidental, recently identified forms of regulated necrosis appear in a programmed 
manner dependent on RIP1 and/or RIP3 activation (Galluzzi et al., 2012). 
The characteristics of apoptotic cell death are DNA fragmentation, nuclear 
condensation, membrane blebbing, and the formation of apoptotic bodies (Kerr et al., 
1972). These apoptotic bodies are phagocytosed by neighboring cells and contain 
intracellular components. In contrast to necrosis, apoptotic cells are removed without 
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causing inflammatory response and damage to the surrounding tissue. Therefore, 
apoptosis plays an important physiological role in the replacement of senescent or 
excessive cells (Vaux and Korsmeyer, 1999). Furthermore, apoptosis exerts 
essential functions during the development of the nervous system by controlling 
synapses and removing excessive and unneeded neural cells (Oppenheim, 1991). 
Pathological pathways of apoptosis have been associated with a lot of 
neurodegenerative diseases, such as AD and PD, and also with acute brain damage, 
such as after cerebral ischemia or traumatic brain injury (TBI) (Mattson, 2000). 
Apoptotic cell death may result from two biochemical cascades, described as the 
intrinsic (also called mitochondrial) pathway and the extrinsic pathway (Figure 1). 
The extrinsic pathway of apoptotic cell death is initiated outside a cell, when 
conditions in the extracellular environment determine cell death. This pathway relies 
on death receptors, such as the Fas receptor that transmit extracellular signals of 
danger. The activation of these death receptors leads to the activation of several 
caspases, including caspase-8 and 3 (Galluzzi et al., 2009). Caspases are proteolytic 
enzymes that cleave important cellular proteins, e.g. actin or laminin, and activate 
nucleases like caspase-activated desoxyribonuclease (CAD), which upon proteolytic 
activation translocates into the nucleus where it cleaves the DNA in the final steps of 
apoptotic cell death.  
The intrinsic apoptosis pathway is initiated within the cell. It is characterized by high 
levels of ROS as well as the activation of the pro-apoptotic protein Bid which leads to 
mitochondrial permeabilization followed by the subsequent release of other pro-
apoptotic proteins like apoptosis inducing factor (AIF), cytochrome c, Omi/HtrA2 or 
Smac/DIABLO (Galluzzi et al., 2009). When AIF is released from the mitochondria it 
translocates to the nucleus where it induces chromatin condensation and large-scale 
DNA fragmentation resulting in caspase-independent cell death (Susin et al., 
1996;Susin et al., 1999).  
In addition, cytosolic cytochrome c forms a complex with apoptosis protease- 
activating factor-1 (Apaf-1) and pro-caspase-9, named apoptosome. The 
apoptosome catalyzes the activation of execution caspases including caspase-3, 6, 
and 7 (Mehta et al., 2007). These caspases induce the breakdown of the cellular 
framework through degradation of substrates like actin or by activation of CAD. 
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Furthermore, caspase activation is triggered by release of Smac/DIABLO or 
Omi/HtrA2 from mitochondria. When released into the cytosol, Smac/DIABLO and 
Omi/HtrA2 can block the anti-apoptotic protein XIAP (x-chromosomal linked inhibitor 
of apoptosis) and other inhibitors of apoptosis thereby activating caspases in an 
indirect manner (Mehta et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Intrinsic and extrinsic pathways of apoptotic cell death in mammalian cells. 
The extrinsic pathway is triggered by members of the death receptor family (e.g. Fas, CD95, necrosis 
factor receptor I). Ligand binding to these receptors leads to activation of caspases and nucleases that 
cleave DNA in the nucleus. Activation of caspase-8 also leads to the cleavage of the pro-apoptotic 
protein Bid into its truncated form (tBid), which links the extrinsic and the intrinsic pathway. The 
intrinsic pathway triggered by intracellular stress is characterized by the activation of Bid which leads 
to mitochondrial membrane permeabilization resulting in the release of other pro-apoptotic proteins, 
such as AIF, Smac, Omi and cytochrome C (cyt c). AIF translocates into the nucleus where it induces 
chromatin condensation. Smac and Omi inhibit XIAP resulting in a direct activation of caspase-3. 
Further, the apoptosome consisting of cyt c, Apaf-1, and caspase-9 activates caspase-3 thereby 
significantly amplifying initial caspase activation upstream of mitochondrial damage.  
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1.3. The role of AIF in neuronal cell death and survival 
AIF is a nuclear encoded ~62 kDa flavoprotein that is located in the inner 
mitochondrial membrane. It is synthesized as a ~67 kDa precursor protein (pro-AIF) 
that is imported into mitochondria via its N-terminal prodomain which contains two 
mitochondrial location sequences (MLS). In the mitochondria the imported pro-AIF is 
processed into the mature ~62 kDa protein (Otera et al., 2005;Susin et al., 1999). 
During intrinsic cell death AIF is cleaved into a soluble ~57 kDa form that is released 
to the cytosol and translocates to the nucleus where it induces chromatin 
condensation and large-scale DNA fragmentation (~50 kbp) (Susin et al., 1996;Susin 
et al., 1999). In fact, AIF was the first mitochondrial protein shown to mediate 
caspase-independent cell death (Susin et al., 1996;Susin et al., 1999). AIF has been 
shown to bind DNA in a sequence-independent manner (Ye et al., 2002). This 
interaction is mediated by the positive electrostatic potential at the surface of AIF and 
leads to chromatin condensation, a fundamental feature of apoptosis (Vahsen et al., 
2004). However, AIF does not degrade naked DNA (Susin et al., 1999), and the 
mechanisms by which AIF leads to DNA fragmentation are not yet clarified. Since 
AIF lacks nuclease activity it has been proposed that AIF mediates DNA 
fragmentation through interaction with other nuclear protein factors. In mammalian 
cells cyclophilin A was identified as a cofactor that directly interacts with AIF (Cande 
et al., 2004). Cyclophilin A has been reported to have calcium-dependent nuclease 
activity (Montague et al., 1994), and it has been suggested that AIF and cyclophilin A 
work synergistically to induce chromatinolysis since the combination of both proteins 
causes degradation of plasmid DNA in vitro (Cande et al., 2004). 
It is now well established that AIF-dependent cell death plays a key role in neuronal 
death in model systems of cerebral ischemia (Culmsee et al., 2005;Plesnila et al., 
2004;Zhu et al., 2003), TBI (Slemmer et al., 2008), and epileptic seizures (Cheung et 
al., 2005).  
Different modulators of mitochondrial AIF release were identified, such as calpain I 
which can induce cleavage and release of AIF from isolated mitochondria (Polster et 
al., 2005). The cleavage of AIF is inhibited by Bcl-2 and Bcl-xL overexpression (Otera 
et al., 2005) suggesting that AIF-cleavage occurs downstream of mitochondrial 
membrane permeabilization since both proteins exert pro-survival functions by 
inhibiting mitochondrial membrane pore formation (Galluzzi et al., 2009). 
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Further, it was demonstrated that the pro-apoptotic protein Bid mediated 
mitochondrial release of AIF in neural cells (Grohm et al., 2010;Landshamer et al., 
2008;Tobaben et al., 2011). In addition, poly(ADP-ribose)polymerase 1 (PARP-1) 
activity was associated with lethal AIF release and genetic deletion, and 
pharmacological inhibition of PARP-1 prevented AIF translocation and provided 
neuroprotection in vitro and in vivo (Wang et al., 2009;Wang et al., 2011;Yu et al., 
2002). Activation of PARP-1, a DNA repair enzyme, is triggered by DNA strand 
breaks as it occurs e.g. after excessive production of free radicals (Wang et al., 
2009). Overactivation of PARP-1 leads to utilization of mitochondrial nicotinamide 
adenine dinucleotide (NAD+), ATP depletion, and an increase in levels of poly(ADP-
ribose) (PAR). Of note, AIF has recently been shown to possess a high-affinity PAR-
binding site, and the physical interaction between PAR and AIF seem to be 
responsible for the resulting cell death after PARP-1 activation. It has been 
demonstrated that about 20 % of mitochondrial AIF is localized at the cytosolic side 
of the outer mitochondrial membrane where it is available for binding of PAR (Yu et 
al., 2009). PAR binding to AIF likely induces a conformation change in AIF that 
lowers its affinity to the mitochondrial membrane leading to its release (Wang et al., 
2011). This kind of caspase-independent form of programmed cell death (PCD) 
involving PARP-1 activation plays an important role in multiple experimental and 
physiopathological scenarios, including stroke, inflammation, and neurodegeneration 
and has been termed parthanatos (David et al., 2009;Galluzzi et al., 2012).  
The cumulative evidence for a key role of AIF translocation to the nucleus in 
paradigms of neuronal cell death led to the conclusion that controlling AIF upstream 
of mitochondrial release may emerge as a promising therapeutic strategy in 
neurological diseases, such as cerebral ischemia and neurodegenerative disorders 
(Delavallee et al., 2011). However, direct inhibition of AIF by small molecules is not 
available so far and previous neuroprotective effects were achieved using siRNA-
mediated gene silencing or in genetic models of reduced AIF expression, such as 
harlequin (Hq) mice, which express only 20 % AIF compared to wildtype mice. For 
example, AIF siRNA attenuated apoptosis in neuronal cells exposed to oxygen-
glucose deprivation (OGD) or glutamate (Landshamer et al., 2008). Further, Cheung 
et al. demonstrated sustained neuronal survival after DNA damage- and excitotoxin-
induced cell death in Hq/Apaf1-/- double mutant mice (Cheung et al., 2006). 
Moreover, AIF deficiency protected brain tissue of Hq mice against hypoxia/ischemia 
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(Zhu et al., 2003;Zhu et al., 2007), focal cerebral ischemia (Culmsee et al., 
2005;Plesnila et al., 2004), or ionizing radiation in vivo (Osato et al., 2010).  
To date, the exact mechanism by which AIF depletion sustains neuronal survival is 
unknown. Reduced translocation of the protein to the nucleus as the underlying 
mechanism of neuroprotection is controversial since neurons of Hq mice or neurons 
exposed to AIF siRNA still express considerable amounts of AIF, which should be 
sufficient for nuclear translocation and induction of apoptosis after its release from 
the mitochondria. In fact, few amounts of cytosolic AIF are sufficient for translocation 
to the nucleus and subsequent induction of chromatin condensation and DNA 
fragmentation. Further, the fast kinetics of AIF release to the nucleus (Landshamer et 
al., 2008) disagrees with a direct protective effect only mediated by reduced AIF 
levels. Thus, other effects may be responsible for the neuroprotective effect of AIF 
depletion, such as metabolic effects at the level of mitochondria. 
Since AIF is a flavoprotein containing binding sites for FAD and NADH with putative 
NADH and NADPH oxidase activities (Joza et al., 2001), loss of AIF may affect the 
redox balance in mitochondria. Previous studies have shown that AIF-depleted cells 
like AIF-/- embryonic stem cells (ESCs) and Hq cells with significantly reduced AIF 
levels exert defects in oxidative phosphorylation and mitochondrial respiratory 
complex stability (Chinta et al., 2009;Vahsen et al., 2004). As a consequence, AIF 
depletion may mediate a metabolic impact that could play an important role for the 
integrity, structure, and function of the mitochondria, including the activity and 
stability of the respiratory chain (Cheung et al., 2006;Joza et al., 2005). Notably, 
inhibition of the mitochondrial respiratory chain can provide preconditioning effects 
thereby protecting cells from a following lethal stress (Wiegand et al., 1999). This 
study addresses the question whether neuroprotection mediated by AIF silencing is 
caused through a preconditioning effect thereby stabilizing mitochondrial function and 
integrity. 
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1.4. Stem cell-based therapy for the treatment of neurodegenerative 
diseases and acute brain injuries 
Transplantation of stem/progenitor cells to the injured brain is a new potentially 
powerful strategy for a broad spectrum of neurodegenerative diseases and acute 
brain injuries (Lindvall et al., 2004;Lindvall and Kokaia, 2006). Stem cells/progenitor 
cells are known to have self-renewing capacity and are able to differentiate into new 
neurons (Götz and Huttner, 2005). The fact that these cells are relatively easy to 
isolate and to expand is an important property for their potential clinical application. 
Furthermore, stem cells may serve as vehicles for the delivery of therapeutic factors 
since they have a high tropism for inflamed and injured tissue (Mitrecic et al., 2012). 
So far, numerous studies showed that transplantation of different kinds of 
stem/progenitor cells provided beneficial effects in several models of 
neurodegeneration and acute brain injury. Accordingly, stem cell-based approaches 
may provide novel therapies especially for the treatment of PD, HD, AD, ALS, spinal 
cord injury (SCI), and stroke (Lindvall et al., 2004;Lindvall and Kokaia, 2006).  
For example, the stem cell-based therapy of stroke is mainly investigated with NSCs, 
mesenchymal stem cells (MSCs), umbilical cord blood and bone mesenchymal stem 
cells (BMSCs) (Lindvall and Kokaia, 2011). These cells can be administered by 
various routes including intravascular injections, or intracerebral and intrathecal 
applications. Human ESC-derived NSCs that were grafted into the ischemic 
boundary in rats subjected to stroke, migrated towards the lesion and improved 
forelimb performance (Daadi et al., 2008). Human MSCs, that were intravenously 
administered, reduced stroke-induced deficits in rats most likely by inducing 
angiogenesis and improving cerebral blood flow (Onda et al., 2008). BMSCs, which 
comprise mesenchymal stem and progenitor cells, can secrete various neurotrophic 
factors and other protective cytokines (Parr et al., 2007). The delivery of BMSCs from 
human or animal origin by systemic or intracerebral routes, promoted significant 
functional recovery after stroke (Li and Chopp, 2009). Umbilical cord blood, 
containing hematopoietic stem cells and other progenitor cells, showed improved 
behavioral outcome in animal models after systemic delivery, even when 
administered 30 days after the insult (Park et al., 2009;Vendrame et al., 
2004;Vendrame et al., 2006;Zhang et al., 2011). Notably, functional improvement 
persisted in rodents for at least one year post-treatment (Shen et al., 2007). Further, 
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functional benefits after stem cell-based therapy were reported in models of cerebral 
ischemia applied in male and female, and in young and old animals. 
There are also the first clinical trials ongoing in which stem cells are transplanted to 
stroke patients. For example, a clinical trial performed with intravenous injection of 
autologous ex vivo cultured MSCs in 30 patients with an ischemic lesion in the 
territory supplied by the middle cerebral artery was reported in 2005 (Bang et al., 
2005). A similar study was described in 2010 with 85 patients as a long-term study 
followed up to 5 years after i.v. application to evaluate the long-term safety and 
efficacy (Lee et al., 2010). Both studies provide evidence that application of MSCs is 
safe and leads to functional recovery.  
The first clinical trial with transplanted NSCs in stroke patients was recently started 
by the UK-based company ReNeuron and includes 12 patients between 6 and 24 
months after stroke. Increasing numbers of conditionally immortalized NSCs (CTX 
cells), isolated from human fetal cortex are implanted into the putamen and tested for 
safety. Additionally, the trial will evaluate a range of potential efficacy measures, such 
as cognitive impairment, functional outcome, and overall disability, for future trials. 
(Mack, 2011). Several other clinical studies using intravenous or intraarterial infusion 
of stem cells in patients with stroke are currently ongoing or prepared, as well as 
studies for stem cell transplantation in patients with PD, AD, ALS, or SCI to 
investigate the efficacy and safety of this new therapeutic approach 
(www.clinicaltrial.gov). 
The exact mechanism of therapeutic effects observed after stem cell/progenitor cell 
transplantation into the brain, however, still remains unclear. Several mechanisms 
have been proposed for the beneficial effects of this type of cell therapy in 
experimental settings of neurodegeneration. A frequently proposed hypothesis is the 
replacement of injured tissue by the transplanted stem cells/progenitor cells through 
differentiation of the engrafted cells into new neurons. However, only very few cells 
survive after transplantation which renders this theory of cell replacement rather 
unlikely (Menasche, 2005;Silva et al., 2005). For example, it was shown that only 
0.02 % of 2 million MSCs injected into the carotid artery were stained for neural 
markers in the ischemic hemisphere (Chen et al., 2002). In addition, functional 
improvement after stem cell transplantation occurs rapidly and is often obvious in one 
week, which is an insufficient time for the transplanted cells to become neurons and 
integrate successfully into the brain circuity (Chen et al., 2001). 
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Thus, it is more conceivable that the stem/progenitor cell application provides 
neuroprotective effects and/or induces repair mechanisms in the injured brain tissue 
(Carletti et al., 2011). This could be mediated by the release of trophic factors by the 
transplanted cells or by stimulation of endogenous growth factor synthesis in the host 
tissue. Further, enhanced angiogenesis, inhibition of apoptosis, and stimulation of 
recruitment, proliferation, and differentiation of endogenous stem cells residing in the 
brain tissue are potential effects of protection discussed in the literature (Isele et al., 
2007;Joyce et al., 2010;Zhu et al., 2011). It is also known, that NSCs exert 
antioxidant properties thereby rescuing the surrounding neurons. In particular, the 
secretion of growth factors, such as vascular endothelial growth fator (VEGF), 
correlated with antioxidant mechanisms in NSCs themselves and the surrounding 
host cells (Madhavan et al., 2008).  
In addition, an interaction of stem/progenitor cells with immunologic cells located in 
organ systems distant from the CNS has been observed, thereby altering the 
systemic responses of the immune system (Walker et al., 2011).  
 
However, before stem cell therapy is established to be a safe and robust strategy for 
the treatment of neurodegenerative disorders it is indispensable to clarify some 
fundamental questions regarding the underlying mechanisms and also the clinical 
application. To date, it remains unknown which type of stem cells is the most suitable 
for therapeutic approaches in neurodegenerative diseases or after acute brain injury. 
The spectrum of potentially available stem/progenitor cells is enormous reaching 
from ESC over NSCs and BMSCs to MSCs, and also induced pluripotent stem cells 
(iPSCs) reprogrammed from fibroblasts (Takahashi and Yamanaka, 2006) or hair 
follicle cells (Petit et al., 2012) may offer new strategies for stem cell-based therapy 
in neurological disorders. Moreover, the optimal number of cells that has to be 
applied to the patients has to be determined. The timing of treatment and the 
optimum route of delivery is another question remaining for stem cell-based therapy.  
A further unresolved question is the optimal age of a patient for stem/progenitor cell 
transplantation and the localization and extent of e.g. the ischemic lesion or the 
progression of the disease. Furthermore, it is unknown which influence complicating 
factors may exert on regenerative mechanisms that are often found in patients with 
neurodegenerative disorders, such as, for example, diabetes, hypertension, or 
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arthereosclerosis. In addition, it is necessary to obtain more knowledge about the 
safety of stem cell transplantation, especially on the potential for tumorigenicity and 
immunologic rejections.  
Beyond that, control standards and quality assurance must be in place to assure a 
standardized cell preparation (Banerjee et al., 2011). Thus, long-term and large-scale 
multicenter clinical studies are required to establish and optimize stem cell-based 
therapy for neurodegenerative diseases. Such studies require huge efforts since they 
need to pass through strict authorization and admission procedures e.g. through the 
European Medicines Agency (EMA) or the Food and Drug Administration (FDA) 
before the clinical trial can be started. 
 
Overall, these obstacles imply that it is highly important to achieve a better 
understanding for the mechanisms of stem cell-mediated therapeutic effects. 
Furthermore, the development of a standardized stem cell-derived composition 
providing neuroprotective effects to acute and chronic neural injuries is highly 
relevant.  
This study investigates CM generated by NPCs undergoing starvation, which offers a 
method for the generation of a standardized composition for the treatment with 
stem/progenitor cells. CM generated by dying cells reflects the properties of the 
surroundings of the stem cell/progenitor cell transplants since only very few cells 
survive the transplantation into the brain (Chen et al., 2002). The aim of this study is 
to investigate the neuroprotective potential of this NPC-derived CM, and more 
importantly, to identify the mediators of neuroprotection. 
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1.5. Neurogenesis – the potential of neural progenitor cells 
Adult neurogenesis has been shown to occur continuously in discrete regions of the 
CNS of all mammals, including humans (Gage, 2000;Temple, 2001a;Temple, 
2001b). Adult neurogenesis occurs primarily in two regions of the adult brain, the 
subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of 
the dentate gyrus in the hippocampus (Bedard and Parent, 2004;Curtis et al., 
2007;Eriksson et al., 1998). Neurons born in the adult SVZ migrate over a great 
distance through the rostral migratory stream and become granule neurons and 
periglomerular neurons in the olfactory bulb. Neurons born in the adult SGZ migrate 
into the granule cell layer of the dentate gyrus and become dentate granule cells 
(Zhao et al., 2008). These neurons are generated from adult NSCs which are cells 
that can self-renew and differentiate into all types of neural cells, including neurons, 
astrocytes, and oligodendrocytes. The NSCs differentiate into NPCs, which can only 
divide a limited number of times. These NPCs develop into mature, non-mitotic 
neurons (Zhao et al., 2008).  
To date, the precise function of adult neurogenesis is still poorly understood. In 
animals SVZ neurogenesis is regulated by the olfactory experience (Lledo et al., 
2006;Lledo and Saghatelyan, 2005). Thus, neurogenesis may be required for special 
brain functions located in the olfactory bulb and the hippocampus, such as learning 
and memory.  
The generation of new neurons is influenced by many intrinsic and extrinsic 
signals.  For example growth factors, such as epidermal growth factor (EGF) and 
fibroblast growth factor 2 (FGF 2), are potent mediators for the maintenance of adult 
NSCs in vitro. In vivo, both factors promote proliferation of NPCs and stem cells in 
the SVZ, but only FGF 2 increases the number of newborn neurons in the olfactory 
bulb (Kuhn et al., 1997).  
Furthermore, signaling through the sonic hedgehog pathway, the neurotrophin brain-
derived neurotrophic factor (BDNF), cytokines and hormones, such as thyroid 
hormone, respectively, are major regulators of different phases of adult 
neurogenesis. Additionally, a variety of intrinsic factors, such as miRNAs, cell-cycle 
regulators, and transcription factors, play critical roles in postnatal neurogenesis 
(Ming and Song, 2011;Mu et al., 2010). 
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Interestingly, adult neurogenesis is also affected by pathological conditions of the 
CNS. For example, seizure activity increases neurogenesis in both regions, the SVZ 
and the SGZ. However, the role of seizure-associated aberrant neurogenesis in 
epilepsy has not yet been resolved (Zhao et al., 2008).  
Furthermore, neurogenesis in both hippocampus and SVZ was enhanced in models 
of focal and global ischemia in rodents.  After ischemic stroke, newborn cells from the 
SVZ migrated to the site of injury, which was guided by blood vessels (Zhao et al., 
2008).  
These findings underline the expectance that neural stem and progenitor cells have 
the potential to compensate for neuronal dysfunction and death and to recover neural 
functions in CNS disorders.  
For the studies in this thesis, NPCs provided by Prof. Gage were used. This cell line 
was isolated from 8-10 weeks old C57BL/6 mice using the whole brain without 
cerebellum and olfactory bulb (Ray and Gage, 2006). Progenitor cells from this cell 
line grow in a special serum-free medium (described in chapter 2.1.4) as a 
monolayer, which offers technical advantages compared to neurospheres that are 
commonly used for research on progenitor cells. Since neurospheres are tightly 
packed, not all cells are accessible for examining their morphology, proliferation, or 
differentiation. Progenitor cells cultured as a monolayer enables the evaluation of the 
cell number, shape, morphology, and other characteristics more accurately. The cells 
are visible in phase contrast microscopy and show elongated cell bodies with multiple 
processes (Figure 2). After passaging, just a small number of spheres fail to attach 
on the uncoated plastic plate. The mouse progenitor cells can be cultivated for 
several months through multiple passages and even be frozen and re-cultured 
without any change in their properties (Ray and Gage, 2006). 
 
 
Figure 2: Morphology of neural progenitor cells 
(NPCs). 
NPCs are growing in a monolayer. The cells are 
phase dark and have elongated cell bodies with 
multiple processes. 100 x magnitude. 
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1.6. The HT-22 cell model 
To investigate preconditioning effects in vitro HT-22 neurons from an immortalized, 
hippocampal cell line were used. HT-22 neurons have been generated from HT-4 
cells, a cell line originating from primary mouse hippocampal neurons. 
Immortalization has been achieved using a temperature-sensitive SV-40 T-antigen 
(Morimoto and Koshland, Jr., 1990). In this cell line, death was induced by exposure 
to glutamate at millimolar concentrations. The glutamate concentration is quite high 
compared to concentrations that are used in primary neurons to induce excitotoxicity 
since the HT-22 cells do not express ionotropic glutamate receptors. Thus, cell death 
is independent of NMDA-receptor stimulation and mediated through competitive 
inhibition of the glutamate-cystine antiporter (xCT). This antiporter is a plasma 
membrane transport protein, which mediates the import of cystine from the 
extracellular space and the concomitant export of glutamate (Murphy et al., 1989). 
Blockade of the xCT, e.g. by high extracellular glutamate, results in depletion of 
cystine and cystein levels, followed by decreased levels of glutathione (GSH). Given 
the crucial role of GSH as a redox scavenger, reduced GSH plasma levels give rise 
to excessive ROS formation, mitochondrial damage, release of mitochondrial AIF, 
DNA damage, and cell death (Sagara et al., 1998;Tan et al., 1998;Tobaben et al., 
2011). This kind of cell death has been termed oxytosis (Tan et al., 2001).  
 
In addition, it was observed that cytosolic calcium levels are increased after 
glutamate treatment in HT-22 cells, despite the absence of NMDA receptors (Tan et 
al., 1998). Since enhanced ROS formation and increased calcium levels are 
established features of neuronal death in neurodegenerative disorders, this model 
system of glutamate-induced oxidative stress in HT-22 cells is a valuable and 
applicable model to investigate molecular mechanisms of PCD in neurons. 
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Figure 3: Simplified model of glutamate-induced apoptosis in HT-22 cells. 
Exposure to high extracellular glutamate concentrations causes a competitive blockade of the xCT, 
which results in a depletion of cystine in the cell. This is followed by a decrease in glutathione (GSH) 
synthesis and causes reduced glutathion peroxidase 4 (Gpx 4) activity. In response to these events 
12/15 lipoxygenase (12/15 LOX) is activated and ROS formation and lipid peroxidation increase. 
Downstream activation and mitochondrial translocation of the BH-3 protein Bid and its truncated form 
tBid cause mitochondrial dysfunction. Consequently, the pro-apoptotic factor AIF translocates from 
mitochondria to the nucleus and cleaves DNA, thereby terminating cell death. Red arrows indicate the 
increases and decreases in cellular molecule levels caused by high glutamate concentrations 
(modified from Tobaben et al., 2011). 
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1.7. Aim of the thesis 
The aim of this thesis was to investigate mechanisms of molecular and cellular 
preconditioning that provide neuroprotective effects as exemplified by siRNA-induced 
AIF depletion and CM obtained from NPCs in a model of glutamate toxicity in HT-22 
cells.  
 
AIF has been recognized as an important protein for mediating caspase-independent 
cell death and also physiological functions in neurons. However, the question how 
AIF deficiency provides neuroprotection has not been clarified so far.  
Thus, the first part of the thesis investigates whether AIF depletion mediates 
preconditioning in a model system of glutamate toxicity in immortalized hippocampal 
HT-22 neurons where glutamate induces lethal oxidative stress, mitochondrial 
fragmentation, and intrinsic pathways of AIF-dependent cell death. The focus of the 
study was to investigate the protective effects on mitochondrial function and integrity. 
Furthermore, this neuroprotective effect was investigated for links to ROS generation, 
AMPK regulation, and complex I inhibition to examine whether the observed 
preconditioning effect was attributed to a metabolic effect.  
 
The second part of the study deals with cellular conditioning effects mediated by 
NPCs. Stem cell as well as progenitor cell transplants are potential therapeutics in 
neurodegenerative diseases and acute brain injuries. However, the optimal 
application and the mechanisms of protection remain unknown. For that reason the 
aim of the second part of this thesis was to establish the production of a CM that 
reflects the conditions after stem/progenitor cell transplantation in the brain. Further, 
the CM should be suitable for in vivo application. One aim during this research was to 
investigate the potency and the stability of this CM. Furthermore, the major aim of 
this study was to identify components of the mixture that mediate the neuroprotective 
effects of CM. These investigations should be the basis for the development of a 
composition obtained from the CM for the treatment of neurological disorders.  
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2. Materials and methods 
2.1. Cell culture 
2.1.1. Cell culture materials 
Sterile plastic ware used in this study is listed in Table 1. 
Table 1: Plastic ware 
Plastic ware Company  
T75 flasks Greiner, Frickenhausen, Germany  
T175 flasks  Greiner, Frickenhausen, Germany 
24-well plates Greiner, Frickenhausen, Germany 
96-well plates Greiner, Frickenhausen, Germany 
ibidi slides 8-well plates Ibidi, Munich, Germany  
15 ml tubes  Greiner, Frickenhausen, Germany  
50 ml tubes  Greiner, Frickenhausen, Germany  
0.5, 1.5, 2 ml tubes Sarstedt, Nümbrecht, Germany  
Cell scraper Sarstedt, Nümbrecht, Germany  
0.22 μm sterile filter  Whatman, Dassel, Germany 
5, 10 ml Injekt® Braun, Melsungen, Germany 
3, 10, 50 kDa Amicon® Ultra Centrifugal 
Filter  Units 
Millipore, Schwalbach, Germany 
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2.1.2. Cultivation of HT-22 cells 
HT-22 cells were originally generated by David Schubert (Salk Institute, San Diego, 
USA) and obtained from Gerald Thiel (Homburg/Saar).  
For standard cultivation HT-22 cells were kept in 75 cm2 culture flasks in a standard 
humidified incubator at 37°C and 5 % CO2. Cells were split twice per week in a ratio 
1:10 - 1:20. For splitting, cells were washed once with phosphate buffered saline 
(PBS, Table 4) to fully remove the growth media. Afterwards, HT-22 cells were 
detached from flask with ~2 ml of Trypsin/EDTA solution (Table 5). When cells were 
detached the protease activity was stopped by adding the 3-fold amount of DMEM 
growth medium (Table 2). Cell suspension was centrifuged at 1,000 rpm for 5 
minutes and resuspended in fresh growth medium. For determination of cell number, 
a counting chamber (Neubauer Zählkammer, Brand, Wertheim, Germany) was used. 
Afterwards, the required cell number was seeded into the appropriate culture dishes 
depending on the respective experiments. The cell densities used in the different 
culture formats are listed in Table 3. 
 
Table 2: HT-22 growth medium 
DMEM-medium with 4.5mg/l glucose and 110 mg/l sodium pyruvate 440 ml 
Heat inactivated fetal calf serum (FCS) 50 ml 
L-Alanyl-L-glutamine 200 mM 5 ml 
Penicillin 10.000 U/ml / Streptomycin 10 mg/ml 5 ml 
 
Table 3: HT-22 cells – cell densities 
Cell culture format cell density (cells/well) 
96-well plate ~ 8,000 cells/well 
24-well plate ~ 60,000 cells/well 
ibidi slide 8-well plates ~ 16,000 cells/well 
E-plate ~ 8,000 cells/well 
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Table: 4 Phosphate buffered saline (PBS), pH 7.4 
NaCl 9 g 
Na2HPO4 0.527 g 
KH2PO4 0.144 g 
HCl (0.1M) q.s. for pH adjustment 
Aqua demin. add to a final volume of 1,000 ml 
 
Table 5: Standard Trypsin/EDTA solution 
Trypsin (7.500 U/mg) 100 mg 
Ethylenediamine-tetra-acetic acid 
(EDTA) 
40 mg 
PBS Table 4 
 
 
2.1.3. Induction of cell death in HT-22 cells 
Cell death in HT-22 cells was induced when cells reached about 70-80 % confluency. 
For induction of cell death in HT-22 cells, glutamate solution at a final concentration 
range of 2-5 mM was used. For glutamate stock solution D,L-glutamic acid 
monohydrate (Sigma-Aldrich, Taufkirchen, Germany) was dissolved in Earle’s 
balanced salt solution (1x EBSS) or Dulbeccos’s modified eagle medium (DMEM; 
PAA Laboratories GmbH; Cölbe, Germany) to a stock concentration of 1 M. The pH 
was adjusted to 7.2 with concentrated sodium hydroxide solution (NaOH).  The stock 
solution was stored at -20°C. For inducing cell death, stock solution was diluted with 
DMEM to final concentrations instantaneously before the treatment and added 
directly to the cells. In experiments including a pretreatment without washout a 
20 mM glutamate solution was prepared and added to the pretreatment solution 
directly to achieve the final concentration. 
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2.1.4. Cultivation of NPCs 
NPCs, provided by Prof. Dr. Fred H. Gage (Salk Institute, La Jolla, USA) (Ray and 
Gage, 2006) were cultured in a standard humidified incubator at 37°C and 5 % CO2.  
Cells were kept in 75 cm2 culture flasks and split three times per week in a ratio 1:3 - 
1:6. For splitting, media was removed and cells were detached with 1 ml 0.05 % 
Trypsin/EDTA (GIBCO) within one minute at room temperature. After adding 10 ml 
DMEM/F12 (PAA, Cölbe, Germany) cells were centrifuged at 1,000 rpm for 
3 minutes. The pellet was washed once with 5 ml DMEM/F12 and centrifuged again. 
The resulting pellet was resuspended in fresh growth medium (Table 6) and seeded 
out as required. NPC growth medium was freshly prepared and used within 1-2 
weeks since stability of the growth factors was limited. For long-term storage the cell 
pellet was resuspended in 1 ml freezing media (Table 7) and stored at -80°C. After 
24 hours the frozen cell suspension was transferred into liquid nitrogen. When 
thawing the cells culture media contained the double amount of N2 supplement until 
NPCs reached standard proliferation rates. 
 
Table 6: NPC growth medium 
Dulbecco’s modified medium Ham’s F12 (DMEM/F12) 50 ml 
N2 supplement  (Invitrogen) 0.5 ml 
Penicillin 10.000 U/ml / Streptomycin 10 mg/ml 0.5 ml 
L-Alanyl-L-glutamine 200 mM 0.5 ml 
Epidermal growth factor 10g/ml (Invitrogen) 0.1 ml 
Basic fibroblast growth factor 10 g/ml (Invitrogen) 0.1 ml 
Heparine 5mg/ml (Sigma-Aldrich) 0.05 ml 
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Table 7: NPC freezing media 
Dulbecco’s modified medium Ham’s F12 (DMEM/F12) 888 µl 
N2 supplement  (Invitrogen) 10 µl 
DMSO (10 %) 100 µl 
Basic fibroblast growth factor 20 ng/ml (Invitrogen) 2 µl 
 
2.1.5. Cultivation of SNL feeder cells 
SNL 76/7 feeder cells (Sigma-Aldrich) are a cell line that can be used as a feeder 
layer to support the growth of mouse ESCs. This cell line was originally generated by 
a STO cell line transfected with a G418-resistance cassette, RV4.0 (Thomas and 
Capecchi, 1987), and a leukaemic inhibitory factor (LIF) expression construct 
(Williams et al., 1988).  
The cells were cultured in a standard humidified incubator at 37°C and 5 % CO2 in 
75 cm2 culture flasks. The cells were split twice a week in a ratio 1:10. Splitting 
procedure was as described for HT-22 cells. Culture media and freezing media was 
prepared as listed in Table 8 and 9. 
 
Table 8: SNL culture medium 
DMEM-medium with 4.5mg/l glucose and 110 mg/l sodium pyruvate 435 ml 
Heat inactivated FCS 50 ml 
MEM non-essential amino acids (NEAA) 10mM 5 ml 
L-Alanyl-L-glutamine 200 mM 5 ml 
Penicillin 10.000 U/ml / Streptomycin 10 mg/ml 5 ml 
 
Table 9: SNL freezing media 
DMEM-medium with 4.5mg/l glucose and 110 mg/l sodium pyruvate 70 % 
Heat inactivated FCS 20 % 
DMSO 10 % 
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2.1.6. Cultivation of primary MEF 
For preparation of primary mouse embryonic fibroblasts (MEFs) embryonic 
C57black/6 mice (E17-18) were used. Small pieces of embryonic skin were dissected 
and put into MEF culture media (Table 10). When fibroblasts started to spread out of 
the skin pieces, the cells were detached using standard trypsin/EDTA solution and 
seeded into a new culture flask to get a well distributed cell monolayer (Xu, 2005). 
Cells were split in the same procedure as HT-22 cells when reaching ~80 % 
confluency on the flask bottom. 
 
Table 10: Primary MEF culture medium 
DMEM-medium with 4.5mg/l glucose and 110 mg/l sodium pyruvate 410 ml 
Heat inactivated fetal calf serum (FCS) 75 ml 
L-Alanyl-L-glutamine 200 mM 10 ml 
Penicillin 10.000 U/ml / Streptomycin 10 mg/ml 5 ml 
 
2.1.7. SiRNA transfection  
For siRNA transfections, the cationic lipid formulation Lipofectamine RNAiMax 
(Invitrogen, Karlsruhe, Germany) was used. Transfections were performed in 24-well 
plates as reverse transfections, i.e. the complexes were prepared within the wells 
before cells and medium were added. For each well 1.2 µl Lipofectamine RNAiMax 
were mixed with siRNA and filled up to 100 µl with Optimem I (Invitrogen). The 
mixture was incubated for 20 minutes at room temperature. Afterwards, 500 µl of an 
antibiotic free cell suspension (33,333 cells/well) was added. After 48 hours cells 
were treated in the 24-well format or seeded into another culturing format depending 
on the respective experiment.  
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2.1.8. Starvation and production of CM 
CM was produced from NPC, MEF, SNL or HT-22 cells. Cells were grown in 75 cm2 
or 175 cm2 culture flasks until they reached ~70 % confluency. Culture media was 
removed and cells were washed once with PBS. Afterwards, cells were treated with 
EBSS with or without phenol red (Table 11 or Sigma-Aldrich). Duration of EBSS 
treatment was dependent on the cell type: NPCs were treated for at least 24 hours, 
HT-22 cells for 48 hours and MEFs and SNL cells for about one week until cells 
underwent starvation. Media were stored at -80°C until further use. Before use the 
CM was centrifuged (1,000 rpm, 10 minutes) and filtered through a 0.22 m 
membrane filter to remove dead cells and cell debris. 
For heat activation, CM was heated up to 60°C for at least 10 minutes. CM was used 
with 6 hours pretreatment in HT-22 cells followed by glutamate treatment if not 
described otherwise. 
 
Table 11: Earle’s balanced salt solution (EBSS 1x) containing phenol red 
EBSS 10x (Sigma-Aldrich) 100 ml 
NaHCO3 2.2 g 
Aqua demin. add to a final volume of 1,000 ml 
HCl (0.1M) q.s. for pH adjustment 
 
2.2. Chemicals and reagents 
All standard chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany) 
and Carl Roth (Karlsruhe, Germany), if not described otherwise. All buffers and 
solutions were prepared using demineralized, ultrapure water supplied by the SG 
Ultra Clear UV plus Reinstwassersystem (VWR, Darmstadt, Germany). 
Demineralized water for aseptic preparation of solutions was sterilized before use by 
a steam autoclave (Systec V-40, Systec GmbH, Wettenberg, Germany). All media 
and solutions that were used in cell culture were sterilized by filtration using 0.22 μm 
filter sets (Sarstedt, Nümbrecht, Germany). 
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2.2.1. Inhibitors of cell death  
Recombinant human peroxiredoxin-1 (prdx-1, Sigma-Aldrich) was dissolved in EBSS 
resulting in a 250 µg/ml stock and stored at -20°C. It was used at final concentrations 
of 12.5 µg/ml, 50 µg/ml and 125 µg/ml for applications in HT-22 cells. HT-22 neurons 
were pretreated with the recombinant protein for 6 hours followed by subsequent 
glutamate treatment. 
Recombinant mouse galectin-1 (gal-1) (R&D Systems, Wiesbaden-Nordenstadt, 
Germany) was dissolved in EBSS at a stock concentration of 100 µg/ml and stored at 
-20°C. For applications in HT-22 cells it was used in a final concentration of 10 µg/ml. 
HT-22 cells were pretreated with prdx-1 for 6 hours before adding glutamate. 
Rotenone (Sigma-Aldrich) was dissolved in DMSO in a stock concentration of 1 mM 
and stored at -20°C until further use protected from light. To achieve protective 
effects in HT-22 cells rotenone was applied at a final concentration of 20 nM if not 
described otherwise.  
For inhibition of caspases the cell-permeable, irreversible, broad-spectrum caspase 
inhibitor Q-VD-OPh (Merck KGaA, Darmstadt, Germany) was used. The solution 
dissolved in DMSO (10 mM) was used at a final concentration of 20-40 µM. 
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) (Sigma-Aldrich) was 
dissolved in ethanol in a stock concentration of 100 mM and diluted in culture media 
to a final working concentration of 100 µM. 
AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide, Sigma-Aldrich), used 
for activation of AMPK, was dissolved in HT-22 medium at a stock concentration of 
100 mM and stored at -20°C until further use. The stock was diluted in culture media 
to final concentrations as indicated. 
For inhibition of AMPK, compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-
pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine) (Merck KGaA, Darmstadt, Germany) was 
used. The lyophilized powder was dissolved in DMSO at a stock concentration of 10 
mM and stored at -20°C until further use. The stock was diluted in media to final 
concentrations as indicated. 
BDNF (R&D Systems) was dissolved in DMSO at a stock concentration of 10 µg/ml 
and stored at -20°C. For treatment in HT-22 neurons, final concentration in media 
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ranged from 25-100 ng/ml. Cells were pretreated 6 hours with BDNF followed by 
subsequent co-treatment of glutamate and BDNF. 
 
2.2.2. Inhibitors of protein synthesis and PI3K 
For inhibition of protein synthesis during the production of CM, actinomycin D or 
cycloheximide (CHX) was added to EBSS that was determined for CM production in 
NPCs. Actinomycin D (Sigma-Aldrich) was dissolved in DMSO at a stock 
concentration of 1 mM and stored at -20°C. For treatment of NPCs it was used in 
final concentrations of 1 µM and 10 µM if not described otherwise. CHX (Sigma-
Aldrich) was dissolved in ethanol at a stock concentration of 0.5 mM and stored at     
-20°C. For application in NPCs it was used at final concentrations of 0.5 µM and 
1 µM if not described otherwise. After NPCs underwent starvation the protein 
synthesis inhibitors were removed from media by a 10 kDa cut off filtration at 
4,000 rpm before testing in the HT-22 cell system. 
For inhibition of phosphoinositide-3-kinase (PI3K) the cell-permeable, reversible 
inhibitor LY 294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) was used. 
LY 294002 was dissolved in DMSO resulting in a 1 mM stock solution. For HT-22 cell 
treatment a final concentration of 10 µM was used. Cells were pretreated with the 
inhibitor for 1 hour followed by a pretreatment containing CM and the inhibitor 
together. Afterwards, the cells were exposed to glutamate. 
 
2.2.3. Digestion of RNA and proteins 
For digestion of RNA, ribonuclease A (RNase A) solution (Sigma-Aldrich) was used 
in a concentration of 70 Kunitz/mg protein. Ribonuclease A targets the 3’phosphate 
of a pyrimidine nucleotide and cleaves single stranded RNA. Since RNase A exerts 
its highest activity at 60°C, CM was incubated with for 30 minutes at 60°C before 
treatment of the cells. 
Protease provided by Qiagen (Hilden, Germany) was applied to digest proteins in 
CM. The lyophilized powder was dissolved in EBSS and 45 mAU/mg protein were 
used for the digestion. CM and protease were incubated for 30 minutes at 37°C for 
digestion. Afterwards, the mixture was incubated for 4 hours at 75°C to inactivate the 
protease. The resulting mixture was then used for cell treatment. 
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2.2.4. Primary antibodies  
All primary antibodies were used at a dilution of 1:1,000 for Western blot analysis in 
Tris-buffered saline containing 0.05 % Tween 20 and 5 % skim milk powder or Tris-
buffered saline containing 5 % BSA (all Sigma-Aldrich) as described in the 
company’s protocol. In this study, the following antibodies have been used: anti-AIF 
(sc-9416, Santa Cruz), anti-Actin C4 (#691001, ImmunOTM) diluted 1:100,000, anti-
AMPK (#2532, Cell Signaling), anti-phospho-AMPK (#2535, Cell Signaling), anti-
LGALS1 (#5418, Cell Signaling) diluted in 5 % BSA, 1x TBS and 0.1% Tween 20, 
anti-MitoProfile® Total OXPHOS Rodent WB Antibody Cocktail (ab110413, abcam), 
anti-Prdx-1 (#8732, Cell Signaling), and anti-TIM23 (#611223, BD Transduction 
LaboratoriesTM). For CM treatment with specific antibodies, the media was incubated 
with the antibodies for 1-2 hours at room temperature before application to the cells. 
 
2.2.5. Secondary antibodies 
For Western blot analysis horseradish peroxidase (HRP) labeled secondary 
antibodies were used (All Vector Labs, Burlingame, California, USA). Secondary 
antibodies were diluted 1:4,000 in Western blotting buffer consisting of Tris-buffered 
saline with 0.05 % tween 20 and 5 % skim milk powder (Sigma-Aldrich).  
 
2.2.6. SiRNA sequences 
For the AIF knockdown the following siRNA sequences were used: AAGAGAAA 
CAGAGAAGAGCCA (AIF siRNA 1), ACAGAGAAGAGCCAUUGCC (AIFsiRNA 12) 
and AUGUCACAAAGACACUGCA (AIF siRNA 2). As negative control the standard 
sequence AAGAGAAAAAGCGAAGAGCCA was used (all Eurofins MWG Operon, 
Ebersberg, Germany). 
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2.2.7. PCR-primer 
For RT-PCR all primers were synthesized at MWG (Eurofins MWG Operon, 
Ebersberg, Germany). Primer sequences were used as listed in Table 12: 
 
Table 12: Primers used for RT-PCR 
AIF fw  5’-GCGTAATACGACTCACTATAGGGAGATCCAGGCAACTTGTTC 
CAGC-3’ 
AIF rev 5’-GCGTAATACGACTCACTATAGGGAGACCTCTGCTCCAGCCC 
TATCG-3’ 
EEF 2 fw 5’-GCTGCCTTGCGTGTCACCGA-3’ 
EEF 2 rv 5’-CCCATGGCGGCCTCATCGTC-3’ 
GAPDH fw
  
5’-AGGCCGGTGCTGAGTAT-3’ 
GAPDH rv 5’-TGCCTGCTTCACCACCTTCT-3’ 
HSP 60 fw 5’-GTCCCTCACTCGCCGCAGAC-3’ 
HSP 60 rv 5’-GCCTGTTCAAAACCAGCGTGC-3’ 
HSP 70 fw 5’-ACGCTAGTCGCGCTCGTGGA-3’ 
HSP 70 rv 5’-TGCGTGGACGAGCTCAGGGT-3’ 
HSP 90 fw 5’-CTTAGGCTTGCCGTGCGAGT-3’ 
HSP 90 rv 5’-TGGTCTGCCCGGACGGTGAA-3’ 
PLA 2 fw 5’-ATGAGGTGCTTGTAGACCCTGATGC-3’ 
PLA 2 rv 5’-CTTGTGGGGGAGGCGGGACA-3’ 
Prdx-1 fw 5’-TTCTCACGGCTCTTTCTGTTT-3’ 
Prdx-1 rv 5’-TTCTGGCTGCTCAATGCTGC-3’ 
Prdx-2 fw 5’-CCGGCTCTTGCTCACGCAGT-3’ 
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Prdx-2 rv 5’-GTGTCACTGCCGGGCTTCCA-3’ 
Prdx-5 fw 5’-TGCATCGACGTGCTTGGCAGG-3’ 
Prdx-5 rv 5’-TCTGGCTCCACGTTCAGTGCC-3’ 
Prdx-6 fw 5’-GGCATGCTTCCTTCTTGCTGGGA-3’ 
Prdx-6 rv 5’-TGACCTAGGACCCACCACTGCC-3’ 
 
2.3. Kits 
Table 13 encompasses all kits used for this study. 
Table 13: Kits 
Kit Company 
BODIPY (581/591 C11) Invitrogen, Karlsruhe, Germany 
Pierce BCA Kit Perbio Science, Bonn, Germany 
NucleoSpin RNA II Kit Machery & Nagel, Düren, Germany 
ELISA Kit Hölzel Diagnostika GmbH, Cologne, 
Germany 
SuperScript III One Step RT-PCR 
System with Platinum® Taq 
Invitrogen, Karlsruhe, Germany 
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2.4. Cell viability assays 
2.4.1. MTT assay 
The MTT assay is a colorimetric assay for measuring the activity of enzymes that 
reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
formazan by either a lyosomal/endosomal compartment or mitochondria (Liu et al., 
1997), resulting in a purple color. The change in absorption characteristics can be 
easily detected by absorptive spectroscopy. 
Cell viability was evaluated 15-24 hours after growth factor withdrawal or glutamate 
treatment on the basis of EBSS or 11-18 hours after glutamate treatment on the 
basis of HT-22 cell culture medium. Quantification of cell viability in NPCs and HT-22 
cells by MTT assay was performed in 96-well plates. MTT (Sigma-Aldrich) was 
dissolved in PBS at a concentration of 2.5 mg/ml. When the morphological changes 
of the cells indicated cell death, the MTT reagent was added to the media at final 
concentrations of 0.25-0.5 mg/ml followed by 1 hour incubation at 37°C. The reaction 
was terminated by removing the media from the cells and freezing the plate at -80°C 
for at least 1 hour. Absorbance was determined after solving the formazan crystals in 
dimethyl sulfoxide (DMSO) at 570 nm (FluoStar, BMG Labtech, Offenbach, 
Germany). Background was detected at 630 nm and substracted accordingly. Cell 
viability was expressed as absorption level relative to controls, which were set to 
100 % viability. 
 
2.4.2. xCELLigence system 
The xCELLigence System monitors cellular events in real-time by measuring 
electrical impedance across interdigitated gold micro-electrodes integrated on the 
bottom of tissue culture E-plates. Usually, cells have a high electrical resistance. 
Thus, the more cells are attached to the electrodes, the larger are the increases in 
impedance.  
Consequently, the system is able to detect changes in cell number (proliferating 
cells), altered attachment properties (cellular death), and especially the kinetics of 
these processes. The results are provided as a curve containing the cell index as a 
function of time (Diemert et al., 2012). 
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For using this system ~8,000 HT-22 cells or 30,000-40,000 NPCs per well were 
seeded out into 96-well E-plates. Prior to seeding of the cells, background 
impedance was determined using 100-200 μl of cell culture medium or EBSS. Next, 
cell suspension was added to a total of 100 μl/well for HT-22 neurons and 200 μl/well 
for NPCs. Treatment of cells was started when the cell index exceeded a value of 
about one. Cell index values were recorded using RTCA Software 1.2 (Roche 
Diagnostics, Penzberg, Germany). After concluding each experiment, E-plates were 
recycled by removing media, washing the plates twice with demineralised water and 
adding standard Trypsin/EDTA for 15-20 minutes. Afterwards, 1xTE was removed, 
the plates were washed a further 3 times and irradiated with UV light for 30 minutes 
to reassure sterility.  
 
2.5. Visualization and characterization of mitochondria 
Mitochondrial morphology in HT-22 cells was visualized using MitoTracker DeepRed 
(Invitrogen). HT-22 cells were seeded onto ibidi slides at least 24 hours before the 
treatment (16,000 cells/well). MitoTracker DeepRed was dissolved in DMSO at a final 
stock concentration of 50 μM and kept protected from light. For applications on cells 
MitoTracker DeepRed reagent was diluted 1:250 in culture medium (final working 
concentration 200 nM) together with DAPI (1 μg/ml) for counterstaining of the nuclei. 
Staining solution was added to the cells for 20 minutes before starting the respective 
treatment. After completing the experiment, cells were washed with PBS, fixed with 
4 % paraformaldehyde (PFA) and washed again twice with PBS. Images were taken 
using a confocal laser scanning microscope running LSM Image Software (Axiovert 
200, Carl Zeiss, Jena, Germany). MitoTracker DeepRed fluorescence was excited at 
a wavelength of 633 nm (band pass filter) and emissions were detected using a 
670 nm long pass filter. Evaluation and classification of mitochondrial morphology 
was performed as described before (Grohm et al., 2010). Mitochondria were counted 
manually and categorized in 3 groups, depending on the degree of fragmentation: 
Category I represents cells with intact tubular network with elongated mitochondria 
that is found in cells under control conditions. Category II and III indicate an 
increasing number of fragmented mitochondria. Mitochondrial fragmentation was 
accompanied by an apoptotic phenotype, showing nuclear condensation and the 
peri-nuclear accumulation of the mitochondrial fragments. For the quantification of 
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mitochondrial morphology, at least 500 cells per condition were counted blind to 
treatment conditions in at least four independent experiments. 
 
2.6. ATP assay 
ATP levels can be detected by a method using the luciferase enzyme that catalyzes 
the following reaction: 
 
  ATP + Luciferin + O2       →     Oxyluciferin + AMP + PPi + CO2 + Light. 
 
For this assay 8,000 transfected HT-22 cells were seeded in each well of a white   
96-well plate (Greiner Bio one, Frickenhausen, Germany) for luminescence 
measurements 48 hours after the transfection. Twenty-four hours after seeding, cells 
were treated with glutamate. ATP levels were detected at indicated time points after 
the onset of glutamate exposure by detection of luminescence using the ViaLight 
MDA Plus-Kit (Lonza, Verviers, Belgium). The cells were treated with nucleotide 
releasing reagent and incubated for 5 minutes at room temperature. Afterwards, ATP 
monitoring reagent was injected into each well and luminescence was detected 
immediately (FluoStar, BMG Labtech, Offenburg, Germany). The emitted light 
intensity was measured for quantification of ATP levels. The values are given as 
relative values in percentage of control levels. 
 
2.7. Detection of lipid peroxides 
For detection of cellular lipid peroxidation BODIPY 581/591 C11 (Invitrogen) was 
used.  BODIPY is a sensitive fluorescent reporter for lipid peroxidation, undergoing a 
shift from red to green fluorescence emission upon oxidation of the phenylbutadiene 
segment of the fluorophore. This oxidation-dependent emission shift enables 
fluorescence ratio imaging of lipid peroxidation in living cells. For detection of cellular 
lipid peroxidation cells were loaded with 2 mM BODIPY solution for 60 minutes in 
standard medium at indicated time points after glutamate treatment. Cells were 
harvested, washed and resuspended in PBS. Flow cytometry was performed using 
488 nm UV line argon laser for excitation and BODIPY emission was recorded at 
530 nm (green) and 585 nm (red) by flow cytometry on a FACScan (BD Bioscience, 
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Heidelberg, Germany). Data were collected from at least 100,000 cells in three 
independent experiments. 
 
2.8. Detection of mitochondrial membrane potential 
For detection of the MMP in whole cells the Mito PT ∆Ψm kit (Immunochemistry 
Technologies, Hamburg, Germany) was used. The kit contains tetramethylrhodamin 
ethal ester (TMRE) which is a lipophilic, cationic fluorescent redistribution dye. This 
dye has a delocalized positive charge dispersed throughout its molecular structure. 
Its lipophilic solubility allows TMRE to penetrate into living cells and into 
mitochondria. Using this kit non-apoptotic cells with healthy mitochondria appear red, 
whereas apoptotic cells show decreased red fluorescence. HT-22 cells were cultured 
in 24-well plates and treated with glutamate 48 hours after transfection. When cell 
death occurs in glutamate-treated controls, the cells were incubated for 20 minutes at 
37°C with TMRE. Afterwards, the cells were collected, washed with PBS and 
suspended in assay buffer. To exclude autofluorescence of the cells a non-treated 
negative control that was not stained by TMRE was prepared. Flow cytometry was 
performed using excitation at 550 nm and detecting emission at 570 nm. Data were 
collected from at least 10,000 cells from at least four independent experiments. 
For detection of the MMP in isolated mitochondria DIOC6(3) fluorescence-based 
assay was performed by Dr. Amalia Dolga. Isolated 25-50 µg mitochondria were 
incubated with 20 nM DIOC6(3) dye. As a positive control for a complete loss of 
MMP, CCCP (50 µM) protonophore was applied on intact mitochondria. MMP was 
analyzed by a FLUOstar Optima fluorescence plate reader using 485 nm excitation 
and 520 nm emission. Measurements were performed in triplicate and are 
representative of at least three independent experiments. 
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2.9. Protein analysis 
2.9.1. Buffers for Western blot analysis 
Following buffers were used for sodium dodecyl sulfate (SDS) gel electrophoresis 
and Western blot analysis:  
 
Stacking gel 3.5 % 
0.5 M Tris HCl solution pH 8.8    2.5 ml 
Acrylamid/bisacrylamide (37.5 : 1) 30 %  1.2 ml 
SDS solution 10 %      0.1 ml 
Ammoniumpersulfate solution 10 %   0.05 ml 
Tetramethylethylenediamine (TEMED)   0.01 ml 
Aqua demin.      ad 10 ml 
 
Collection gel 12.5 % 
1.5 M Tris HCl solution pH 8.8    2.5 ml 
Acrylamid/bisacrylamide (37,5:1) 30 %   3.34 ml 
SDS solution 10 %      0.1 ml 
Ammoniumpersulfate solution 10 %   0.05 ml 
TEMED       0.01 ml 
Aqua demin.      ad 10 ml 
 
5x sample buffer Western blot 
1M Tris-HCl pH 6.8     70 ml 
Glycerol       30 ml 
D,L-Dithiotreitol (DTT)     9.3 g 
SDS        10 g 
β-Mercaptoethanol      1 ml 
Bromophenol blue sodium salt    12 mg 
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1 x Electrophoresis buffer 
Tris base       3 g 
Glycine       14.4 g 
SDS        1 g 
Aqua demin.      ad 1000 ml 
 
1x Transfer buffer, pH 8.3 
Tris base       3 g 
Glycine       14.4 g 
Methanol       100 ml 
HCl 0.1 M       q.s 
Aqua demin.      ad 1000 ml 
 
1x TTBS, pH 7.5 
Tris Base       2.4 g 
NaCl        29.2 g 
HCl 0.1 M       q.s. 
Aqua demin.      ad 10 ml 
 
1x Blocking buffer 
Skim milk powder      25 g 
TBST        ad 500 ml 
 
Stripping buffer, pH 2 
Glycine       15 g 
SDS        1 g 
Tween 20       10 ml 
HCl conc.       q.s. 
Aqua demin.      ad 1,000 ml 
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2.9.2. Protein preparation and mitochondria isolation 
For obtaining total cell protein extracts HT-22 cells were seeded into 24-well cell 
culture plates (Greiner Bio one). Cells were washed with PBS, detached with a cell 
scraper and lysed with 100 ml lysis buffer containing mannitol 0.25 M, Tris 0.05 M, 
EDTA 1 M, EGTA 1 M, DTT 1 mM, triton-X 1 % (all from Sigma-Aldrich), 
supplemented with Complete Mini Protease Inhibitor Cocktail (Roche) (1 tablet per 
10 ml). The lysate was frozen at -80°C until further use. To remove insoluble 
membrane fragments, extracts were centrifuged at 13,000 x g for 15 minutes at 4°C 
after thawing.  
For mitochondria isolation and mitochondrial enriched extracts, cells were cultivated 
in 24-well cell culture plates (Greiner Bio one). Cells were detached using 1x TE and 
centrifuged at 1,000 rpm for 5 minutes. After washing the cells once with PBS cells 
were lysed in a buffer containing 250 mM sucrose (Merck, Darmstadt, Germany), 
20 mM HEPES (Sigma-Aldrich), 3 mM EDTA (Sigma-Aldrich) supplemented with 
Complete Mini Protease Inhibitor Cocktail (1 tablet for 10 ml buffer, pH 7.5). Cells 
were disrupted using a glass douncer (25 passes) followed by 15 passes with a 20G 
needle. After centrifugation at 900 x g for 10 minutes supernatant was collected and 
the pellet was disrupted a second time in the same way. After second centrifugation, 
the collected supernatant was centrifuged at 16,800 x g for 10 minutes and the 
resulting pellet was suspended in fresh buffer. For pure extracts the pellet was 
washed three times in buffer or EBSS depending on the experiment. 
 
For determining the amount of protein in the probes the principle of bicinchonic acid 
(BCA) assay was used. The assay is based on two reactions. First, the peptide 
bonds in proteins reduce Cu2+ ions to Cu+ under alkaline conditions. The amount of 
reduced Cu2+ is proportional to the amount of protein present in the solution. This is 
followed by formation of a purple-colored chelate complex of BCA with Cu+ ions. The 
macromolecular structures of the protein, the amount of peptides, and the four amino 
acids cysteine, cystine, tryptophan, and tyrosine are responsible for this color 
reaction of the BCA. This provides a basis to monitor the reduction of alkaline Cu2+ 
by proteins and, thus, determine the protein concentration in biochemical samples 
and cell extracts (Walker, 1994).  
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Protein amounts in extracts were determined using the Pierce BCA kit (Perbio 
Science, Bonn, Germany). To this end, 5 μl of each sample were diluted in 95 μl 
1x PBS. A standard curve containing 0 - 150 μg bovine serum albumin (BSA) (Perbio 
Science, Bonn, Germany) per 100 μl, 5 μl of the respective lysis buffer, and 1x PBS 
add to 100 μl was prepared. Next, 200 μl of a 1:50 mixture of reagent B : reagent A 
(Perbio Science, Bonn, Germany) was added to each sample. Samples were 
incubated for 30 minutes at 60°C.  At this temperature, peptide bonds assist in the 
formation of the reaction product, so the assay sensitivity is increased since the 
variances caused by unequal amino acid composition are minimized. One hundred μl 
of each sample were pipetted into a 96-well plate (Nunc, Wiesbaden, Germany). 
Absorption at 590 nm was determined using a microplate reader (Fluostar OPTIMA, 
BMG Labtech, Offenburg, Germany) and protein amounts of the test samples were 
calculated from the standard curve. 
 
2.9.3. Gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) has been 
used to separate proteins according to their different molecular mass. Gels were 
prepared using BIO-RAD gel casting stand and casting frames. Gels were prepared 
using a separation gel with a concentration of 12.5 % polyacrylamide and a stacking 
gel with 3.5 % polyacrylamide. The specific buffers used for the generation of gels 
and subsequent electrophoresis are provided in 2.9.1.. Prior to electrophoresis, 
samples were prepared using 20-30 μg of raw protein extract and adding 5 x SDS 
sample buffer. Samples were heated at 90°C for 10 minutes and loaded to the gel 
after reaching room temperature. For comparative evaluation of molecular mass, 5 μl 
of PageRulerTM Plus Prestained Ladder (Fermentas, St. Leon-Rot, Germany) were 
loaded next to the samples. Electrophoresis was performed initially at 60 V for about 
30 minutes to allow for sample collection and increased later to 120 V. Following 
electrophoretic separation, proteins were blotted on a polyvinylidenfluorid membrane 
(PVDF, Bio-Rad, Munich, Germany) according to the recommendations by Bio-Rad 
at 15 V for 60 minutes. PVDF membranes were first activated in methanol and then 
incubated for 10 minutes in 1 x transfer buffer before blotting. Meanwhile, Whatman 
blotting paper and the acrylamide gel were incubated for 10 minutes in transfer 
buffer. Blotting was carried out by stacking one layer of Whatman paper on top of the 
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anodic plate, followed by the PVDF membrane, the acrylamide gel as the third, and 
another final layer of Whatman paper on top. Blotting was carried out in a Trans-Blot 
SD semi-dry transfer cell (Bio-Rad, Munich, Germany) using extra thick Whatman 
filter paper (Bio-Rad, Munich, Germany) and 1x transfer buffer. After blotting the 
PVDF membranes were transferred directly into blocking buffer and incubated for 
1 hour at room temperature. Afterwards, blots were probed with the primary 
antibodies (diluted in blocking buffer) overnight at 4°C. The next day, membranes 
were washed three times with TBST for 5 minutes and probed with the appropriate 
HRP-conjugated secondary antibody in blocking solution for 1 hour. After washing 
3 times with TBST for 15 minutes each, membranes were incubated with 
chemiluminescent substrate solution HRP-Juice (PJK GmbH, Kleinblittersdorf, 
Germany). Chemiluminescent signals were recorded and quantified by densitometric 
analysis using the semi-automated Chemidoc-XRS Imaging System and the 
dedicated Quantity One software package (both, Bio-Rad, Munich, Germany). 
Alternatively, towards blotting, some gels were stained by Coomassie Blue R250. 
Here, the gel was incubated for 1 hour in Coomassie staining solution containing 
0.1 % R250, 45 % methanol, 45 % aqua demin. and 10 % pure acetic acid. 
Afterwards, the gel was discolored overnight in destaining solution containing 30 % 
methanol, 10 % pure acetic acid and 60 % aqua demin., until single bands were 
visible. 
 
2.10. RNA analysis 
2.10.1. RNA preparation 
For RNA extraction HT-22 cells were grown in 24-well plates at an average density of 
60,000 cells/well. RNA extracts were prepared using the Nucleo Spin II Kit 
(Macherey und Nagel, Düren, Germany) according to the manufacturer’s instructions. 
Briefly, HT-22 cells were washed with PBS and harvested in cell lysis buffer R1 
supplemented with 1 % β-mercaptoethanol. For each group, 2-4 wells were pooled to 
gain appropriate amounts of mRNA. Before continuing with the extraction, all 
samples were shock-frozen in liquid nitrogen and left to thaw slowly on ice. Next, the 
raw extracts were filtered through Nucleospin-RNA II columns to remove cellular 
debris. The supernatant was supplemented with ethanol, mixed carefully and loaded 
on a NucleoSpin RNA II column to extract nucleic acids by adsorption to the silica 
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matrix of the column. Excessive electrolytes were removed by washing with MDB 
buffer (supplied with the kit). To remove possible contaminations with genomic DNA 
recombinant DNAse was added. Further, purification of the column-bound RNA was 
achieved by subsequent purification, using RA2 and RA3 buffers. RNA was eluted in 
RNAse free water supplied with the Nucleo Spin Kit II. RNA-concentration was 
determined by UV-Vis absorption spectroscopy at 260 nm. For intermediate storage 
RNA-extracts were transferred to the -80°C freezer. 
 
2.10.2. RT-PCR 
Following RNA purification, mRNA was amplified using the Super Skript III OneStep 
PCR kit with Platinum Taq supplied by Invitrogen. Sequence specific primers were 
used as described in Table 12 in section 2.2.7. Each sample was prepared according 
to the following scheme given in Table 14-22. 
 
Table 14: ONE STEP PCR sample composition AIF, HSP 60, HSP 70, HSP 90, prdx-1, 
prdx-2, prdx-5, prdx-6, PLA 2, eEF 2 
2x reaction buffer 12.5 μl 
Sample (0.1 μg) x μl  
fw primer (10 μM) 0.5 μl 
rv primer (10 μM) 0.5 μl 
SuperScript III enzyme 1 μl 
Nuclease free water added to a final volume of 25 μl. 
 
Table 15: ONE STEP PCR sample composition GAPDH 
2x reaction buffer 12.5 μl 
Sample (0.1 μg) x μl 
fw primer (5 μM) 1 μl 
rv primer (5 μM) 1 μl 
SuperScript III enzyme 0.5 μl 
Nuclease free water added to a final volume of 25 μl. 
 
For amplification the following cycler programs were used. 
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Table 16: ONE-Step PCR cycler program – murine GAPDH 
60° C 30 min 
95° C 2 min 
95° C 30 sec 
57° C 1 min  20-25 cycles 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
Table 17: ONE-Step PCR cycler program – murine AIF 
60° C 30 min 
95° C 2 min 
95° C 30 sec 
57° C 1 min  30 cycles 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
Table 18: ONE Step PCR cycler program - murine prdx-1 
60° C 30 min 
95° C 2 min 
95° C 30 sec 
56° C 1 min  25 cycles 
70° C 2 min 
70° C 10 min 
4° C ∞ 
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Table 19: ONE Step PCR cycler program - murine prdx-2, prdx-5, eEF 2, HSP 90 
60° C 30 min 
95° C 2 min 
95° C 30 sec 
63° C 1 min  20 cycles 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
Table 20: ONE Step PCR cycler program - murine prdx-6, PLA 2 
60° C 30 min 
95° C 2 min 
95° C 30 sec 
64.1° C 1 min 27 cycles 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
Table 21: ONE Step PCR cycler program - murine HSP 60 
60° C 30 min 
95° C 2 min 
95° C 30 sec 
61.3° C 1 min  20 cycles 
70° C 2 min 
70° C 10 min 
4° C ∞ 
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Table 22: ONE Step PCR cycler program - murine HSP 70 
60° C 30 min 
95° C 2 min 
95° C 30 sec 
63° C 1 min  27 cycles 
70° C 2 min 
70° C 10 min 
4° C ∞ 
 
2.10.3. Agarose gel electrophoresis 
For visualization PCR products were analyzed by agarose gel electrophoresis and 
subsequent detection by SYBR Gold (Invitrogen) an intercalating agent that 
increases its fluorescent emission upon DNA binding. For gel preparation, agarose 
(1.5 %, Sigma-Aldrich) was suspended in tris/borate/EDTA (TBE) buffer (10 x stock, 
Invitrogen) and dissolved by heating up the suspension in a microwave oven. After 
dissolving, 2 µl of SYBR Gold was added into 100 ml suspension, stirred carefully 
and the solution was filled into the gel cartridge to allow gel formation. For 
subsequent gel loading, a comb was inserted into the gel, to generate the pockets. 
Samples were loaded using 1-5 μl of PCR product, 2 μl of Blue Juice sample buffer 
(Sigma Aldrich) added with nuclease-free water up to a total volume of 7 μl. In 
addition to the samples 4 μl of a pre-prepared 100 bp reference marker (Fermentas, 
St. Leon-Roth, Germany) was loaded on the gel. Electrophoresis was conducted at 
100 V for about 1 hour. Stained PCR products were detected by UV light excitation 
and fluorescent emission using the Chemidoc Imaging System (Bio Rad, Munich, 
Germany). Pictures were taken and analyzed using Quantitiy One software (Bio-Rad, 
Munich, Germany). 
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2.11. Isolation of apoptotic bodies 
Isolation of apoptotic bodies was performed following a protocol by Hristov et al. 
(Hristov et al., 2004). CM was collected and clarified from cell debris by centrifugation 
at 800 x g for 10 minutes. Afterwards, the medium was further centrifuged at 
16,000 x g for 20 minutes to isolate the apoptotic bodies and to obtain apoptotic 
bodies-depleted medium. The pellet was resuspended in EBSS. 
 
2.12. ELISA assay 
To determine the concentration of prdx-1 in CM a mouse peroxiredoxin-1 ELISA kit 
(Hölzel Diagnostika GmbH, Cologne, Germany) was used. This assay employs the 
quantitative sandwich enzyme immunoassay technique. All reagents were brought to 
room temperature before using the kit. Prdx-1 standard solution was freshly prepared 
for every experiment. One hundred μl of samples and standards were added into the 
microwells of the assay plate, which was pre-coated with a specific prdx-1 antibody. 
Afterwards, the plate was covered with adhesive stripes and incubated at 37°C for 
1 hour. The liquid of each well was removed and 100 μl of biotin antibody was added. 
After covering the wells the plate was incubated for 1 hour at 37°C. Each well was 
aspirated and washed three times with 200 μl wash buffer. Next, 100 μl of 
horseradish peroxidase (HRP)-avidin was pipetted into each well and the plate was 
incubated for another hour at 37°C. The liquids were removed and wells were 
washed 5 times with wash buffer. The plate was incubated with 90 μl of TMB 
substrate for 15-30 minutes protected from light until the blue color developed. The 
reaction was stopped by adding 50 μl of stop solution to each well. The optical 
density was determined immediately using a microplate reader (Infinite M200, Tecan 
Group Ltd., Männedorg, Switzerland) set to 450 nM. Wavelength correction was set 
to 540 nm and readings at 540 nm were subtracted from the readings at 450 nm. 
This subtraction corrects the optical imperfections within the plate. Concentrations of 
prdx-1 in CM were calculated by a linear regression fit of the measurements of the 
standards. 
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2.13. MALDI-TOF analysis 
MALDI-TOF analysis was performed by Jörg Kahnt from the Max-Planck-Institute, 
Marburg. Probes were concentrated by Amicon Ultra 10,000 MWCO filtration 
(Millipore, MA, USA) at 4,300 U/min. Samples were digested with sequencing-grade 
modified trypsin (Promega) and the resulting peptide mixtures were analyzed by 
nanoLC (PepMap100 C-18 RP nanocolumn and UltiMate 3,000 liquid 
chromatography system, Dionex) and automated MSMS (4800 Proteomics Analyzer 
MDS Sciex). MSMS data were searched against an in-house Mus musculus protein 
database using Mascot embedded into GPS explorer software (MDS Sciex). For 
interpretation, focus was on the peptides found with a total ion score higher than 45 
and at least 2 peptide counts. Findings with ion scores higher than 45 and lower than 
two peptide counts are listed for completeness. The ion score for an MSMS match is 
based on the calculated probability, that the observed match between the 
experimental data and the database sequence is a random event. The reported 
score is -10Log(P). So, during a search, if 1,500 peptides fell within the mass 
tolerance window about the precursor mass, and the significance threshold is chosen 
to be 0.05, this would translate into a score threshold of 45. For interpretation 
fragmentation patterns were determined using BLAST search in Pubmed database 
(www.ncbi.nlm.nih.gov/blast). 
 
2.14. Aceton precipitation 
For aceton precipitation fresh CM was mixed with the 4-fold amount of cold aceton 
(Roth, Karlsruhe, Germany) and kept at -20°C over night. The next day the solution 
was centrifuged at 13,000 x g, at 4°C for at least 30 minutes. Supernatant was 
removed and the pellet resuspended in EBSS. For investigation of the supernatant 
aceton was removed by evaporation at 40°C. 
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2.15. Cut off filtration 
For size exclusion filtration CM or control media was filtrated through a 0.22 µM 
cellulose filter to remove dead cells and cell debris. Afterwards, media was 
centrifuged through a 3 kDa, 10 kDa, or 50 kDa cut off filter (Millipore, Schwalbach, 
Germany) at 4,000 rpm, at 4°C until concentrate volume was below 500 µl. The 
concentrates were stored at -80°C till further use. 
 
2.16. Digestion of CM 
For RNA digestion 70 Kunits Ribonuclease A (Sigma-Aldrich) per mg protein was 
used. To get an optimal digestion CM and ribonuclease were kept at 60°C for 
30 minutes before treating the cells.  
For protein digestion, Protease (Qiagen) was used in a concentration of 45 mAU per 
mg protein. Digestion was performed at 37°C for 30 minutes. Afterwards, the 
protease was inactivated by heat at 70°C for at least 1 hour. 
 
2.17. Preparation of cell lysates 
For cell lysates NPC or SNL feeder cells were washed with PBS and resuspended in 
1 ml EBSS. If not described otherwise cells were lysed by a Digital Sonifier® (VWR, 
Darmstadt, Germany) for 2 minutes in a 1 second sonification 1 second break 
interval at an amplitude of 20 % on ice. The lysate was diluted to the final volume 
with EBSS.  
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2.18. Dialysis and lyophilisation  
For dialysis CM, heated at 60°C for 10 minutes was filled into a Spectra/Por® dialysis 
tube (MWCO 6,000-8,000) (Serva electrophoresis, Mannheim, Germany) and 
incubated at 4°C overnight in 1 liter aqua demin.  
For lyophilization the sample was filled into a vented tube and put into a LDC-1 m 
Alpha 1-4 freeze dryer (Martin Christ GmbH, Osterode, Germany) under vacuum 
overnight until volume was constricted to ~ 0.5-1 ml. Further dilutions were done with 
EBSS. 
 
2.19. Gel filtration by Äkta analysis 
For SDS gel filtration of CM ÄKTAprime plus (GE Healthcare, Munich, Germany) was 
used with PrimeView 5.0 software. Five ml CM were loaded onto a HiLoadTM 16/600 
SuperdexTM 75 pg column. The column was washed with 120 ml aqua demin. and 
120 ml EBSS before loading. The fractions were collected in volumes of 7 ml and 
stored at -80°C until further use. The applied program is listed in Table 23. 
 
Table 23: Program for ÄKTAprime plus 
Action Breakpoint Volume 
[ml] 
Flow rate 
[ml/min] 
Fraction 
size [ml] 
Inject valve 
position 
Equilibration 1 0 1 0 Load 
Sample injection 2 15 1 0 Inject 
Wash 3 20 1 7 Load 
Elution 4 45 1 7 Load 
Re-equilibration 5 170 1 7 Load 
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2.20. Statistical analysis 
All data are presented as means ± standard deviation (S.D.). For statistical 
comparison between two groups Mann-Whitney-U-test was used. For statistical 
comparisons between treatment groups analysis of variance (ANOVA) was 
performed followed by Scheffé’s post hoc test. Calculations were performed with the 
Winstat standard statistical software package (R. Fitch Software, Bad Krozingen, 
Germany).
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3. Results 
3.1. AIF deficiency mediates neuroprotection through a 
preconditioning effect 
3.1.1. AIF gene silencing by siRNA attenuates glutamate toxicity 
Downregulation of AIF in HT-22 neurons was achieved using different sequences of 
AIF-targeting siRNA (AIF siRNA 1, AIF siRNA 12, and AIF siRNA 2). AIF siRNA 12 
showed no reduction of AIF expression on mRNA level whereas AIF siRNA 1 and 2 
significantly reduced AIF expression at the mRNA level (Figure 4). Thus, 
AIF siRNA 12 was not used for further experiments. The AIF knockdown achieved 
with sequences 1 and 2 was further verified by Western blot analysis (Figure 4). 
 
 
 
 
 
Figure 4: AIF silencing by different AIF siRNA sequences. 
AIF knockdown was verified by RT-PCR and Western blot analysis 72 hours after transfection. AIF 
expression of AIF siRNA (20 nM) transfected cells was compared to non-transfected control cells and 
cells treated with scrambled (scr) siRNA (20 nM). 
 
AIF silencing significantly attenuated glutamate-induced apoptosis in HT-22 neurons. 
HT-22 cells exposed to glutamate for 11-18 hours showed typical morphology of cell 
death: the neuronal cells appear rounded and shrunken, and detached from the 
culture dish, whereas cells pretreated with AIF siRNA preserved their normal spindle-
shaped morphology and were rescued from glutamate-induced apoptosis 
(Figure 5 A). Cell viability was quantified using the MTT assay, which confirmed the 
protective effect of AIF siRNA 1 and 2 (Figure 5 B, C). Further, real-time detection of 
cell death was performed by cell impedance measurements over at least 15 hours 
with the xCELLigence system, which revealed delayed cell death in AIF-silenced 
cells. The most pronounced protective effects were achieved with transfection of AIF 
siRNA 2, which showed sustained protection against cell death and proliferation over 
time similar to control cells transfected with scrambled siRNA (Figure 5 E). In 
contrast, AIF siRNA 1 provided only transient protective effects with a delay of cell 
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death of 1-2 hours compared to controls exposed to glutamate (Figure 5 D). 
However, time of protection varied in the experiments depending on the sensitivity, 
passage, and density of the HT-22 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: AIF knockdown by different AIFsiRNA sequences attenuates glutamate toxicity.  
A: AIF siRNA (20 nM) prevents glutamate-induced (5 mM, 12 h) apoptosis. 100 x magnitude. B: MTT 
assay confirms the protective effect of AIF depletion by AIF siRNA 1 (20 nM) following glutamate 
exposure (5 mM, 11 h) (n = 7; *** p < 0.001, compared to glutamate-treated control and scrambled 
(scr) siRNA). C: MTT assay 72 hours after transfection shows protective effect of AIF siRNA 2 (20 nM) 
towards glutamate exposure (3 mM, 12 h) (** p < 0.01; n = 6, compared to glutamate-treated control 
and scrambled (scr) siRNA). All statistics were obtained using ANOVA, Scheffé test. 
D, E: xCELLigence real-time impedance measurement: HT-22 cells were treated with glutamate (glut, 
3 mM) 72 hours after transfection. D: AIF siRNA 1 (20 nM) shows short transient protective effect 
against glutamate-induced cell death compared to cells transfected with scrambled (scr) siRNA          
(n = 5). E: AIF siRNA 2 (20 nM) shows stronger protection over time (n = 8).  
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3.1.2. AIF siRNA preserves mitochondrial integrity and function from 
glutamate damage 
In order to investigate if the protective effect of AIF deficiency was attributed to a 
preconditioning effect at the level of mitochondria, mitochondrial morphology and 
function were examined. Neurons exposed to glutamate toxicity show disturbed 
mitochondrial morphology dynamics resulting in detrimental mitochondrial 
fragmentation (Grohm et al., 2010). Under standard culture conditions, HT-22 cells 
predominantly expose elongated mitochondria with a tubular network, which are 
equally distributed throughout the cytosol. This morphology is described as 
category I. Category II contains cells that are still viable and mitochondria which are 
already partly fragmented resulting in short tubules and small round fragments. In 
contrast, cells of category III contain mitochondria which are highly fragmented and 
accumulate close to the nucleus. In addition, cells of category III show signs of cell 
death such as pyknotic nuclei.  
The increased rate of mitochondrial fission in damaged HT-22 cells as well as peri-
nuclear accumulation of the organelles after exposure to glutamate was prevented by 
AIF siRNA 1 and 2 (Figure 6). AIF-silenced HT-22 cells receiving glutamate showed 
significantly reduced category III mitochondria compared to control cells and cells 
transfected with scrambled siRNA treated with glutamate. The amount of category I 
mitochondria in AIF-depleted cells exposed to glutamate and in untreated controls 
was similar. This result suggests that the protective mechanism underlying AIF 
deficiency occurs before the release of AIF from the mitochondria into the cytosol. 
To prove this conclusion, the formation of lipid peroxides was investigated, which is 
associated with irreversible mitochondrial damage and increased ROS production. 
AIF-silenced cells showed significantly reduced production of lipid peroxides 
compared to controls exposed to glutamate and significantly attenuated the 
secondary increase in lipid peroxidation that was associated with mitochondrial 
damage and cell death in this model system (Cregan et al., 2002) (Figure 7 A). 
Again, AIF siRNA 2 mediated stronger protective effects compared to AIF siRNA 1, 
and also showed protective effects after 11 hours of glutamate treatment, whereas 
cells transfected with AIF siRNA 1 already showed an increase in lipid peroxides 
9 hours after glutamate treatment. For that reason AIF siRNA 2 was used for further 
investigations. 
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Figure 6: AIF gene silencing provides 
mitochondrial fission.  
A: Fluorescence photomicrographs show that 
AIF siRNA (20 nM) prevents the fission of 
mitochondria in glutamate-exposed (3 mM, 
14 h) HT-22 neurons. Cells were stained with 
MitoTracker DeepRed 30 minutes before the 
glutamate treatment. Bar scale 20 µm. 
B: Quantification of mitochondrial morphology: 
Category I (Cat I): fused, Category II (Cat II): 
intermediate, Category III (Cat III): fragmented 
mitochondria; at least 500 cells were counted 
per condition blind to treatment conditions. 
Values are given from six independent 
experiments (### p < 0.001 compared to 
category I glutamate-treated control and 
scrambled (scr) siRNA; *** p < 0.001 
compared to category III glutamate-treated 
control and scrambled (scr) siRNA). Statistics 
were obtained using ANOVA, Scheffé test. 
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Further, ATP levels were examined after glutamate exposure to assess the functional 
integrity of mitochondria in AIF-depleted cells. Since cell injury results in a rapid 
decrease in cytoplasmic ATP levels the aim was to find out if the AIF-depleted cells 
show alterations in ATP levels in the absence or presence of toxic glutamate 
concentrations. In both cases, ATP levels of AIF-silenced cells were similar to the 
ATP levels in non-treated control cells and cells transfected with scrambled siRNA 
(Figure 7 B). The endpoint for the experiment was assessed for the glutamate-
treated control cells starting with the onset of cell morphology alteration and 
culminating in cell detachment and death (Diemert et al., 2012;Tobaben et al., 2011).  
In addition, the MMP was investigated in control cells compared to AIF-silenced cells. 
Under standard culture conditions, AIF-depleted cells showed significantly lower 
MMP than control cells (Figure 7 C). Further, TMRE staining revealed that glutamate 
toxicity in non-silenced control cells was associated with pronounced MMP whereas 
AIF-depleted cells showed significantly higher MMP at the same time point. Carbonyl 
cyanide chlorophenylhydrazone (CCCP) was applied at the end of the experiment as 
a positive control for a complete loss of MMP. Further, the slight depolarization under 
control conditions was verified by DIOC6(3) measurements in isolated mitochondria. 
These measurements were performed by Dr. Amalia Dolga (Figure 15 D, 
chapter 3.1.6.). 
Taken together, these results suggest a preconditioning effect by AIF depletion which 
protects HT-22 cells against glutamate toxicity at the level of mitochondria.  
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Figure 7: AIF siRNA preserves mitochondrial integrity. 
A: Lipid peroxides were measured by BODIPY FACS analysis at indicated time points following 
glutamate treatment (5 mM). Values are given from three independent experiments; ** p < 0.01; 
*** p < 0.001 compared to glutamate-treated (7 h) control and scrambled (scr) siRNA; ### p < 0.001, 
compared to glutamate-treated (9 h) control and scrambled (scr) siRNA; * p < 0.05 compared to 
glutamate-treated control (11 h). B: Forty-eight hours after transfection cells were seeded into 96-well 
plates. Following 24 hours cells were treated with glutamate (3 mM) for 11 hours. ATP levels from AIF-
depleted cells (20 nM) were preserved from loss in ATP levels (n = 6; ** p < 0.01 compared to 
glutamate-treated control cells and scrambled (scr) siRNA). C: MMP, measured by TMRE, is protected 
from glutamate toxicity (3 mM, 15 h). In AIF-depleted cells MMP is significantly depolarized. Values 
are given from six independent experiments; ### p < 0.001; ## p < 0.01 compared to untreated control 
cells and scrambled (scr) siRNA; *** p < 0.001 compared to glutamate-treated control cells and 
scrambled (scr) siRNA. All statistics were obtained using ANOVA, Scheffé test. 
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3.1.3. ROS inhibition has no effect on neuroprotection mediated by 
AIF gene silencing  
Preconditioning effects are often described to promote minor decreases in the 
efficiency of NADH oxidation by the respiratory chain, which increases mitochondrial 
ROS release followed by activation of mitoKATP channels (Busija et al., 
2008;Dirnagl and Meisel, 2008;Jou, 2008;Ravati et al., 2000;Ravati et al., 
2001). To investigate whether this mechanism was also consistent in the applied 
model system, cells were treated with the antioxidant trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid), which should reduce the protective effect of 
siRNA if resulting from a slight increase in ROS levels. Since trolox alone prevented 
HT-22 cells from glutamate-induced cell death the experiment was performed with a 
trolox pretreatment starting with the transfection followed by a washout 24 hours 
before the glutamate treatment (Figure 8 A). In this way, overlapping protective 
effects of AIF silencing and trolox were avoided. The trolox pretreatment did not 
change the protection against glutamate toxicity mediated by AIF siRNA 2 
(Figure 8 B). This result was in accordance with the fact that lipid peroxide levels 
remained unchanged in AIF-silenced HT-22 cells (chapter 3.1.2.).  
These results suggest that increased ROS production in AIF-depleted cells is not the 
major mechanism of the observed preconditioning effect. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Trolox pretreatment does not affect neuroprotection mediated by AIF deficiency. 
A: HT-22 cells were pretreated with trolox (100 µM). Forty-eight hours later the cells were seeded in a 
96-well plate. The following day cells were treated with glutamate. Trolox was removed at different 
time points before glutamate treatment (3 mM; 13 h) (∆ = time between trolox washout and glutamate 
treatment; n = 8). *** p < 0.001, ** p < 0.01 compared to glutamate-treated control cells. B: Trolox 
pretreatment (100 µM, 48 h; ∆ = 24 h) did not affect neuroprotection mediated by AIF siRNA 2 (n = 8). 
*** p < 0.001, ** p < 0.01 compared to glutamate-treated (3 mM, 11 h) control cells and scrambled 
(scr) siRNA. Statistics were obtained using ANOVA, Scheffé test. 
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3.1.4. AMPK is not affected in the AIF deficiency model system of 
HT-22 cells 
AMPK is a serine/threonine kinase containing a catalytic α subunit and regulatory β 
and γ subunits. Under stress conditions energy is consumed and AMPK activation 
leads to altered cellular metabolism and gene expression to inhibit anabolic 
processes, stimulate catabolism, and restore ATP levels (Ronnett et al., 2009). In 
2007 Pospisilik et al. demonstrated that AMPK is activated in muscle-specific AIF 
knockout mice without apparent changes in AMPK protein expression (Pospisilik et 
al., 2007). Thus, it was investigated here, whether AIF gene silencing in HT-22 
neurons mediated neuroprotection through AMPK regulation. The AMPK activator 
AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) significantly 
attenuated glutamate toxicity in HT-22 cells in a concentration-dependent manner 
(Figure 9 A). However, AICAR also exerted slightly toxic effects under control 
conditions and reduced cell proliferation (Figure 9 A, B). In combination with AIF-
silenced neurons AICAR did not affect the protective effect of AIF depletion 
(Figure 9 C) but the proliferation rate was decreased as detected by the 
xCELLigence system (Figure 9 B).  
Interestingly, AMPK inhibition by compound C also preserved HT-22 cells in a 
concentration-dependent manner already in the µM range (Figure 10 A). 
Compound C did not show toxic effects in HT-22 cells, and the neuroprotective effect 
mediated by AIF-depleted cells was further increased by compound C 
(Figure 10 B, D).  
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Figure 9: Protective effect of AICAR 
in HT-22 cells.  
A: HT-22 cells were treated with 
different concentrations of AICAR for 
6 hours pretreatment followed by a co-
treatment with glutamate (3 mM, 13 h); 
*** p < 0.001 compared to glutamate-
treated control cells; # p < 0.05, 
### p < 0.001 compared to untreated 
control cells; n = 8. B: Real-time 
impedance measurement of HT-22 
cells transfected with AIF siRNA 2 
(20 nM) and treated with AICAR 
(5 mM, 6 h pretreatment) and 
glutamate (3 mM) (n = 5). C: Cell 
viability of AIF-depleted cells treated 
with AICAR (3 mM, 6 h pretreatment) 
followed by 10 h exposure to 
glutamate (4 mM, 10 h) was 
determined by MTT assay. * p < 0.05, 
*** p < 0.001 compared to glutamate-
treated scrambled (scr) siRNA; 
### p < 0.001 compared to glutamate-
treated AIF siRNA 2 (n = 6). All 
statistics were obtained using ANOVA, 
Scheffé test. 
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Figure 10: Compound C exerts 
additive protective effects on AIF-
depleted cells in providing 
neuroprotection against glutamate 
toxicity. 
A: HT-22 cells were treated with 
different concentrations of 
compound C (comp C) for 6 h 
pretreatment followed by a co-
treatment with glutamate (2 mM, 
11 h). *** p < 0.001, ** p < 0.01 
compared to glutamate-treated control 
cells (n = 8). B: Real-time 
measurement of HT-22 cells 
transfected with AIF siRNA 2 (20 nM) 
and treated with compound C (5 µM, 
6 h pretreatment) subsequent 
glutamate treatment (3 mM) (n = 5). 
C: Cell viability of AIF-depleted cells 
co-treated with compound C (5 µM, 
6 h pretreatment) followed by 
10 hours co-treatment with glutamate 
(4 mM, 10 h) was determined by MTT 
assay. * p < 0.05, *** p < 0.001 
compared to glutamate-treated 
scrambled (scr) siRNA; ### p < 0.001 
compared to glutamate-treated AIF 
siRNA 2 (n = 6). All statistics were 
obtained using ANOVA, Scheffé test. 
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Furthermore, Western blot analyses were performed to investigate effects of AIF 
depletion on AMPK protein expression levels. After AIF downregulation, however, 
changes in the levels of p-AMPK, which is the activated form of AMPK, or the basal 
AMPK levels were not detected (Figure 11 A). As a positive control for the antibodies, 
cell lysates of HT-22 cells treated with AICAR or compound C were used. The 
downregulation of AMPK by compound C was confirmed by Western blot. 
Interestingly, the inhibition of AMPK also mediated decreased AIF expression levels. 
After exposure to AICAR, a slight increase in p-AMPK could be detected whereas the 
basal AMPK levels remained unchanged.  
These results suggest that AMPK does not play a major role for the neuroprotective 
effects mediated by AIF depletion in the HT-22 model system.  
 
 
 
 
 
 
 
 
 
Figure 11: Western blot analysis of AMPK expression levels in HT-22 neurons. 
Protein expression levels were determined 72 hours after transfection. No changes in p-AMPK or 
AMPK levels could be detected. As control for the antibodies cells were treated with compound C 
(10 µM, 16 h) or AICAR (5 mM, 16 h).  
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3.1.5. Silencing of AIF mediates a decrease in mitochondrial 
complex I expression 
Previous studies in different model systems implied that AIF-deficiency may reduce 
levels of mitochondrial complex I (Benit et al., 2008;Vahsen et al., 2004). Thus, the 
mitochondrial complex protein expressions were detected by Western blot analysis in 
AIF-silenced HT-22 cells. AIF-depleted cells showed significantly reduced levels of 
complex I 72 hours after transfection. Other complexes of the respiratory chain were 
not significantly affected by AIF siRNA in the used cell line compared to control cells 
and cells transfected with scrambled siRNA. Interestingly, inhibition of mitochondrial 
complex I by rotenone (20 nM) was associated with slightly decreased expression 
levels of AIF (Figure 12 A, B). This suggests that mitochondrial complex I and AIF 
may regulate each other’s stability in mitochondria. Furthermore, rotenone treatment 
did not only affect complex I, but also decreased complex II, IV, and V (Figure 12 A). 
 
Figure 12: Preconditioning effect mediated 
by mitochondrial complex I down-
regulation. 
A: Western blots of mitochondrial enriched 
cell extracts (30 µg) show that AIF depletion 
leads to a downregulation of complex I 
(NDUFA 8: NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex 8) 72 hours 
after transfection. Other complexes showed 
no significant changes in their expression after 
AIF depletion (ATP 5A: ATP synthase 
(complex V); UQCRC 2: ubiquinol-
cytochrome c reductase core protein 2 
(complex III); MTCO 1: mitochondrially 
encoded cytochrome c oxidase 1 (complex 
IV); SDHB: succinate dehydrogenase 
complex, subunit B (complex II)). 
Furthermore, rotenone treatment (20 nM, 
18 h) leads to a slight decrease of AIF 
expression. B: Quantification of Western blot 
analysis. AIF and NDUFA 8 specific bands 
were normalized to TIM 23. Values are given 
as percentage of control from four 
independent experiments. *** p < 0.001, 
* p < 0.05 compared to scrambled (scr) 
siRNA; ##  p  < 0.01, ### p < 0.001 compared 
to control . 
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3.1.6. Low dose rotenone treatment preserves cells from glutamate 
neurotoxicity 
To further link the determined protective effects of AIF-deficient cells with the 
downregulation of mitochondrial complex I it was tested if inhibition of complex I by 
rotenone also resulted in a neuroprotective effect in the applied model system. The 
specific complex I inhibitor rotenone protected HT-22 cells against glutamate toxicity 
in a concentration-dependent manner as determined by the MTT assay 
(Figure 13 A). Higher concentrations of rotenone (> 50 nM) induced apoptosis in   
HT-22 neurons (Figure 13 B).  
 
   
Figure 13: Low dose rotenone leads to 
transient neuroprotective effects by 
preconditioning. 
A: MTT assays show that rotenone (10 nM 
and 20 nM) is able to protect HT-22 cells from 
glutamate-induced (3 and 5 mM, 13 h) cell 
death (n = 8; *** p < 0.001 compared to 
glutamate-treated control (3 mM); ## p < 0.01 
compared to glutamate-treated control 
(5 mM); ANOVA, Scheffé test). B: Cells 
treated with higher doses of rotenone (50 nM, 
200 nM, and 500 nM, 15 h) undergo 
apoptosis. (n = 8; **p < 0.01; ***p < 0.001; 
ANOVA, Scheffé test). C: HT-22 cells were 
plated on a 96-well E-plate and cellular 
impedance was continuously monitored by the 
xCELLigence system. Cells were pretreated 
with rotenone 20 mM for 9 hours. After 
washout of rotenone pretreated cells showed 
a transient protective effect against glutamate-
induced cell death (3 mM) (n = 6). 
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Similar to AIF-silencing the neuroprotective effect was just transient when measuring 
cell viability by impedance measurements (Figure 13 C). The neuroprotective effect 
was observed in a co-treatment of rotenone and glutamate (Figure 13 A) as well as in 
a rotenone pretreatment followed by a washout before adding glutamate 
(Figure 13 C). 
Notably, mitochondrial fragmentation as a sign of disturbed mitochondrial 
morphology dynamics was also attenuated when cells were treated with rotenone 
(Figure 14 A, B). After glutamate exposure, rotenone receiving cells showed higher 
amounts of long tubular mitochondria of category I compared to control cells and 
lower amounts of fragmented mitochondria of category III whereas glutamate-treated 
controls had mostly fragmented mitochondria that were located around the nucleus. 
 
 
Figure 14: Low doses of rotenone prevent 
mitochondrial fission. 
A: Fluorescence photomicrographs show that 
rotenone (20 nM) prevents the fission of 
mitochondria that is apparent in glutamate-
exposed (3 mM, 14 h) HT-22 neurons. Cells 
were stained with MitoTracker DeepRed 
30 minutes before glutamate and rotenone 
treatment. Bar scale 20 µm. B: Quantification 
of mitochondrial morphology: Category I: 
fused, Category II: intermediate, Category III: 
fragmented mitochondria; at least 500 cells 
were counted per condition blinded to 
treatment conditions (n = 4, * p < 0.05; 
## p < 0.01 compared to glutamate-treated 
control). 
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Further, to prove the hypothesis that slight complex I inhibition protected from 
oxidative stress by a preconditioning effect, levels of lipid peroxides after rotenone 
treatment were examined. Rotenone alone did not alter lipid peroxide levels under 
standard culture conditions but it preserved cells from an increase in lipid 
peroxidation and thus, from further ROS production after the glutamate challenge 
(Figure 15 A).  
Since it is known that strong inhibition of complex I alters cytoplasmic ATP levels 
(Tretter et al., 2004) HT-22 cells receiving low doses of rotenone were investigated. 
In a concentration of 20 nM rotenone did not affect basal levels of ATP. However, 
glutamate-induced loss of ATP levels was prevented by rotenone in the same 
concentration, which further confirmed rotenone’s protective effect at low 
concentrations (Figure 15 B). 
Similar to HT-22 cells transfected with AIF siRNA, next the MMP of rotenone-treated 
cells was assessed to further test for functional integrity of the organelles. Cells 
exposed to rotenone-mediated complex I inhibition showed significantly lower MMP 
than control cells under normal culture conditions. These findings confirmed the 
conclusion that AIF-silenced cells follow a similar preconditioning effect as rotenone-
treated cells, i.e. through reduced activity of mitochondrial complex I. Furthermore, 
glutamate-induced ultimate mitochondrial depolarization as a late endpoint of 
mitochondrial damage in this model system of oxytosis was prevented in rotenone-
treated cells (Figure 15 C). Again the slight depolarization under culture conditions 
mediated by rotenone was confirmed by DIOC6(3) staining in isolated mitochondria 
performed by Dr. Amalia Dolga (Figure 15 D). 
Collectively, these results favor the hypothesis that AIF depletion is linked to a 
decrease in complex I expression levels and respiratory chain activity. These 
preconditioning effects lead to a stabilization of mitochondria and thus prevent cell 
death after the glutamate challenge and related induction of oxidative stress      
(Öxler et al., 2012).  
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Figure 15: Low doses of rotenone prevent mitochondrial integrity and function. 
A: Lipid peroxides were measured by BODIPY FACS analysis 13 hours following glutamate (glut) 
treatment (2 and 3 mM). Values are given from three independent experiments; *** p < 0.001 
compared to glutamate-treated control cells (2 mM); ### p < 0.001 compared to glutamate-treated 
control cells (3 mM). B: Rotenone receiving cells (20 nM) were preserved from loss in ATP levels 
14 hours after glutamate treatment (3 mM). N = 8; *** p < 0.001 compared to glutamate-treated control 
cells. C: MMP measured by TMRE is significantly (# p < 0.05) decreased by rotenone (20 nM, 15 h) 
compared to control cells. After glutamate treatment (3 mM, 15 h) MMP is significantly increased by 
rotenone (20 nM) (*** p < 0.001) compared to glutamate-treated control cells (n = 4). ## p < 0.01 
compared to untreated control. D: Seventy-two hours after transfection MMP was measured by 
DIOC6(3) assay. AIF-depleted mitochondria and rotenone receiving cells (20 nM, 18 h) are 
depolarized (n = 3; *** p < 0.001; ## p < 0.01 compared to control).  
 
 
 
 
 
 
 
 
Results   66 
 
 
3.2. Neuroprotection mediated by NPC-derived conditioned medium 
3.2.1. NPCs undergoing starvation in a caspase-dependent manner 
protect neuronal cells against damage by growth factor 
withdrawal and glutamate toxicity 
In this study the aim was to mimic the conditions after NPC transplantation in vivo by 
withdrawal of growth factor support of cultured NPCs in vitro. To this end, cultured 
NPCs were deprived of both EGF and bFGF. As expected, such growth factor 
withdrawal induced apoptotic cell death in the NPCs which rounded up and partly 
detached from the surface of the culture plate within 24 hours (Figure 16 A) (Diemert 
et al., 2012). The medium from the dying NPCs was collected and investigated in  
HT-22 cells for attenuating oxidative stress induced by glutamate and growth factor 
withdrawal on the basis of EBSS. CM attenuated the glutamate toxicity as detected 
by MTT cell viability assays. Furthermore, CM prevented cell death induced by EBSS 
treatment alone which, depending on the sensitivity of HT-22 cells, also induces 
starvation (Figure 17 A).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: NPCs cultivated without growth factors EGF and bFGF undergo starvation.  
A: Representative pictures of the cell morphology of NPCs deprived of growth factors (24 h)       
+/− Q-VD-OPh co-treatment (40 µM). B: Measurement of cellular impedance of NPCs grown with and 
without growth factors (GF). Co-administration of the pan-caspase inhibitor Q-VD-OPh (40 µM) 
prevents cell death induced by starvation; n = 5.  C: Quantification of cell death by MTT assay 
24 hours after growth factor withdrawal (n = 12; *** p < 0.001 compared to glutamate-treated control; 
ANOVA, Scheffé test).  
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To rescue NPCs from EBSS-induced starvation, cells were treated with the broad 
caspase inhibitor Q-VD-OPh (N-(2-Quinolyl)valyl-aspartyl-(2,6-difluorophenoxy) 
methyl ketone). Q-VD-OPh is a cell-permeable, irreversible caspase inhibitor that 
exhibits anti-apoptotic properties against all major caspase-mediated cellular 
apoptosis pathways. This inhibitor prevented NPCs from EBSS-induced cell death 
(Figure 16 A-C). DMSO in the same concentration as in the resulting Q-VD-OPh 
probe was used to exclude damage mediated by the solvent. This is in line with 
former experiments of Stefanie Neunteibl showing that EBSS-induced starvation in 
NPCs leads to cleavage of caspase-3 (personal communication). 
CM obtained from NPCs rescued by Q-VD-OPh failed to prevent apoptosis induced 
by glutamate in HT-22 cells (Figure 17 B). Importantly, Q-VD-OPh alone does not 
protect HT-22 cells from glutamate.  
 
 
 
 
 
 
 
 
 
 
 
Figure 17: CM from dying NPCs protects HT-22 cells.  
A: NPC CM protected HT-22 cells against growth factor withdrawal (–GF) and glutamate-induced 
toxicity (3 mM, 15 h) demonstrated by MTT assays; (n = 8, *** p < 0.001; ANOVA, Scheffé test). 
B: CM produced from NPCs prevented from cell death by the broad caspase inhibitor Q-VD-OPh 
(40 µM) showed no protective effect from glutamate-induced apoptosis (3 mM, 15 h) in HT-22 cells. 
CM produced from dying NPCs was used as positive control. The experiment was repeated two times 
independently (n = 6, *** p < 0.001, ANOVA, Scheffé test). 
 
 
  
Results   68 
 
 
3.2.2. Heating increases the protective effect of CM 
To further specify which components were responsible for the protective effect of CM 
a temperature gradient with diluted CM 1:4 was applied. Diluted CM pre-incubated at 
room temperature did not show a protective effect against glutamate-induced cell 
death in HT-22 cells. Surprisingly, significant protection was achieved after heating 
the medium up to 50-80°C (Figure 18 A), with a maximum protective effect obtained 
at 60°C. Real-time analyses using impedance measurements confirmed that NPC 
CM heated at 60°C exerted sustained protective effects compared to native NPC CM 
that was pre-incubated at room temperature (Figure 18 B). Higher temperatures up to 
more than 90°C destroyed the protective effect and heating at 100°C even resulted in 
toxic effects (Figure 18 A). This result can be explained either by an activation of 
substances at about 60°C or by an inactivation of toxic components or substances 
and enzymes which antagonized the protective contents. Furthermore, protective 
substances in CM seem to be heat stable at temperatures up to 80°C. 
 
 
 
 
 
 
 
 
 
 
Figure 18: Heat activation of NPC CM. 
A: Diluted NPC CM (1:4) was incubated at different temperatures for 30 minutes before pretreatment 
in HT-22 cells. MTT assay demonstrated a protective effect against glutamate-induced neurotoxicity 
(3 mM) mediated by NPC CM heated up at 50-80°C but not at 37°C, 90°C, or 100°C (n = 6; ANOVA, 
Scheffé Test). B: HT-22 cells were plated on a 96-well E-plate and cellular impedance was 
continuously monitored by the xCELLigence system. NPC CM heated up to 60°C for 10 minutes 
showed significant longer protection against glutamate (glut) toxicity (3 mM) compared to CM kept at 
room temperature (RT) (n = 3).  
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3.2.3. Identification of the chemical nature of compounds 
responsible for the neuroprotective effect of CM 
The next step was to identify the chemical nature of the contents mediating the 
neuroprotective effect of NPC CM. Since it is known that various miRNAs can have 
protective effects in models of neurodegenerative diseases, such as AD (Wang et al., 
2008), CM was treated with RNase, which was inactivated by heat before treating 
HT-22 cells. However, the RNase treatment did not alter the protective effect of CM 
(Figure 19 A).  
Next, CM was treated with protease to test if proteins are responsible for the 
neuroprotective effect. Pretreatment of CM with protease showed a very strong 
reduction in cell viability (Figure 19 B), which is may be explained by toxic 
degradation products.   
Since proteases may have other unspecific effects, including accumulation of toxic 
degradation products, aceton precipitation with CM was performed. Such 
precipitation and dilution of precipitate should verify that the protective effect of CM 
resulted from proteins. Interestingly, the precipitated proteins resulting after 
centrifugation of the mixture of CM and aceton were still active and also showed 
strong neuroprotection against glutamate-induced cell death (Figure 19 C). In 
addition, the neuroprotective activity of the aceton precipitate was further accelerated 
by heating. As demonstrated in Figure 19 D, heating of the precipitate to 50°C or 
60°C for 10 minutes significantly increased the protective effect compared to 
precipitate that was kept at 37°C. 
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Figure 19: Investigation of the chemical nature of protective components in CM.  
A: NPC CM pretreated with RNase showed no reduction in protective effects against glutamate 
damage (3mM, 15 h) compared to untreated NPC CM  in HT-22 cells (n = 5, *** p < 0.001). B: NPC 
CM pretreated with protease failed to prevent glutamate-induced toxicity (3 mM, 18 h) in HT-22 cells. 
CM without protease treatment was used as positive control (n = 8, *** p < 0.001). C: Proteins in NPC 
CM were precipitated by aceton. After separation by centrifugation precipitated proteins (pellet) 
showed significant neuroprotection against glutamate damage (3 mM, 16 h) in HT-22 cells. 
Supernatant failed to prevent cells from apoptosis (n = 5, *** p < 0.001). D: Precipitates from NPC CM 
pretreated with aceton were heated up at 37-70°C for 10 minutes. Precipitates at 50°C and 60°C 
showed significant stronger protective effects against glutamate toxicity in HT-22 cells as precipitate 
heated up to 37°C (n = 8, * p < 0.05, ** p < 0.01). All statictics were obtained with ANOVA, Scheffé 
test. All results were verified by at least three independent experiments. 
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3.2.4. Inhibition of protein synthesis during starvation 
To further investigate if the protective proteins in CM are already existent in cells 
under standard culture conditions or if they are produced only during cell death after 
growth factor withdrawal, CM was produced in the presence of protein synthesis 
inhibitors. Afterwards, this CM was tested for protective effects in HT-22 cells. The 
antibiotic actinomycin D and the fungicide cycloheximide (CHX) were used for 
inhibition of protein synthesis. To first determine at which concentrations these 
inhibitors were tolerated in NPCs, different concentrations of actinomycin D and CHX 
were tested under standard culture conditions. As shown in Figure 20 both 
substances already exert toxic effects at concentrations in the nanomolar range. To 
ensure that NPCs still undergo starvation in the presence of protein synthesis 
inhibitors the same concentrations were tested in NPCs treated with EBSS 
(Figure 20). Neither actinomycin D nor CHX provided any protective effect against 
growth factor withdrawal. 
 
 
 
 
 
 
 
 
 
Figure 20: Toxicity of protein synthesis inhibitors in NPCs. 
A, B: NPCs were treated with actinomycin D or cycloheximide (CHX) in different concentrations. Both 
substances provided apoptosis in the nanomolar range. None of the substances affected the cell 
death induced by growth factor deprivation during EBSS treatment. The experiment was repeated 
2 times. *** p < 0.001 compared to control in NPC medium, ### p < 0.001 compared to EBSS control; 
n = 6, ANOVA, Scheffé test.  
 
The CM generated by co-treatment of EBSS and either CHX or actinomycin D were 
tested in the HT-22 model of glutamate toxicity for protective activity. Both inhibitors 
of protein synthesis did not affect the protective properties of CM (Figure 21 A-D). 
Actinomycin D and CHX alone did not have any effect on apoptosis induced by 
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glutamate at low concentrations. In order to avoid additional effects, however, the 
protein synthesis inhibitors were removed from CM before HT-22 cell treatment.  
Thus, the proteins responsible for the neuroprotective effect of CM seem to be 
already expressed in the NPCs under standard culture conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: CM generated in the presence of protein synthesis inhibitors protects HT-22 
neurons against glutamate-induced cell death. 
A, B: HT-22 cells treated with CM produced in the presence of actinomycin D (actino. D, 1 nM and 
10 nM) prevent glutamate toxicity (3 mM, 15 h); n = 6. C,D: CHX (0.5 nM and 1 nM) had slight toxic 
effects on HT-22 cells. CM produced in the presence of CHX, however, still provided significant 
neuroprotective effect; n = 7. *** p < 0.001. All statistics were obtained using ANOVA, Scheffé test. 
Experiments were performed three times independently. 
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3.2.5. Neuroprotective effect of NPC lysate 
For further confirmation that the lysis of the dying cells was the essential step to 
generate neuroprotective properties in CM, NPCs from standard cultures were lysed 
by sonication. As shown by MTT assays, also cell lysates were able to protect 
against glutamate-induced cell death. However, the protective effect of such lysates 
was only detected when the cells were sonicated less than 5 minutes (Figure 22 A). 
This is likely due to the amount of proteases released during the sonication. Thus, for 
further analysis sonication time for the following experiments was restricted to 
2 minutes. Heating at 60°C did not have the same strong effect on the 
neuroprotective effect in the NPC lysate as compared to NPC CM from dying cells. In 
some experiments, the protective effect of the lysate was even less potent after 
heating compared to the native lysate (Figure 22 B), in other experiments heating did 
not alter the protective effect at all.  
 
 
 
 
 
 
 
Figure 22: NPC lysate provides neuroprotection. 
A: NPCs were sonicated for 5 or 8 minutes (US = ultrasonic). Cells sonicated for 8 minutes failed to 
prevent cells from glutamate-induced cell death (3 mM, 16 h). CM produced from growth factor 
deprived NPCs was used as positive control (n = 5, *** p < 0.001; * p < 0.05, ANOVA, Scheffé test). 
B: NPCs were sonicated for 2 minutes. NPC lysate provided neuroprotection against growth factor 
withdrawal mediated by EBSS (21 h) and glutamate toxicity (3 mM, 15 h). Heated lysate was less 
potent in its protective properties compared to non-heated lysate (n = 6; *** p < 0.001 compared to 
glutamate-treated EBSS control; # p < 0.05, ### p < 0.001 compared to EBSS without glutamate;       
+ p < 0.05 compared to glutamate-treated NPC lysate at RT; ANOVA, Scheffé test).  
 
 
 
 
  
Results   74 
 
 
3.2.6. Cell type specifity of CM 
To test, if the neuroprotective effect of CM is specific for NPCs, another CM was 
produced from dying HT-22 cells. HT-22 cells were more resistant to EBSS treatment 
than NPCs, and they had to be incubated under conditions of starvation for 48 hours 
to obtain CM from dying cells. This HT-22 CM was able to attenuate glutamate 
toxicity in the HT-22 cell line and the effect was still observed after heating the CM to 
60°C (Figure 23 A). Furthermore, cells treated with HT-22 CM showed higher viability 
than the control cells treated with EBSS, which indicated a protective effect not only 
against glutamate treatment but also against EBSS-induced starvation. 
Additionally, CM was generated from primary mouse embryonic fibroblasts (MEFs) 
that underwent starvation. This medium failed to protect HT-22 cells from glutamate-
induced apoptosis. Moreover, heating of MEF CM had no effect on the properties of 
the medium (Figure 23 B). Furthermore, SNL feeder cells from a modified mouse cell 
line were used as another source for CM. CM from MEFs as well as SNL CM was 
obtained from incubations of the cells in EBSS for about one week since these cells 
were less sensitive for starvation than NPCs. Similar to the MEF CM, the SNL CM did 
not protect against glutamate-induced cell death (Figure 23 C). Surprisingly, when 
SNL feeder cells were lysed by ultrasonication, significant protective effects were 
achieved in the glutamate-treated HT-22 cells with and without heating the lysate at 
60°C, as quantified in the MTT assay (Figure 23 D). Since this result was in contrast 
with the findings of CM generated from SNL feeder cells, real-time analysis using the 
xCELLigence system was performed. This experiment clearly demonstrated that the 
protective effect of SNL lysate was only transient whereas sustained protective 
effects over several hours were obtained with the lysate or CM from NPCs 
(Figure 23 E).  
Overall, these data suggest that the neuroprotection of CM is mediated specifically 
from neural cell lines and is much more potent than CM or cell lysate from fibroblasts. 
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Figure 23: CM and cell lysates from other cell types.  
A: HT-22 cells were incubated with EBSS for 2 days. HT-22 CM prevented HT-22 cells against 
apoptosis mediated by glutamate and growth factor withdrawal with and without heat treatment. (n = 6, 
### p < 0.001 compared to EBSS, *** p < 0.001 compared to glutamate-treated EBSS, ANOVA, 
Scheffé test). B, C: HT-22 cells were pretreated with CM from dying primary MEF (B) and dying SNL 
cells (C). Both CM failed to prevent HT-22 cells from glutamate neurotoxicity (3 mM, 15 h) in MTT 
assay also after heat treatment at 60°C for 10 minutes (n = 7, ANOVA, Scheffé test). D: SNL cells 
lysed by ultrasonic sound protected HT-22 cells against glutamate toxicity (3 mM, 15 h) (n = 6;          
*** p < 0.001; ANOVA, Scheffé test). E: SNL and NPC cells (100,000 cells each) were lysed for 
120 seconds. Lysed NPCs showed significant stronger protective effect comparable to CM against 
glutamate toxicity (3 mM) in HT-22 cells. 
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3.2.7. Mitochondria from NPCs do not provide neuroprotective 
effects 
Recently, it was reported that mitochondrial transfer from BMSCs protect against 
lung injuries (Prockop, 2012). To examine whether mitochondrial transfer also 
mediates neuroprotection in NPC CM, isolated mitochondria from NPCs were 
investigated in the HT-22 model. However, isolated mitochondria failed to prevent 
glutamate-induced cell death in HT-22 neurons as detected by the MTT assay 
(Figure 24). Thus, other components of the NPCs have to be responsible for the 
neuroprotective effects of CM. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Isolated mitochondria of NPCs do not protect against glutamate-induced toxicity. 
Isolated mitochondria from NPCs (NPC Mito) were tested in HT-22 cells towards glutamate toxicity 
(3 mM, 15 h) and growth factor withdrawal (EBSS, 21 h) (n = 6). *** p < 0.001, * p < 0.05 compared to 
EBSS. The experiment was repeated two times independently. Statistics were obtained using ANOVA, 
Scheffé test. 
 
 
 
  
Results   77 
 
 
3.2.8. Apoptotic bodies from NPC do not mediate neuroprotective 
effects 
Apoptotic bodies have been demonstrated to enhance the differentiation of human 
endothelial progenitor cells in vitro (Hristov et al., 2004). For this reason CM was also 
investigated for apoptotic bodies to mediate neuroprotection. However, apoptotic 
bodies isolated from NPCs did not protect against glutamate-induced cell death 
whereas the remaining compounds of CM still protected HT-22 cells from apoptosis 
(Figure 25). CM was used as positive control.  
 
 
 
 
 
 
 
 
Figure 25: Apoptotic bodies fail to prevent glutamate-induced cell death. 
CM was centrifuged at 16,000g for 30 minutes to isolate apoptotic bodies. The pellet containing the 
apoptotic bodies did not protect HT-22 cells against glutamate toxicity (3 mM, 15 h). The supernatant 
had still the same protective properties as CM used as control (n = 7). *** p < 0.01 compared to 
glutamate-treated EBSS. Experiment was repeated two times independently. Statistics were obtained 
using ANOVA, Scheffé test. 
 
3.2.9. Cut off filtrations limit the protein size  
To get further insights which proteins were responsible for the neuroprotective effect 
of CM, size exclusion filtration using a 10 kDa cut off filter (Millipore, Darmstadt, 
Germany) was performed. After the cut off filtration the CM fractions were heated at 
60°C. The filtrate containing proteins smaller than 10 kDa failed to attenuate 
glutamate toxicity whereas the concentrate with proteins higher than 10 kDa still 
showed significant protection against glutamate induced damage (Figure 26 A). The 
fact that this fraction did not reach 100 % of cell viability can be attributed to the 
protein loss by adsorption to the filter membrane. To further narrow the molecular 
weight range of the protective protein components in CM, size exclusion with a 
50 kDa cut off filter was assessed. The filtrate which contains proteins lower than 
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50 kDa reached the same protective effect as non-filtered CM that was used as a 
positive control in this experiment (Figure 26 B). The concentrate containing 
components higher than 50 kDa did not prevent HT-22 cells from glutamate-induced 
cell death. 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Size exclusion filtration identifies neuroprotective fractions at molecular weights 
between 10 and 50 kDa. 
A: Heated concentrate and filtrate of CM resulting from a 10 kDa cut off filtration were tested for their 
protective effects in glutamate-treated HT-22 cells (n = 6; *** p < 0.001, ANOVA, Scheffé test). 
Experiment was repeated two times. B: After 50 kDa cut off filtration only the filtrate prevented 
glutamate-induced cell death. Fractions were heated at 60°C for 10 minutes before HT-22 cell 
treatment (n = 6, *** p < 0.001, ANOVA, Scheffé test). The experiment was performed two times 
independently. 
 
These results indicate that the components of CM mediating the neuroprotective 
effect have a molecular size ranging between 10 and 50 kDa.  
 
3.2.10. Coomassie staining of NPC CM 
In order to visualize the CM proteins at their molecular size, CM was transferred on a 
SDS gel followed by coomassie blue staining. NPC CM as well as proteins 
precipitated by aceton, and NPC culture medium deprived of EGF and FGF obtained 
after 24 hours incubation in NPC showed several strong protein bands (Figure 27). 
Most proteins had a molecular size between 40 kDa and 70 kDa. As a negative 
control MEF CM was used. As expected almost no bands were detected in MEF CM 
and NPC culture media after 24 hours apart from medium additives. 
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Figure 27: Coomassie staining of 
CM on a SDS gel. 
NPC CM, aceton precipitated proteins 
of CM, MEF CM, NPC culture 
medium, and CM produced by growth 
factor deprived NPC culture medium 
and was separated on a SDS gel and 
stained by coomassie blue. From 
each sample 40 µg of total 
proteinwere loaded on the gel.  
 
 
 
 
3.2.11. MALDI-TOF analyses identify proteins in CM 
To determine the proteins in CM, MALDI-TOF analyses were performed. MALDI-TOF 
was used to analyze the CM concentrate after 10 kDa cut off filtration, filtrate from 
50 kDa cut off filtrations, CM heated at 60°C, CM from NPCs treated with Q-VD-OPh, 
lysed NPCs, SNL CM, and HT-22 CM. The samples were concentrated by 10 kDa 
cut off filtration to increase the signal, by default. 
Analyses of NPC CM, concentrated by a 10 kDa cut off filter resulted in a broad 
spectrum of different factors including proteins involved in redox regulation, like 
peroxiredoxins (prdxs), biosynthesis regulating proteins, like eukaryotic elongation 
factor 2 (eEF2), and stress response proteins, such as members of the HSP family. 
In addition, proteins mediating DNA repair were identified in the CM, e.g. histone 2A 
(Attachment 1). To narrow down this list Q-VD-OPh treated CM was analyzed. 
However, in the probes of Q-VD-OPh treated CM no proteins could be detected. This 
confirms the former finding that cell lysis is necessary to obtain neuroprotective 
effects. As a further attempt to exclude proteins from the list, the filtrate of 50 kDa cut 
off filtration was analyzed. These probes were also concentrated by a 10 kDa cut off 
filtration so that the probes should contain mainly proteins with a molecular weight 
ranging between 10 and 50 kDa. The protein list resulting from these experiments 
was reduced by half compared to the first list from the 10 kDa cut of filtration. 
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Proteins that were found in both experiments and that have a molecular weight 
between 10 and 50 kDa were e.g. members of the prdx family (20-30 kDa) and 
galectin-1 (gal-1; 14 kDa) (Attachment 2). Furthermore, proteins with higher 
molecular weight than 50 kDa, such as HSP 70 or 90, which are also interesting 
candidates for mediating neuroprotective effects were excluded from this list. 
Analysis of CM after heating to 60°C did not provide different or new findings but 
confirmed interesting candidate proteins, such as prdx family members, gal-1, and 
members of the HSP family (Attachment 3). Analysis of NPC lysates did not provide 
useful data (Attachment 4). Only very few proteins could be identified in the lysate 
which may result from the fact that the lysate samples contained too many proteins 
and their signals were overlapping and disturbing each other. 
In addition, also the CM generated by HT-22 neurons and SNL feeder cells were 
analyzed. Interestingly, HT-22 CM, which also showed neuroprotective effects in 
former analyses, contained peroxiredoxin-1 (prdx-1), which was also consistent in all 
the other NPC generated probes (Attachment 5). The analysis of SNL CM that is not 
protective only detected structural proteins, such as vimentin and actin 
(Attachment 6). 
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3.2.12. RT-PCR analysis of interesting proteins from the MALDI-
TOF results 
The MALDI-TOF analyses of the concentrated CM (Attachment 1) identified several 
proteins that were of interest when examining neuroprotective effects. The first 
protein family of interest is the prdx family. Prdxs are an ubiquitous family of 
antioxidant enzymes that also control cytokine-induced peroxide levels and thereby 
mediate signal transduction in mammalian cells (Wood et al., 2003). It has already 
been shown that some of these protein family members, including prdx-2, 5, and 6 
can mediate neuroprotective effects (Hu et al., 2011;Plaisant et al., 2003;Tulsawani 
et al., 2010). Since prdx-1 was found in all MALDI-TOF analyses from 
neuroprotective samples its expression on RNA level in NPCs during treatment with 
EBSS was further investigated by RT-PCR. Since also prdx-2 and 6 were found in 
some samples at least with a peptide count-value of 1 and neuroprotective effects of 
prdx-5 are described in the literature (Plaisant et al., 2003), also these expression 
levels were determined. Prdx-1 expression level was significantly reduced in NPCs 
after EBSS treatment whereas prdx-2 and prdx-5 showed no changes in their 
expression levels during growth factor withdrawal. In contrast, RNA level of prdx-6 
was increased after 10 and 20 hours (Figure 28). 
Another protein family identified by the MALDI-TOF analyses that may mediate 
neuroprotective effects is the HSP family. HSPs cope with stress-induced 
denaturation of other proteins thereby mediating stress tolerance (Romi et al., 2011). 
There is evidence in the literature that exogenous HSPs, such as HSP 70, are 
involved in the regulation of neuronal survival (Robinson et al., 2005). Since HSP 60, 
70, and 90 were found in the MALDI-TOF analyses of CM their RNA expression 
levels in NPCs during EBSS treatment was further investigated. HSP 70 expression 
was strongly downregulated after 6 hours of EBSS treatment but no changes were 
found after 10 or 20 hours. Thus, this decrease in expression seems to be just a 
short-time stress reaction. The expression level of HSP 90 was stable over 6, 10, and 
20 hours of growth factor withdrawal whereas HSP 60 showed a continuous 
decrease in RNA expression during EBSS treatment (Figure 28). 
In addition, the RNA expression levels of phospholipase A 2 (PLA 2) and eEF 2 were 
detected at different time points after growth factor withdrawal. PLA 2 was of interest 
since it is known that several types of PLA 2s are degraded at about 60°C and the 
Results   82 
 
 
enzyme is also known to have neurotoxic properties (Farooqui et al., 2006;Karray et 
al., 2012a) which is in accordance with the activation of CM at about 60°C. eEF 2 
catalyzes ribosomal translocation during protein synthesis and acts as a biochemical 
sensor in dendrites (Sutton et al., 2007). For eEF 2 expression levels a continuous 
increase was detected (Figure 28). A short time increase of PLA 2 expression was 
observed after 6 hours that diminished again during longer EBSS treatment. GAPDH 
was used as loading control.  
These data already indicate that the protein regulation after growth factor deprivation 
is very complex and involves a lot of different proteins, and an up- as well as 
downregulation of these proteins can be observed. 
 
 
 
 
Figure 28: Changes in mRNA mediated by 
growth factor deprivation.  
mRNA expression levels of prdx-1, 2, 5, 
and 6, HSP 60, 70, and 90, eEF2, and PLA2 
were determined 0, 6, 10, and 20 hours after 
EBSS treatment by RT-PCR. GAPDH was 
used as loading control. The experiment was 
repeated independently two times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Results   83 
 
 
3.2.13. Peroxiredoxin-1 and galectin-1 as protective components   
of CM 
Since prdx-1 is described to play a role for neuronal survival in HT-22 cells (Sun et 
al., 2008) and, furthermore, prdx-1 was identified by MALDI-TOF analyses in all 
experiments, it was investigated whether prdx-1 is able to mediate protection against 
oxidative stress in HT-22 cells. The used recombinant protein was of human origin 
because of availability but human and mouse prdx-1 gene sequences converge in 
95 % (Table 24).  
 
Table 24: Gene alignment of human and mouse prdx-1 
HUMAN Peroxiredoxin-1 MOUSE Peroxiredoxin-1 
MSSGNAKIGHPAPNFKATAVMPDGQFKDIS
LSDYKGKYVVFFFYPLDFTFVCPTEIIAFS 
DRAEEFKKLNCQVIGASVDSHFCHLAWVNT
PKKQGGLGPMNIPLVSDPKRTIAQDYGVLK 
ADEGISFRGLFIIDDKGILRQITVNDLPVG
RSVDETLRLVQAFQFTDKHGEVCPAGWKPG 
SDTIKPDVQKSKEYFSKQK 
MSSGNAKIGYPAPNFKATAVMPDGQFKDIS
LSEYKGKYVVFFFYPLDFTFVCPTEIIAFS 
DRADEFKKLNCQVIGASVDSHFCHLAWINT
PKKQGGLGPMNIPLISDPKRTIAQDYGVLK 
ADEGISFRGLFIIDDKGILRQITINDLPVG
RSVDEIIRLVQAFQFTDKHGEVCPAGWKPG 
SDTIKPDVNKSKEYFSKQK 
Identities = 190/199 (95%) 
 
The human recombinant prdx-1 was tested in HT-22 cells at different concentrations 
using the xCELLigence system for detection of cell viability. Human prdx-1 prevented 
glutamate-induced cell death in HT-22 cells in a dose-dependent manner         
(Figure 29 A-C). Interestingly, the protective effect did not vary when the protein was 
previously heated at 60°C. At a concentration of 125 µg/ml recombinant prdx-1 
showed a stable protection against glutamate-induced cell death (Figure 29 A). At a 
concentration of 25 µg/ml the protective effect of prdx-1 was comparable with the 
effect of CM that was not previously heated (Figure 29 B). At a concentration of 
12.5 µg/ml the recombinant protein still exerted a transient delay in cell death of 
about 1 hour (Figure 29 C). 
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Figure 29: Human recombinant prdx-1 attenuates glutamate toxicity in a concentration-
dependent manner. 
A-C: HT-22 cells were plated on a 96-well E-plate and cellular impedance was measured 
continuously. The cells were pretreated with human recombinant prdx-1 in three different 
concentrations either with or without heating at 60°C for 10 minutes. After 6 hours glutamate (3 mM) 
was added into the wells. CM was used as a positive control (n = 3).  
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Western blot analyses demonstrated that HT-22 cells treated with heated as well as 
non-heated CM showed a significant increase in prdx-1 levels of about 30-40 % 
(Figure 30). This result suggested that HT-22 cells either take up prdx-1 out of the 
medium or that CM causes a signal to the cells resulting in an increase in the 
intracellular expression levels. The increase in endogenous prdx-1 levels detected 
after incubation with CM was much less compared to treatment with recombinant 
human prdx-1 at the concentration of 25 µg/ml.   
 
 
 
 
 
 
 
Figure 30: CM increases prdx-1 protein levels in HT-22 cells. 
Western blot analysis of HT-22 cells treated with CM or recombinant prdx-1 for 24 hours. HT-22 cells 
treated with CM showed an increase in prdx-1 levels but not as strong as recombinant prdx-1 in a 
concentration of 25 µg/ml. The effect was consistent with and without glutamate treatment (3 mM, 
18 h). Actin was used as loading control.  
 
In order to evaluate how far prdx-1 contributed to the protective effects of CM, the 
medium was pretreated with a specific antibody against prdx-1. As demonstrated in 
Figure 31 B the protective effect of CM was reduced by the anti-prdx-1-antibody but a 
transient protective effect was still detected over several hours. However, this result 
was not reproducible all the time. In 5 of overall 8 experiments the antibody 
attenuated the protective effect of CM. In the remaining 3 experiments the protective 
effect of CM was not affected which can be due to inefficiency of the antibody. 
Apparently, even neutralizing prdx-1 using the antibody was insufficient to fully block 
the protective effect of the CM. This suggests that additional factors significantly 
contribute to the observed neuroprotection by CM whereas prdx-1 may be 
dispensable. 
To further verify the results obtained with prdx-1 so far, the quantitative amount of 
prdx-1 in CM was determined by ELISA measurements. ELISA measurements 
detected prdx-1 amounts of about 3 ng/ml in CM (Table 25). To exclude disturbing 
interactions between CM and the ELISA also the recovery rate of prdx-1 was 
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determined in single measurements. No disturbing interactions of CM were detected. 
Compared to the amount of recombinant human prdx-1 that was required to provide 
protective effects, the prdx-1 content detected in CM by ELISA was too little to 
explain neuroprotection of CM through prdx-1 alone. Total protein amount 
determined by BCA analyses detected protein concentrations in CM around 1 mg/ml. 
Thus, prdx-1 is likely just a part of a variety of protective proteins in NPC CM. 
However, it is still possible, that other components in CM activate prdx-1 or that the 
human recombinant protein has to be added at high concentrations to mediate 
neuroprotection in the HT-22 cells. 
 
Mouse prdx-1 (ng/ml) Total protein amount (mg/ml) 
2.8 1.1 
3.4 1.0 
4.3 1.1 
3.4 1.4 
  Table 25: Content of prdx-1 in CM compared to total protein  
amount 
Prdx-1 levels were determined by ELISA measurements and total protein  
amounts by BCA measurements in 4 independent experiments. 
 
 
A second interesting candidate protein that was found in all MALDI-TOF analyses 
and that is also described in the literature to provide neuroprotective effects is gal-1 
(Chang-Hong et al., 2005;Lekishvili et al., 2006). For that reason recombinant mouse 
gal-1 was tested in the system of glutamate toxicity in HT-22 cells. Recombinant   
gal-1 prevented glutamate-induced toxicity in HT-22 cells as detected by the 
xCELLigence system (Figure 31 A). This neuroprotective effect was only slightly 
reduced by heating gal-1 at 60°C. Pretreatment of CM with a specific gal-1 antibody 
significantly attenuated the protective effect of CM but CM still provided 
neuroprotection against glutamate toxicity for several hours. However, similar to the 
experiments with the prdx-1 antibody this result was not reproducible in every 
experiment. In three of four independent experiments the protective effect of CM was 
reduced by the anti-gal-1 antibody, whereas in one experiment the antibody failed to 
attenuate the protection mediated by CM. This suggests that gal-1 partly contributed 
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to the protective effect of CM, but may as well be dispensable. In one experiment, 
where both the prdx-1 antibody and the gal-1 antibody affected the potency of CM, a 
combination of both antibodies showed an additive effect reducing CM protection 
more effectively than the individual antibodies (Figure 31 B). To exclude that the 
effects observed with the anti-prdx-1 and the anti-gal-1 antibodies were attributable 
to unspecific and/or concentration-dependent effects of the antibodies, CM was 
treated with a specific anti-AMPK antibody at different concentrations. No effect on 
CM was detected in this control experiment using the xCELLigence system 
(Figure 31 C). 
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Figure 31: Recombinant gal-1 and prdx-1 may provide additive neuroprotective effect. 
A: Real-time measurement of mouse recombinant (rec.) gal-1 (10 µg/ml) indicates a transient 
protective effect against glutamate toxicity (3 mM) in the HT-22 model system (n = 3). The graph is 
representative for three independent experiments. B: Specific antibodies (AB) against gal-1 and   
prdx-1 (5 µg/ml each) reduced the potency of CM. Combination of both antibodies showed an additive 
effect (n = 4). C: To exclude unspecific and concentration dependent antibody effects CM was treated 
with AMPK antibody in two different concentrations (5 and 10 µg/ml) (n = 4). 
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It has been reported that gal-1 stimulates the secretion of growth factors, such as 
BDNF (Qu et al., 2010). Growth factors, such as BDNF and VEGF, are lively 
discussed in several models of stem cell-mediated neuroprotection (Uzun et al., 
2010), and they are known to be efficient at very low concentrations (pg/ml; Cho et 
al., 2012) so that it is conceivable that they are under the detection limit the MALDI-
TOF system. To investigate whether BDNF mediates neuroprotection in the applied 
model system, different concentrations of BDNF were tested in HT-22 neurons 
treated with glutamate. BDNF failed to rescue cells from glutamate-induced cell 
death (Figure 32). This is in accordance with former reports showing that HT-22 cells 
do not express functional TrkB receptors and even after viral infection TrkB 
expressing HT-22 cells cannot be rescued from oxidative glutamate toxicity by BDNF 
but only from serum deprived cell death (Rössler et al., 2004). Thus, secretion of 
BDNF does not affect the neuroprotective effect of CM in the HT-22 cell model 
system. 
 
 
 
 
 
 
 
 
 
Figure 32: BDNF does not protect HT-22 neurons from glutamate toxicity. 
Cells were pretreated with BDNF (6 h) in different concentrations. BDNF failed to prevent 
glutamate-induced  (3 mM, 15 h) cell death in HT-22 cells at all applied concentrations (n = 6). 
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3.2.14. Inhibition of PI3K 
It has been shown in previous studies that BMSC CM mediated protection through 
stimulation of PI3K (Isele et al., 2007). In addition, Western blot analyses performed 
by Dr. Amalia Dolga and Stefanie Neunteibl demonstrated that NPC CM activated 
Akt within minutes in primary cortical neurons (personal communication), which 
suggested an involvement of the PI3K/Akt pathway in the neuroprotective effects 
mediated by CM. For that reason HT-22 cells were pretreated with the PI3K-Inhibitor 
LY 294002 that acts on the ATP-binding site of the enzyme, before a combination 
treatment of LY 294002 with either recombinant prdx-1, gal-1, or CM. LY 294002 
clearly reduced the protective effect of recombinant prdx-1 (Figure 33 A) as well as of 
recombinant gal-1 (Figure 33 B) as detected by xCELLigence measurements. 
Further, the PI3K-inhibitor slightly reduced the protective effect of NPC CM in two 
independent experiments (Figure 33 C) whereas CM-mediated protection remained 
unaffected in two other experiments (Figure 33 D). These observations suggest that 
the protective properties of NPC CM are likely attributed to a mixture of components 
that may include protective effects mediated by the PI3K pathway, e.g. caused by the 
proteins prdx-1 and gal-1, however, not exclusively. Thus, the inhibition of one out of 
several protective pathways may be compensated by other protective components of 
CM which are yet unknown.  
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Figure 33: PI3K inhibition reduces neuroprotection in HT-22 cells. 
A: PI3K inhibitor LY 294002 (10 µM) significantly reduced the protective effect mediated by prdx-1 
(25 µg/ml) towards glutamate toxicity (3 mM). The experiment was repeated two times independently      
(n = 3). B: Protection towards glutamate (glut, 3 mM) toxicity mediated by gal-1 (10 µg/ml) was 
reduced by LY 294002 (10 µM). The experiment was performed three times independently.               
C, D: xCELLigence measurement of co-treatment of CM and LY 294002 (10 µM) showed different 
results during glutamate (glut, 3 mM) treatment. In two experiments the protection mediated by CM 
was slightly reduced (C). In two experiments no change in the protective properties of CM was 
observed (D) (n = 3).  
 
  
Results   92 
 
 
3.2.15. Gel filtration separates CM into several protective fractions 
To further determine proteins that contribute to the neuroprotective properties of CM, 
the medium was separated by gel filtration. The PrimeView 5.0 software detected 
protein peaks in several fractions (Figure 34 A) that were collected and tested in the 
HT-22 model system for neuroprotective properties. At least one fraction still 
provided neuroprotection towards glutamate-induced apoptosis in HT-22 neurons as 
detected by MTT measurements in three independent experiments (Figure 34 B) 
although some fractions also exposed slightly toxic effects. 
 
 
 
 
 
 
 
 
 
 
Figure 34: Gel filtration of CM. 
A: CM was separated by gel filtration and several protein peaks could be detected by the PrimeView 
5.0 software. B: Protective fraction as well as toxic fractions could be detected by MTT measurements 
in HT-22 cells undergoing glutamate-induced cell death (3 mM, 18 h). The graph is a representative 
example for three independent experiments. N = 6; *** p < 0.001 compared to glutamate-treated 
EBSS. Statistics were obtained using ANOVA, Scheffé test. 
 
 
However, in MALDI-TOF analysis no proteins could be detected in any of these 
fractions. Further investigations are needed to clarify whether most of the proteins in 
the separated fractions were lost on the column and if protein amounts that were 
below the detection limit of MALDI-TOF analysis could still provide neuroprotection, 
or if technical problems during the MALDI-TOF measurements are responsible for 
this result. 
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3.2.16. Methods for CM concentration  
For further investigations of CM in studies in vivo and also for clinical use it would be 
important to isolate the protective components of CM in a concentrated composition.  
For that reason lyophilization of heated CM was assessed. The volume of the media 
was reduced to about one-tenth of the original volume and then tested in different 
dilutions in the HT-22 cell system. Both lyophilized CM as well as lyophilized EBSS 
control showed toxic effects (Figure 35 A). This was due to hyperosmolaric salt 
concentrations from the lyophilization of EBSS. Further, cell viability of HT-22 cells 
measured after the treatment with diluted lyophilized CM showed no significant 
difference to the same medium that was additionally exposed to glutamate, which 
indicates that the protective properties of CM were not lost during the lyophilization 
process. Thus, the next step was to combine the lyophilization with a former dialysis. 
The dialysed and lyophized CM showed no toxic effects, however, it failed to protect 
HT-22 cells against lethal glutamate concentrations (Figure 35 B). This result 
suggests that during dialysis protective substances are lost, probably by adsorption 
to the membrane.  
A further attempt to concentrate CM was the use of size exclusion cut off filters. 
Heated CM was concentrated by a 3 kDa cut off filter to one-tenth of the original 
volume and tested in different dilutions to determine the efficacy of this concentration 
method. The concentrate prevented starvation of HT-22 cells in a 1:2 dilution and 
glutamate toxicity in a 1:6 dilution. However, 1:10 dilution, which represents the 
original volume failed to prevent cell death in HT-22 neurons (Figure 35 C). Non-
concentrated, heated CM as a control failed to prevent HT-22 cells from glutamate-
induced cell death already in a 1:4 dilution (data not shown). Thus, CM can be 
concentrated by cut off filtration, but then a lot of protective substances may be lost 
by adsorption to the membrane filter or by the loss of one or more cofactors that 
increase the neuroprotective potential of CM. To investigate whether NPC CM 
contents such a cofactor the concentrate of a 3 kDa cut off filtration was diluted with 
the 3 kDa filtrate instead of the EBSS buffer. Interestingly, the neuroprotective 
potential of the concentrate that was recombined with the filtrate showed significantly 
stronger neuroprotective effects against glutamate-induced cell death compared to 
the 3 kDa concentrate alone. Importantly, the 3 kDa filtrate showed no protective 
properties at the same dilution alone (Figure 35 D). This finding suggests an 
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additional cofactor with a molecular weight lower than 3 kDa that increases the 
neuroprotective potential of CM without providing neuroprotective effects by itself.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Attempts to concentrate CM.  
A: CM and EBSS were concentrated by lyophilization (lyo) to one-tenth of the original volume. 
Afterwards, the concentrate was diluted with EBSS and tested in the HT-22 cell system. All dilutions 
showed toxic effects confirming the toxicity mediated by hyperosmolarity (n = 6). *** p < 0.001 
compared to EBSS. B: CM was dialyzed and lyophylized (dl) to one-tenth of the original volume. The 
dilutions showed neither toxicity nor protective effects against glutamate-induced (3 mM, 15 h) cell 
death (n = 6). *** p < 0.001 compared to glutamate-treated EBSS.  C: CM was concentrated by 3 kDa 
cut off filtration to one-tenth of its original volume. CM just protected HT-22 cells from glutamate 
damage (3 mM, 15 h) up to a 1:6 dilution. CM was protective against growth factor withdrawal in 
EBSS just up to a 1:2 dilution (n = 5). *** p < 0.001 compared to glutamate-treated EBSS; ## p < 0.01 
compared to EBSS. D: All statistics were performed using ANOVA, Scheffé test. D: CM heated at 
60°C was filtrated by a 3 kDa cut off filter. The fractions were tested separated and in combination with 
each other in a 1:2 dilution. Proliferation rate was monitored by the xCELLigence system. The 
combination of the 3 kDa concentrate and the filtrate showed comparable protection against 
glutamate-induced (3 mM, glut) cell death as undiluted heated CM without cut off filtration. 
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3.2.17. Stability of CM and cell lysates 
For further investigations in vivo and also later clinical application and storage it is 
essential to know how stable the neuroprotective effect of CM is at room temperature 
and at body temperature. Since in vivo experiments using implantable mini-osmotic 
pumps as infusion system were planned CM heated at 60°C was stored at 37°C for 4 
or 7 days to mimic in vivo conditions. The CM showed significant protective effects 
against glutamate-induced toxicity at all storage conditions without any detectable 
loss in potency (Figure 36 A). The protective effect against growth factor withdrawal 
was slightly decreased after 7 days in some experiments. This underlines the high 
potency and temperature stability of CM and makes it suitable for storage at room 
temperature and further studies in vivo. 
In contrast, cell lysates of NPCs showed significant decreases of the neuroprotective 
effects against glutamate-mediated cell death after 4 and 7 days exposure to 37°C 
(Figure 36 B). Also, a protective effect against growth factor withdrawal could not be 
detected with the incubated NPC lysate.  
Thus, these results show that CM is more stable towards storage at 37°C compared 
to cell lysate which makes CM from starving cells superior for further investigations.  
 
 
 
 
 
 
 
 
 
 
Figure 36: Stability of NPC CM and lysate. 
A: CM was heated at 60°C for 10 minutes and afterwards stored at 37°C for 4 or 7 days. As control 
CM stored at -80°C was used. Afterwards, these CMs were used in the HT-22 model of glutamate-
induced (3 mM, 19 h) toxicity (n = 7; *** p < 0.001 compared to glutamate-treated EBSS control;     
### p < 0.001, # p < 0.05 compared to EBSS without glutamate; ANOVA, Scheffé test). B: NPCs were 
lysed for 120 seconds and afterwards, heated at 60°C for 10 minutes. Lysated NPCs showed reduced 
protective effect after 4 and 7 days at 37°C compared to CM kept at -80°C during this time                
(** p < 0.01; n = 6, ANOVA, Scheffé test). 
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3.2.18. Pre- versus post-treatment 
Since CM is a possible therapeutic for application in the treatment of 
neurodegenerative diseases it is important to know if also a post-treatment with CM 
has neuroprotective capacities. For that reason a post-treatment with CM in the    
HT-22 model system was performed. NPC CM protected HT-22 cells from glutamate-
induced cell death after 2, 4, 6, and 8 hours of glutamate treatment (Figure 37 A). 
When applied 10 hours after the onset of glutamate exposure, CM did not exert full 
protective effects, but still preserved a significant higher cell viability compared to 
glutamate-treated cells.  
In contrast, when HT-22 neurons were pretreated with CM for several hours followed 
by washout and subsequent glutamate treatment, the cells were not protected from 
cell death (Figure 37 B). 
 
 
 
 
 
 
 
 
 
 
Figure 37: Pre- and post-treatment with CM. 
A: HT-22 cells were treated with glutamate (3 mM, 22 h). CM was added at indicated time points after 
the glutamate addition. Until 8 hours post-treatment CM could prevent glutamate-induced cell death 
without any loss in potency (n = 8; *** p < 0.001 compared to glutamate-treated EBSS; ### p < 0.001 
compared to 2, 4, 6, and 8 hours post-treatment; ANOVA, Scheffé test). B: Cells were pretreated with 
CM for indicated time points followed by a washout and subsequent glutamate (3 mM, 14 h) treatment. 
CM co-treated with glutamate was used as positive control (n = 8; *** p < 0.001 compared to 
glutamate-treated EBSS; ANOVA, Scheffé test). 
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4. Discussion 
The data of this thesis demonstrate the potential of molecular and cellular 
preconditioning effects for attenuating neural cell damage induced by oxidative 
stress. At the molecular level many mechanisms for preconditioning converge at 
mitochondria, such as an increased production in ROS, opening of mitoKATP 
channels, or mitochondrial membrane depolarization. The data of the first part of this 
study provide strong evidence for a preconditioning effect by AIF gene silencing, 
which protects mitochondrial function and integrity in a paradigm of lethal oxidative 
stress in a neural cell line. Depletion of AIF preserved mitochondrial morphology, 
MMP and ATP levels after induction of oxidative stress in HT-22 cells, and this 
mitoprotective effect also significantly attenuated the secondary increase in lipid 
peroxidation, which was associated with mitochondrial damage and cell death in this 
model system (Tobaben et al., 2011). Preconditioning by AIF depletion was further 
associated with reduced complex I expression levels. Surprisingly, low doses of the 
complex I inhibitor rotenone also affected AIF expression levels and achieve 
protective effects against glutamate-induced cell death in the used model system 
similar to the effects observed after AIF silencing. These results suggest that AIF 
silencing provides protection against oxidative cell death at the level of mitochondria 
and not at the level of apoptotic DNA damage in the nucleus. Furthermore, these 
data indicate an association between AIF and complex I thereby regulating each 
other’s stability. 
In addition, preconditioning effects are known to be also mediated by intercellular 
communication in which cells protect neighboring cells e.g. by the transfer of 
protective substances (Brown, 2007). The ability of cellular communication in 
paradigms of lethal stress was used to generate CM from dying NPCs in the second 
part of the thesis. The investigations with this CM demonstrated strong 
neuroprotective effects against starvation and glutamate-induced cell death in HT-22 
neurons. The neuroprotective effect of this CM was stable during storage at 37°C, 
specific for neural cell lines and consistent up to 8 hours after the onset of toxic 
glutamate exposure. Importantly, the findings provide evidence that cell death and 
lysis of the NPCs is necessary to mediate neuroprotection whereas many 
researchers link the neuroprotective effect of progenitor cell application to cell 
engraftment and neuronal differentiation (Uzun et al., 2010;Yamane et al., 2010). 
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Notably, heating CM to 60°C further increased the neuroprotective effects of NPC 
CM. Furthermore, this study identified proteins as the main mediators of 
neuroprotection in NPC CM and demonstrated that the strong neuroprotective 
potential of the medium is due to a broad mixture of several different substances, 
such as prdx-1 and gal-1. In addition, also the contribution of a low molecular weight 
cofactor to the neuroprotective potential of NPC CM was shown. 
 
4.1. Importance of preconditioning and conditioning effects in 
neuronal cell survival as a therapeutic strategy 
The present study shows clear evidence for the neuroprotective potential of 
preconditioning effects against otherwise lethal stress. The protective effects 
mediated by AIF deficiency or by dying cells, such as NPCs after growth factor 
withdrawal, clearly feature the exceptional ability of cells to change an intrinsic deficit 
into an advantage towards following stress situations.  
The major goal of studying such mechanisms, which have evolved in different tissues 
to withstand injurious challenges, is to therapeutically exploit them by boosting or 
exogenously substituting neuroprotectants after e.g. acute nervous system insults. 
Furthermore, an aim of preconditioning research is to establish strategies that 
prevent patients against anticipated brain injuries, such as brain surgeries or in 
patients with a high risk to develop ischemic defects. For example, 20-30 % patients 
after subarachnoid haemorrhage have delayed neurological ischemic defects 
associated with vasospasm several days after the initial event (Dirnagl et al., 
2009;Dirnagl and Meisel, 2008).  
So far, there are several forms of preconditioning described in the literature. 
Pharmacological or chemical preconditioning against cerebral ischemia is mediated 
by compounds that interfere with the cellular respiratory chain or oxygen sensing 
thereby mimicking or inducing hypoxia. These substances can be inhibitors of the 
respiratory chain such as nitroproprionic acid (Riepe et al., 1997a), mitoKATP channel 
openers such as diazoxide (Prass et al., 2002), HIF inductors such as desferoxamine 
(Nagy et al., 2004), or modulators of the oxidative phosphorylation function such as 
acetylsalicylic acid (Riepe et al., 1997b). The data of this thesis demonstrate that 
preconditioning mediated by AIF depletion is due to an interaction with the respiratory 
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chain, which leads to higher tolerance against later oxidative stress stimuli of the 
mitochondria. This finding is underlined by similar neuroprotective effects found with 
the pharmacological complex I inhibitor rotenone. 
Brief exposure to volatile anaesthetics, such as halothane, isoflurane or sevoflurane 
also results in a protected stage against ischemia long after they have been removed 
from the organism (Kapinya et al., 2002). The mechanisms behind anaesthetic 
induced delayed neuroprotection are similar to mechanisms identified as mediators 
from other forms of preconditioning, including e.g. the involvement of inducible nitric 
oxide synthase (iNOS) and KATP channels (Dirnagl and Meisel, 2008). 
Preconditioning with volatile anesthetics, which protects brain and heart in 
experimental models are already tested in clinical trials after the onset of 
cardiopulmonary bypass. For example, desflurane was shown to provide 
pharmacological preconditioning thereby reducing myocardial necrosis and improving 
the cardiac performance in the postoperative periods in coronary artery bypass graft 
surgery in a double-blinded, randomized, and placebo-controlled study (Meco et al., 
2007). 
Another interesting aspect for therapeutic application is “remote preconditioning” also 
called “preconditioning at a distance”. This means that brief preconditioning applied 
to one organ can also protect other organs. Dave et al. demonstrated that tolerance 
for ischemia can be induced in brain by remote preconditioning in a rat model of 
asphyxial cardiac arrest (ACA). Remote preconditioning was induced by tightening 
the upper two-thirds of both hind limbs using a tourniquet for 15 or 30 minutes two 
days before onset of the ACA.  Remote preconditioned animals showed significant 
higher number of normal neurons compared to control groups seven days after 
resuscitation. The identities of the signaling pathways involved in the observed 
neuroprotection following remote preconditioning are not exactly known. However, 
researchers have demonstrated that pathways involving protein kinase C (PKC), 
iNOS, suppression of inflammatory pathways, prostaglandins, free radicals, the 
mitoKATP channels, and NF-B are responsible for observed protective effects of 
remote preconditioning (Dave et al., 2006). 
Also, ischemic postconditioning has been reported in the brain (Burda et al., 2006). 
Ischemic postconditioned rats show a prolonged phosphorylation of Akt, Erk, and 
p38MAPK in the cortex and the neuroprotective effect can be prevented by an 
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inhibition of PI3K (Pignataro et al., 2008). Postconditioning offers a new therapeutic 
strategy as it may be applied after the onset of an ischemic insult. It seems to be 
effective in protecting the human heart during coronary angioplasty (Staat et al., 
2005), however, for practical reasons it is very unlikely to use postconditioning in 
stroke patients (Dirnagl and Meisel, 2008). Since NPC CM investigated in this study 
showed strong neuroprotective effects up to 8 hours post-treatment this could be a 
new method to use conditioning effects for therapeutic applications after the onset of 
a neural insult. 
In clinical neurology and neurosurgery there is no established pre- or 
postconditioning treatment after cerebral insults available, to date. Clinical trials are 
needed to test the safety and efficacy of preconditioning strategies for protecting the 
brain against anticipated damage. A clinically used preconditioning stimulus must be 
subthreshold and should not cause any persistent damage. Thus, the therapeutic 
range of preconditioning is narrow (Dirnagl et al., 2009;Dirnagl and Meisel, 2008). 
Whether preconditioning mimetics, such as mild inhibition of mitochondrial respiration 
as it was found in this study by AIF gene silencing or by rotenone fall into this small 
range remains questionable. Tools for transient and specific inhibition of AIF and 
exact monitoring of the respiratory chain activity in vivo would be necessary to 
therapeutically use these targets. 
However, the application of a CM, e.g. from apoptotic cells perfectly links the needed 
damaging insult that can be generated ex vivo with the resulting neuroprotective 
effect in vivo. Among other later discussed advantages when applying a defined 
composition instead of cells, such conditioning strategies can use the potential of 
cells to react to adverse environmental effects and are maybe superior to classical 
preconditioning.  
Collectively, this study underlines the importance of research on the self-protecting 
mechanisms in the nervous system against oxidative stress and other neurological 
insults, to develop new strategies for the therapy of neurological diseases, where 
progressive neural damage and death causes the symptoms. In addition, it 
underlines the amazing adaptability of cells to their environment by which they 
ensure their survival. 
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4.2. Molecular preconditioning – neuroprotection mediated by AIF 
depletion 
4.2.1. AIF deficiency mediates mitoprotection 
The data presented in the first part of this thesis clearly indicated that neuroprotection 
mediated by AIF silencing occurs at the level of mitochondria, thereby mediating 
morphological and functional protection of these organelles. AIF depletion prevented 
mitochondrial morphology from glutamate-induced fragmentation and peri-nuclear 
accumulation. Overbalance in mitochondrial fragmentation is an early event in 
neurological diseases and acute brain injuries (Chan, 2004;Chen et al., 2003;Lin and 
Beal, 2006). The protection of the semi-tubular mitochondrial network in AIF-silenced 
cells suggests a protective effect upstream of mitochondrial membrane 
permeabilization.  
At the functional level AIF-silencing preserved ATP levels, prevented MMP, and 
attenuated production of lipid peroxides towards otherwise lethal glutamate 
concentrations. Mitochondria are the so-called “powerhouse” supplying the cell with 
metabolic energy in form of ATP (Wallace, 2005). Thus, the conserved ATP levels 
and the preserved MMP under oxidative stress in AIF-silenced HT-22 neurons 
indicate intact functionality of the mitochondria and preservation of the energy supply 
of the cells. Additionally, a slight depolarization as detected in AIF-silenced neurons 
under normal culture conditions is often associated with preconditioning effects 
(Hisatomi et al., 2009;Orozco et al., 2006;Sedlic et al., 2010), and can be explained 
by the downregulation of complex I as discussed in chapter 4.2.2.. Such a slight 
depolarization of the MMP may cause a reduction of the electron transfer to 
molecular oxygen, thereby diminishing ROS production. In addition, it could reduce 
the uptake in mitochondrial calcium by the ca2+ uniporter or activate signaling 
cascades to induce cell survival programs and thus, lead to the observed 
neuroprotective effect (Sack, 2006). Therefore, these data indicate that the protective 
effect of AIF deficiency is mediated by a preconditioning effect, which has its initial 
point within the mitochondria.  
This hypothesis is further supported by the preserved secondary increase in lipid 
peroxides in AIF-depleted cells, which demonstrates another proof for intact 
mitochondrial function and integrity. It is interesting to note that glutamate induces a 
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first increase in ROS formation before the onset of detectable cell death and a 
second strong increase in ROS when cellular damage becomes evident. The first 
increase seems to be attributed to the activation of 12/15-LOX whereas the second, 
higher increase is related to mitochondrial damage and the subsequent production of 
large amounts of ROS in the mitochondria (Tobaben et al., 2011). 
The finding that AIF silencing provides protection against oxidative cell death at the 
level of mitochondria is additionally supported by former data that demonstrate that 
the detrimental nuclear changes and DNA fragmentation mediated by AIF in different 
models of neuronal cell death occur within a few minutes after AIF release from the 
mitochondria (Daugas et al., 2000) and very little AIF protein that is still present after 
AIF siRNA treatment or in Hq mice is able to induce PCD (Cregan et al., 
2002;Daugas et al., 2000). These reports make it very unlikely that AIF knockdown 
should prevent from neuronal cell death just by sustained translocation to the 
nucleus.  
Collectively, the present data of this thesis indicate that AIF downregulation mediates 
mitoprotection by a preconditioning effect caused within the mitochondria that 
increases the tolerance towards oxidative stress. 
 
4.2.2. Preconditioning mediated by complex I inhibition 
The present study demonstrate that the protective effect of AIF silencing is 
associated with reduced complex I expression levels in the HT-22 cell line. This 
finding is consistent with previous reports in Hq mice and other cell models for AIF 
depletion (Vahsen et al., 2004; Benit et al., 2008). Further, direct inhibition of 
complex I by the specific inhibitor rotenone in nM range decelerated mitochondrial 
damage after oxidative stress in HT-22 neurons and showed similar effects as 
obtained with AIF silencing. The protective effect mediated by low dose rotenone was 
also persistent when cells were pretreated with rotenone only, which indicated again 
a preconditioning effect. Furthermore, also rotenone slightly decreased the MMP, 
which confirmed an underlying mechanism of preconditioning. This depolarization 
can be explained by the mechanism of action of complex I as described in Figure 38. 
In the first step of the respiratory chain electrons are transferred from NADH 
(nicotinamide adenine dinucleotide) to the primary electron acceptor flavin 
mononucleotide (FMN). The electrons are further transferred through a chain of 
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conserved iron-sulphur (Fe-S) clusters, and finally to ubiquinone. The membrane 
spanning part of the enzyme lacks covalently bound prosthetic groups, but it is 
suggested to contain the proton translocating machinery by which protons are 
pumped from the matrix into the intermembrane space, thereby generating a proton 
gradient that is necessary for later ATP production by the oxidative phosphorylation. 
The transfer of two electrons from NADH to ubiquinone (Q) is coupled to the 
translocation of four (current consensus value) protons across the membrane, 
however, how the electron transfer is linked with the translocation of protons is still 
not fully understood (Efremov and Sazanov, 2011). Inhibition of complex I leads to a 
reduced proton gradient at the inner mitochondrial membrane and thus, can explain 
the depolarization mediated by rotenone and AIF depletion. Although AIF itself is not 
a part of complex I, a role of AIF in the biogenesis and/or maintenance of this 
polyprotein complex has been postulated (Vahsen et al., 2004). The data of this 
study indicate that also rotenone treatment alone slightly decreases AIF expression 
levels, which suggests a mutual stabilization of AIF and complex I thereby regulating 
neural survival towards oxidative stress. The fact that high doses of the complex I 
inhibitor rotenone lead to lethal stress is in accordance with a common link of AIF 
and mitochondrial complex I since mice that are completely depleted in AIF, are also 
no longer viable (Brown et al., 2006;Joza et al., 2001). 
Complex I is part of a complex I/III/IV supercomplex (the so-called respirasome) 
which is essential for the stability/assembly of complex I as the major entry point of 
respiratory chain substrates. The mitochondrial complexes I (NADH dehydrogenase) 
and III (cytochrome c reductase) form a stable core respirasome to which complex IV 
(cytochrome c oxidase) can also bind (Schägger, 2001). Complex I is one of the 
largest known membrane proteins and consists of 45 protein subunits from which 
seven are encoded by the mitochondrial genome. The remaining subunits are 
encoded in the nucleus, translated in the cytosol and imported into the mitochondria 
(Dimauro and Rustin, 2009). Biochemical analyses postulate that the depletion of 
complex I in AIF-deficient cells derive from reduced expression of several of these 
nuclear encoded subunits (Vahsen et al., 2004). 
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Figure 38: Proposed mechanism of complex I. 
Complex I has a L-shaped structure with a hydrophobic and a hydrophilic arm. NADH transfers two 
electrons (e
-
) to the first cofactor FMN (green) and then through a chain of Fe-S clusters (red and 
yellow spheres) to the ubiquinone binding site. This transfer is linked with the translocation of four 
protons across the membrane (modified from Efremov and Sazanov, 2011; www.rcsb.org). 
 
There are controversial studies showing that neither AIF depletion nor its full deletion 
has major effects on the expression levels of respiratory chain subunits on the mRNA 
level in AIF-deficient ES and HeLa cells (Vahsen et al., 2004). However, another 
study reports a partial reduction on mRNA levels of respiratory chain subunits in 
muscle- and liver-specific AIF knockout mice (Pospisilik et al., 2007). Thus, AIF may 
regulate complex I levels by post-transcriptional mechanisms. Further investigations 
are needed to determine how exactly AIF is involved in the stability or the assembly 
of complex I and why this stabilization is mutual, i.e. affects also AIF stability as 
shown here using the complex I inhibitor rotenone.  
It is established that inhibition of the respiratory chain can induce tolerance to e.g. 
focal cerebral ischemia (Wiegand et al., 1999). Since AIF plays a major role in 
intrinsic pathways of caspase-independent neuronal death in model systems of 
cerebral ischemia (Culmsee et al., 2005;Plesnila et al., 2004;Zhu et al., 2003;Zhu et 
al., 2007) a preconditioning effect mediated by complex I inhibition is feasible. 
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Preconditioning effects are often described to promote a small decrease in the 
efficiency of NADH oxidation by the respiratory chain, which leads to an increase in 
mitochondrial ROS formation followed by activation of mitoKATP channels (Busija et 
al., 2008;Dirnagl and Meisel, 2008;Ravati et al., 2000;Ravati et al., 2001). However, 
no increase in lipid peroxides was detected in AIF-depleted cells, and also 
pretreatment with the radical scavenger trolox did not change the effect of AIF siRNA 
in this study. This finding suggests that increased ROS production in AIF-silenced 
cells is not the major mechanism of the preconditioning effect. These data are in line 
with previous studies showing that ROS production under basal conditions or 
stimulated by complex I inhibitors were not different in mitochondria from Hq mouse 
brain compared to wildtype mitochondria (Chinta et al., 2009). In conclusion, AIF may 
not directly modulate ROS production in mitochondria. However, it would be of 
interest whether the mitoKATP channels system is affected during AIF depletion-
mediated preconditioning to further confirm this hypothesis.  
Collectively, the results provide strong evidence that AIF depletion is linked to a 
decrease in complex I expression level and respiratory chain activity resulting in a 
slight mitochondrial depolarization. These preconditioning effects lead to a 
stabilization of mitochondria and thus, to delayed cell death after the glutamate 
challenge and related induction of oxidative stress. In addition, the data indicate a 
mutual stabilization of AIF and mitochondrial complex I. 
 
4.2.3. AMPK is not involved in the HT-22 model system 
The data presented in this study suggest that neuroprotection mediated by AIF 
silencing is not due to changes in the activity of AMPK since protein levels of AMPK 
as well as p-AMPK remained unaffected by AIF siRNA. Further, co-treatment of AIF 
siRNA with an AMPK activator or inhibitor did not reduce the neuroprotective effect of 
AIF siRNA against glutamate-induced cell death. An involvement of AMPK would 
suggest also changes in the ATP levels since AMPK monitors energy production and 
energy expenditure and regulates its activation dependent on the AMP:ATP ratio 
(Weisova et al., 2011). In this study AIF-depleted HT-22 cells maintained their ATP 
levels under control conditions as well as under oxidative stress similar to cells 
treated with the complex I inhibitor rotenone. Thus, the slight inhibition of the 
respiratory chain seems not to have such a high impact on the ATP production that 
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could activate AMPK. Another explanation could be that the energy production is 
preserved otherwise, e.g. by changed metabolism with increased glycolysis 
independent of AMPK.  
These results suggest that AMPK does not play a superior role in the regulation of 
cell survival mediated by AIF deficiency in the investigated model system. 
 
However, the data of this thesis also show that variations in the AMPK activity affect 
cell survival rate in the HT-22 model system of glutamate-induced cell death in 
general. This is in line with reports from the literature that indicate an important role 
of AMPK for the regulation of neuronal cell death and survival is several other model 
systems. For example, Culmsee et al. demonstrated that AMPK is highly expressed 
in neurons in the developing rat brain and further, AMPK activation promotes 
neuronal survival in primary hippocampal neurons following glucose deprivation 
(Culmsee et al., 2000). In contrast, Venna et al. reported that ischemic 
preconditioning which leads to improved behavioral outcomes in a mice model of 
stroke was associated with an inhibition of AMPK. This neuroprotective effect was 
abolished by pharmacological activation of AMPK and also AMPK-α2 null mice that 
lack the catalytic isoform of AMPK failed to demonstrate a preconditioning response 
(Venna et al., 2012).  
The contrary reports from the literature about how AMPK can mediate 
neuroprotection, as well as the findings in this study, showing that AMPK activation 
can mediate neuroprotection and neurotoxic effects may be explained by a recent 
study from Davila et al.. That study indicates that the effects of AMPK in the 
regulation of neuronal survival and cell death are strongly dependent on the duration 
and intensity of AMPK activation or inhibition. The authors demonstrate that AMPK 
mediates a two-step activation of forkhead box O3 (FOXO3), which generates a 
coherent feed-forward loop thereby determining excitotoxic cell fate. According to this 
hypothesis, short periods of AMPK activity allow p-AMPK to exert its pro-survival 
effects, whereas prolonged activation results in induction of cell death. The decision 
point is controlled by AKT-mediated dephosphorylation of FOXO3 in the first 
activation step. If the period of AMPK activation overcomes this delay of the first step, 
FOXO3 becomes activated in a second step, which results in Bim activation and 
apoptosis (Davila et al., 2012). Referring to this hypothesis, the performed 
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experiments in this thesis seem to be in an intermediate state of step one and two, in 
which activation of AMPK mediated by AICAR still provides neuroprotection against 
glutamate toxicity by its pro-survival functions, maintaining the cellular ATP levels, 
but also shows already slight toxic effects under control conditions (Figure 9 A).  
For the activation of AMPK in HT-22 cells AICAR was used in the mM range. These 
high concentrations are necessary since AMPK activation is regulated by the ratio of 
AMP:ATP and AICAR acts by its metabolite AICAR-monophosphate (ZMP), which 
mimics AMP. ZMP activates AMPK by both allosteric activation and, more 
importantly, by promoting phosphorylation of the -subunit (Thr172) mediated by an 
upstream kinase complex. Phosphorylation of Thr172 produces at least 100-fold 
activation, so that it is quantitatively much more important than the allosteric 
activation that increases enzyme activity up to 5-fold (Towler and Hardie, 2007). The 
high concentrations of AICAR needed for the activation may also support unspecific 
effects. Furthermore, Guigas et al. demonstrated that AICAR inhibits cellular 
respiration by an AMPK-independent mechanism and thus, cellular effects mediated 
by AICAR are not necessarily caused by AMPK activation (Guigas et al., 2007). 
Also, compound C used in this study may provide side effects next to its property as 
an inhibitor of AMPK. Its inhibitory effect results from reversible competition with 
ATP, but the exact mechanism of action is not further specified (Zhou et al., 2001). In 
addition, it has been reported that compound C does not exclusively inhibit AMPK but 
it also inhibits respiration and suppresses ROS generated by mitochondria (Emerling 
et al., 2007). Thus, other methods such as overexpression or siRNA approaches may 
offer more reliable tools for the investigations on AMPK. However, these efforts were 
not justified in this study since there was no hint for an involvement of AMPK in the 
mediation of AIF-depleted neuroprotection in the performed experiments. 
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4.2.4. AIF and its modulators as therapeutic targets 
To date, direct inhibition of AIF by pharmacological compounds is not available. This 
is foremost attributable to the fact that apart from its apoptotic functions AIF also 
provides vital redox functions that are indispensable for cell life (Vahsen et al., 2004). 
The complete loss of AIF expression during embryogenesis leads to growth 
retardation and death during midgestation (Brown et al., 2006;Joza et al., 2001), and 
long-lasting downregulation of AIF results in progressing ataxia as found in Hq mice, 
which express just 20 % of AIF compared to wildtype mice. The ataxia manifests as a 
side-to-side, unsteady gait with a lateral tremor visible at rest. Moreover, progressive 
cerebellar cortical atrophy has been characterized in these mice, with an apoptotic 
loss of granule cells and a necrotic loss of Purkinje cells occurring subsequently. 
Further, the animals show retinal degradation resulting in blindness, growth 
retardation and weight loss. In addition, hemizygous males and homozygous females 
are afflicted with baldness (Benit et al., 2008;Klein et al., 2002). Apart from that, it 
has been reported that mice with muscle-specific loss of AIF develop severe dilated 
cardiomyopathy and skeletal muscle atrophy (Joza et al., 2005). Pathogenetic AIF 
mutations are also known to occur in humans causing muscular atrophy, neurological 
and psychomotoric abnormalities and progressive mitochondrial encephalomyopathy 
(Modjtahedi et al., 2010). All these adverse effects of permanent AIF defects lead to 
the conclusion that AIF is not a recommended direct target for the therapy of 
neurodegenerative diseases or acute brain injury, to date. However, development of 
tools that selectively target the pro-apoptotic function of AIF or that can downregulate 
AIF for a short time only could avoid the adverse effects of long-term inhibition and 
establish AIF as an interesting therapeutic target. So far, mechanisms of AIF release 
upstream of mitochondrial damage are suggested as potential targets for therapeutic 
strategies. 
In the past years, different modulators of mitochondrial AIF release were identified, 
such as calpain I (Polster et al., 2005), the pro-apoptotic protein Bid (Grohm et al., 
2010;Landshamer et al., 2008;Tobaben et al., 2011), and PARP-1 (Wang et al., 
2009;Wang et al., 2011;Yu et al., 2002), that are of interest as indirect therapeutic 
targets of AIF. Polster et al. demonstrated that both precursor and mature forms of 
AIF are cleaved by calpain I near the amino terminus in vitro. This cleavage is 
essential for the release of AIF from the mitochondria and the subsequent induction 
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of chromatin condensation and cellular death (Polster et al., 2005). So far, several 
calpain inhibitors are in the focus of preclinical studies in animal models of ischemia 
and indicate neuroprotective potential (Bartus et al., 1994;Koumura et al., 
2008;Markgraf et al., 1998). Another modulator of AIF release is the pro-apoptotic 
bcl-2 family member Bid. AIF translocation to the nucleus is preceded by increasing 
translocation of Bid to mitochondria, and peri-nuclear accumulation of Bid-loaded 
mitochondria in neurons (Landshamer et al., 2008). The inhibition of Bid by small 
molecule inhibitors, such as BI6C9 as a target for neurological disorders is subject of 
previous and ongoing studies (Culmsee et al., 2005;Grohm et al., 2010;Landshamer 
et al., 2008). In addition, PARP-1 activation, followed by increased PAR levels, is 
associated with the lethal release of AIF. Recent findings indicate that PAR binding to 
AIF’s PAR-binding motif acts as the transducer that mediates AIF release from the 
mitochondria, allowing AIF to translocate to the nucleus. Therefore, also PARP-1 is 
an interesting therapeutic target and PARP-1 inhibition has been shown to reduce 
nuclear AIF translocation in a model of ischemic neuronal cell death (Culmsee et al., 
2005). Also in an in vitro model of rat SCI pharmacological inhibition of PARP-1 
showed histological protection and persistence of reflex activity (Nasrabady et al., 
2011) and a further study demonstrated that prevention of PARP activation protected 
against both ROS-induced cells injury in vitro and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced nigrostriatal dopaminergic damage in an in vivo 
mouse model of PD (Iwashita et al., 2004).  
Thus, all these regulators of mitochondrial damage and AIF release are validated as 
potential therapeutic targets in models of neuronal degeneration and death, and 
further highlight the importance for a deeper understanding of AIF and its 
mechanisms in regulating neuronal cell death and survival. 
 
Taken together, the data of this thesis provide novel data showing a preconditioning 
effect of AIF silencing in mitochondria that includes mitochondrial complex I 
reduction, functional and morphological preservation of mitochondria, and prolonged 
cell survival after the glutamate challenge and related induction of oxidative stress. 
Both, targeting AIF release and its pro-apoptotic activation as well as mechanisms 
underlying AIF depletion-mediated preconditioning may be promising strategies of 
neuroprotection. 
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4.3. Molecular conditioning – life from dying NPCs 
4.3.1. Life from death: cell death mediates neuroprotection 
The second part of the present study provides evidence that cell death of NPCs 
mediates neuroprotection to surrounding neural cells under lethal stress. The results 
demonstrated that growth factor withdrawal of NPCs lead to caspase-dependent cell 
death. The induction of starvation could be prevented by the broad-spectrum 
caspase inhibitor Q-VD-OPh. CM of dying NPCs prevented hippocampal HT-22 
neurons from glutamate-induced lethal stress and EBSS-induced starvation for 
several hours and even up to 8 hours after the toxic insult. Furthermore, CM also 
protected primary cortical neurons from glutamate toxicity (Neunteibl, personal 
communication). The finding that also HT-22 neurons themselves can mediate 
neuroprotective properties during starvation but not fibroblasts, indicated a specific 
effect for neural cell lines.  
The rescue of NPCs from starvation by the caspase inhibitor Q-VD-OPh abolished 
the neuroprotective effect of CM and also cell lysates of NPCs mediated 
neuroprotection towards glutamate-treated HT-22 cells. These data suggest that only 
dying NPCs secrete a sufficient amount of substances that mediate protection in 
neighboring neurons. Since inhibitors of protein synthesis did not affect the 
generation of neuroprotective CM from dying NPC, the protective substances are 
likely already expressed in the healthy cells, and only their release increased after 
induction of apoptotic cellular stress. The proposed ability of apoptotic cells to 
provide signaling cues for their environment and to support surrounding cells has 
been also demonstrated in other settings, such as ß-cell mass regeneration (Bonner 
et al., 2010), inhibition of inflammation during wound healing (Li et al., 2010) and 
planarian regeneration (Pellettieri et al., 2010). The fact that the ability of apoptotic 
cells to rescue surrounding cells is already described in invertebrates indicates an 
evolutionarily conserved regeneration mechanism. 
The finding that CM from dying stem cells provides neuroprotective effects is new 
and reflects conditions after stem/progenitor cell transplantation since the survival 
rate after stem/progenitor cell transplantation is very low (Chen et al., 
2002;Menasche, 2005;Silva et al., 2005). In former studies, CM from various 
stem/progenitor cells was demonstrated to provide neuroprotection but none of these 
indicated that starvation or cell lysis was a crucial step for enhancing the protective 
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potential (Cho et al., 2012;Isele et al., 2007;Lim et al., 2008;Menasche, 2005;Scheibe 
et al., 2012). The data of this thesis indicate that the low survival rate after stem cell 
transplantation may be very important for the highly potent neuroprotective benefit in 
neurodegenerative diseases and acute brain injuries.  
There are also some differences between NPC CM used in this study and CM from 
other stem cells reported in the literature. For example, Isele et al. demonstrated that 
BMSC CM attenuated staurosporine (STS) or amyloid-beta peptide-induced 
apoptosis in a concentration-dependent manner in primary embryonic rat neurons 
(Isele et al., 2007). This protective effect was abolished by a specific PI3K inhibitor. 
The data of this thesis demonstrate that inhibition of the PI3K pathway by the same 
inhibitor affect the neuroprotective effects only marginal, and indicate that there are 
more than just one pathway responsible for the neuroprotective benefit. Furthermore, 
the neuroprotective effect of BMSC CM was abolished by heating over 90°C (Isele et 
al., 2007) as also shown for NPC CM, but so far, nobody described an activation of 
the neuroprotective potential by moderate heat as it was done in this thesis. 
The isolation of protection-mediating substances by aceton precipitation supported 
the conclusion that proteins are responsible for the observed neuroprotective effect. 
This hypothesis was further confirmed by pre-incubation of CM with a protease, 
which abolished the beneficial effect of CM. The spectrum of the proteins mediating 
neuroprotection could be even narrowed down by the results from the cut off 
filtrations. The results clearly indicated that the main mediators of neuroprotection in 
CM have a molecular size between 10 and 50 kDa. In experiments with cut off filters 
it should always be kept in mind that the separation of the fractions is not stringent, 
and the fractions can still contain proteins with a molecular weight around the size of 
the filter. Thus, it is conceivable that also substances with another molecular weight 
may contribute to or reinforce the potency of CM. Furthermore, the present data 
identified already two proteins, prdx-1 and gal-1, to participate in the mediation of the 
neuroprotective properties of NPC CM as discussed in chapter 4.3.3.1. and 4.3.3.2.. 
Importantly, the findings of this study clearly demonstrated the contribution of a 
cofactor to the neuroprotective effect that did not mediate protection alone but in 
combination with the broad mixture of CM as demonstrated by the separation of the 
fractions with the 3 kDa cut off filter.  
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Moreover, other components, such as miRNA, apoptotic bodies, or mitochondria, 
could cause further protective signals. It has been demonstrated that various 
miRNAs can have protective effects in models of neurodegenerative diseases, such 
as AD (Wang et al., 2008). The RNase that was applied to CM in the experiments of 
this thesis was able to cleave single stranded RNA. Thus, mature miRNA would have 
been also prone to digestion. However, the RNase treatment did not alter the 
neuroprotective effect of CM, which excluded RNA and miRNA as the main 
protective components of CM. Furthermore, apoptotic bodies have been 
demonstrated to enhance the differentiation of human endothelial progenitor cells in 
vitro (Hristov et al., 2004), but also isolation of apoptotic bodies from dying NPCs did 
not provide any neuroprotective benefit. This is in accordance with the fact that 
RNase did not affect the protective properties of CM since the described protective 
effects of apoptotic bodies are often linked with the delivery of miRNA (Zernecke et 
al., 2009). 
Recently, it was reported that mitochondrial transfer from BMSCs protected against 
lung injuries (Prockop, 2012), but also isolated mitochondria from NPCs failed to 
protect HT-22 cells against glutamate-induced cell death. Furthermore, microvesicles 
can be excluded as mediators of neuroprotection since CM was filtrated through a 
0.22 µm filter by default without losing protective properties. 
 
The used CM mimics conditions after stem-cell based therapy that is currently 
investigated for the treatment of neurodegenerative diseases and acute brain injuries 
(Lindvall et al., 2004;Lindvall and Kokaia, 2006). Thus, CM from dying cells is an 
adequate model for the investigation of the mechanisms that mediate protective 
effects after stem/progenitor cell transplantation. Further, and most importantly, CM 
may offer an alternative to cell transplants in the treatment of degenerative diseases 
of the nervous system. In this way CM could overcome risks and limitations of the 
classical transplantation therapy as discussed in chapter 4.3.4.. 
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4.3.2. Heat activation of CM 
Interestingly, heat treatment at about 60°C significantly increased the neuroprotective 
potency of CM, and the neuroprotective effect of CM was only abolished at 
temperatures higher than 90°C. The finding, that also the aceton precipitate could be 
activated at 60°C indicates that the activation results from a protein. Enzymes and 
proteins typically function at temperatures below 60°C and denature if exposed to 
higher temperatures. The thermostability of proteins depends on a lot of various 
factors, such as amino acid composition, hydrophobic interactions, ion pairing, and 
hydrogen bonds within the protein. This stability can be improved by adjusting 
external environmental factors including cations, substrates, co-enzymes, and 
modulators (Ebrahimi et al., 2011). The performed experiments demonstrated that 
the proteins that are responsible for the neuroprotective effect of CM are heat stable 
up to 80°C. The identification of HSPs that are known to be activated through high 
temperatures, and the fact that recombinant gal-1 and prdx-1 are still active after 
heating at 60°C renders these proteins likely to contribute to the protective effect of 
CM.  
One explanation for the increase in the neuroprotective potential could be the 
activation of proteins or enzymes by heat. The most prominent proteins that are 
known to be activated at higher temperatures are the HSPs. However, heat activation 
of these proteins is usually achieved at temperatures around 40-45°C (Romi et al., 
2011). So far, there are no investigations of CM at higher temperatures described in 
the literature, most likely because temperatures as found for activation of the NPC 
CM in this thesis are considered to inactivate and denaturate most proteins. It is not 
described in the literature, for example whether HSPs are also activated at 
temperatures around 60°C as indicated for the NPC CM. 
Another explanation for the increase in the neuroprotective potential of CM after 
incubation at high temperatures could be that inhibitory or toxic substances are 
inactivated, whereas the neuroprotective substances are more thermostable. For 
example, such a neurotoxic enzyme could be phospholipases A2 (PLA 2). It has 
been reported that PLA 2 activity in normal human serum was remarkably decreased 
by incubation at 55°C for only 5 minutes (Funatomi and Hatta, 1991), and also 
phospholipases from other organisms are described to lose their activity at about 
60°C (Karray et al., 2012b). Furthermore, an inhibition of PLA 2 has been 
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demonstrated to provide direct neuroprotective effects in SY5Y neuronal cells in 
response to neurotoxic CM from differentiated HL-60 macrophages (Chen et al., 
2012). These data support the hypothesis that heat activation of NPC CM may result 
from an inhibition of one or more enzymes that otherwise provide neurotoxic effects. 
In this case, CM would offer an advantage towards the direct application of stem cells 
since the particular protocol for CM production allows to get rid of toxic substances 
by heat incubation, whereas stem cells may release toxic components in the host 
tissue. Thus, identification of the neuroprotective components in CM which are heat 
stable is highly relevant for therapeutic aspects. 
 
4.3.3. Neuroprotective components in the mixture of CM 
4.3.3.1. Peroxiredoxins 
MALDI-TOF analyses of CM detected different prdxs in all investigated protective 
samples. Prdxs are a family of small (22-27 kDA) non-seleno peroxidases with six 
mammalian isoforms. Their role as antioxidants results from their peroxidase activity 
that reduces and detoxifies hydrogen peroxide, peroxynitrite and a wide range of 
organic hydroperoxides.  
Prdxs can be divided into three major subclasses, which are the typical 2-cysteine  
(2-Cys) prdxs (including prdx-1 to 4), atypical 2-Cys prdx (prdx-5), and 1-Cys prdx 
(prdx-6). All three groups share the same peroxidatic active-site structure and thus 
have the first step of peroxide reduction in common in which the peroxidatic cystein 
(Cys-SH) attacks the peroxide substrate and is oxidized to a cysteine sulfenic acid 
(Cys-SOH) (Wood et al., 2003).  
 
Cys-SH         +        R-OOH             Cys-SOH     +     ROH 
        prdx reduced              cysteine sulfenic acid 
 
However, the typical and the atypical 2-Cys prdx contain two redox-active cysteins, 
whereas the 1-Cys prdx contains just one, and the second step of the reaction in 
which the cysteine sulfenic acid reacts back to the reduced prdx form distinguishes 
the three subclasses. Typical 2-Cys prdx are the largest class of prdxs and obligatory 
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forming homodimers containing two identical redox-active cysteins. In the second 
step of peroxide reduction the cysteine sulfenic acid from one subunit is attacked by 
the resolving cystein located in the C terminus of the other subunit to form a stable 
intersubunit disulfide bond. The catalytic cycle is closed by reduction of the disulfide 
bond through cell specific disulfide oxidoreductases, such as thioredoxin or 
tryparedoxin (Wood et al., 2003). 
 
 
  SOH       -H20   S Disulfide-     SH 
 2-Cys Prdx     2-Cys Prdx                   2-Cys Prdx 
   SH     S reductase     SH 
 
     
The atypical 2-Cys prdxs have the same mechanism as typical 2-Cys prdx, however, 
they are functionally monomeric so that the peroxidatic cytein and the corresponding 
resolving cystein are contained within the same polypeptide (Seo et al., 2000). In 
contrast, 1-Cys prdx conserves only one peroxidatic cysteine and it is presumably 
reduced by a thiol-containing reductant (Choi et al., 1998). 
The physiological importance of prdxs is illustrated by their abundance as well as 
studies in knockout mice. For example, mice lacking prdx-1 develop severe 
haemolytic anemia, and are predisposed to certain cancers in the haematopoietic 
system. In addition, prdx-1 knockout mice have a 15 % reduction in lifespan 
(Neumann et al., 2003). Also, prdx-2 knockout mice develop a spontaneous 
phenotype of hemolytic anemia (Yang et al., 2008a), whereas prdx-6 knockout mice 
show exaggerated lipopolysaccharide (LPS)-induced acute lung injury and 
inflammation with increased oxidative stress, inflammatory responses, and matrix 
degradation (Yang et al., 2011). 
In the CNS, prdxs are believed to act as free radical scavengers and are capable of 
protecting of a variety of cell types, including neurons, as reported in models of 
ischemic neuronal death in vitro, in overexpression models, and in 
neurodegenerative diseased tissue (Botia et al., 2008;Boulos et al., 2007;Fang et al., 
2007;Hattori and Oikawa, 2007;Smith-Pearson et al., 2008). 
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The prdx isoform that was identified in all MALDI-TOF analyses was prdx-1. The 
finding that prdxs are released from NPCs under conditions of growth factor 
withdrawal was recently supported by the report that prdx-1, 2, 5, and 6 are secreted 
into brain tissue 12 hours after stroke onset and act outside of the cell. In that study, 
the extracellular prdxs, particular prdx-5 and 6, and, to a less degree, prdx-1 and 2, 
were associated with post-ischemic inflammation by the induction of cytokines and 
increased infarct volume. However, in many investigations the study did not further 
differentiate between effects mediated by the different prdx isoforms in further detail, 
and thus, it is possible that mainly prdx-5, which was not detected in CM, was 
responsible for the increased inflammation (Shichita et al., 2012).  
The present study demonstrated that recombinant prdx-1 had neuroprotective effects 
in the HT-22 cell model system. However, the amount of released prdx-1 that was 
detected in CM in this study was in the nanomolar range whereas the recombinant 
protein was applied at micromolar concentrations to prevent glutamate-induced cell 
death in the HT-22 model system. Nevertheless, the reduced potency of CM after 
treatment with specific prdx-1 antibody demonstrated that prdx-1 was in any case an 
additive component that contributed to the neuroprotective effect of CM. It is possible 
that the human recombinant protein is not as potent as endogenous mouse prdx-1 in 
the model system of mouse cells. Further, it is conceivable that other components or 
cofactors in CM are able to activate the enzyme in a way that less prdx-1 is needed 
to provide neuroprotection.  
There is also evidence from the literature that prdx-1 is able to mediate 
neuroprotective effects. Recently, lentiviral-mediated overexpression of prdx-1 has 
been demonstrated to protect against 6-hydroxydopamine-induced cell death in 
mouse dopaminergic neurons in vitro and in vivo (Hu et al., 2011). In addition to its 
role as an antioxidant enzyme, the neuroprotective effect of prdx-1 could be also due 
to an interaction with the apoptosis signal-regulating kinase 1 (ASK-1). Prdx-1 is 
described to interact with ASK-1 via the thioredoxin-binding domain thereby inhibiting 
the activation of ASK-1, which further results in the inhibition of downstream signaling 
cascades, such as the p38 pathway (Kim et al., 2008b). 
Beyond that, prdx-1 expression has been reported to be increased in LPS-activated 
microglia which protects against H2O2 mediated microglial death also via inhibition of 
the p38 pathway (Kim et al., 2008a). The protection of microglia is a very interesting 
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aspect for neuroprotection in vivo since microglia are the main immune cells in the 
brain, and well established to be involved in neurodegenerative diseases. Beyond the 
neurotoxic effects of microglial activation by induction of an inflammatory state, 
microglia have been associated with neuroprotective effects, such as phagocytosis of 
dead neurons and clearance of debris (Polazzi and Monti, 2010). Thus, for in vivo 
application an effect of prdx-1 on microglia could also contribute to a neuroprotective 
effect.  
The data of this thesis also demonstrated increased prdx-1 expression levels in    
HT-22 cells after the treatment with NPC CM. This could result either from 
exogenous prdx-1 that was taken up from the media, or from other signals mediated 
by CM that lead to an increase of endogenous prdx-1. An increase in endogenous 
prdx-1 levels could result from the transcription factor nuclear factor (erythroid-
derived 2)-like 2 (Nrf-2). During oxidative stress, Nrf-2 can regulate the expression of 
genes whose protein products are involved in the detoxification of ROS, and it has 
been demonstrated that the prdx-1 gene is a target of Nrf-2 (Kim et al., 2007). To 
investigate whether endogenous prdx-1 in the HT-22 cell model system was 
increased by induction of Nrf-2, the PI3K inhibitor LY 294002 as an upstream 
regulator of Nrf-2 was used. Previous studies already demonstrated that it is possible 
to inhibit the Nrf-2-dependent induction of prdx-1 expression when targeting PI3K in 
SH-SY5Y cells (Nakaso et al., 2003). Inhibition of PI3K marginally affected the 
neuroprotective effects of CM. Therefore, an induction of endogenous prdx-1 by Nrf-2 
only could play a minor role in the neuroprotection mediated by NPC CM in this 
study. 
Taken together, the data of this thesis indicate that prdx-1 has the potential to 
mediate neuronal survival against glutamate-induced cell death in HT-22 neurons, 
and it seems to be one additive compound in the broad mixture of CM providing 
neuroprotective effects.  
 
Other members of the prdx family, such as prdx-2 and 6 were also identified in some 
MALDI-TOF experiments in this study, and these may also enhance neuroprotection. 
For example, it was shown that prdx-2 protected against 6-hydroxydopamine-induced 
death of mouse dopaminergic neurons in vitro and in vivo. This neuroprotective effect 
of prdx-2 was mediated by inhibition of the ASK-1 pathway (Hu et al., 2011). In 
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addition, overexpression of prdx-2 in transgenic mice reveals in reduced brain injury 
and improves neurological recovery up to 3 weeks after transient focal cerebral 
ischemia compared to wildtype littermates (Gan et al., 2012). 
For prdx-6, neuroprotective effects against hypoxia-induced retinal ganglion cell 
(RGC) damage have been described. RGCs exposed to hypoxia show reduced 
expression of prdx-6 which results in increased intracellular ROS levels and apoptotic 
cell death which can be prevented by overexpression of prdx-6 (Tulsawani et al., 
2010). In another study, overexpression of prdx-6 was associated with protective 
effects against oxidative stress in primary cortical neurons that overexpress retinoic 
acid receptor-related orphan receptor  (ROR), a transcription factor that plays an 
essential role for the development of Purkinje cells (Boukhtouche et al., 2006). 
Overall, there is clear evidence from the literature that prdxs have the ability to 
provide neuroprotection in vitro and in vivo. The data of this study indicate that prdxs, 
especially prdx-1, participate to the neuroprotective effects that CM provides against 
oxidative stress. 
 
4.3.3.2. Galectin-1 
Another interesting protein identified in CM by MALDI-TOF analyses in this study was 
gal-1. To date, there are 15 family members of the galectin protein family identified in 
mammals. They all have a conserved carbohydrate-recognition domain (CRD) of 
about 130 amino acids, which are responsible for β-galactoside binding. While some 
galectins contain only one CDR and are biologically active as monomers (gal-5, -7, 
and -10), as homodimers (gal-1, -2, and -11) or as oligomers (gal-3), others contain 
two CDRs (gal-4, -6, -8, -9, -12) (Camby et al., 2006). 
Galectins are primarily localized in the cytosol, but they are also found in nuclei and 
intracellular plasma membrane. They exert functions inside of the cell where they 
regulate signal transduction independently of their lectin activity by protein-protein 
interactions. Galectins, however, can also be secreted and function outside of the cell 
which is mainly dependent on their lectin activity (Yang et al., 2008b). Gal-1 was the 
first protein of this family discovered in 1994 (Barondes et al., 1994). Gal-1 exists as 
a monomer (~14.5 kDa), as well as a homodimer (~29 kDa) in solutions. Both forms 
are able to bind to carbohydrates, however, the monomeric form with a lower level of 
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affinity. Furthermore, gal-1 can also exist in an oxidized form that lacks lectin activity 
(Camby et al., 2006). 
Gal-1 has a lot of various biological functions including functions in the immune 
system, tumor formation, and the development of the neural system and muscle 
tissue. For example, in the immune system it contributes to the immunosuppressive 
activity of T regulatory cells, suppresses B-cell proliferation, and is involved in the 
activation of macrophages. It further favors tumor growth and migration, and 
participates in tumor cell evasion of immune response. In addition, it promotes cell 
differentiation in muscle cells (Yang et al., 2008b). All these functions are mediated 
by binding of gal-1 to various binding partners, such as carbohydrates, Ras, 
membrane glycoproteins, integrins, and several other proteins (Camby et al., 2006). 
In neural and stem cells different properties of gal-1 have been described. It has 
been demonstrated that recombinant gal-1 promoted neurite outgrowth from a mouse 
olfactory neuron cell line (Puche and Key, 1995). The reduced form of gal-1 
promotes proliferation of NSCs thereby interacting with β-1-integrin, which modulates 
cell adhesion (Sakaguchi et al., 2010). Thus, gal-1-null mice have fewer NPCs in the 
adult brain compared to their wildtype littermates (Sakaguchi et al., 2006). Also, an 
enhancement of axonal regeneration in peripheral nerves by the oxidized form of  
gal-1 has been described (Horie et al., 1999). Moreover, gal-1 inhibited glutamate 
toxicity in cerebellar cells (Lekishvili et al., 2006), and it has been further shown that 
oxidized gal-1 provided neuroprotection in a transgenic mouse model of ALS (Chang-
Hong et al., 2005).  
Recently, gal-1 was identified to be a pivotal regulator of microglial activation 
(Starossom et al., 2012). There are two different kinds of activation states in 
microglia. Classical activation, such as induced by LPS or interferon-, leads to a M1 
phenotype that is associated with neurodegeneration, whereas alternative activation, 
such as induced by interleukin (IL)-4, results in a M2 phenotype that has been shown 
to be anti-inflammatory and neuroprotective. Starossom et al. found gal-1 to bind with 
a significantly higher affinity to M1-type microglia, which responds in a shift to the M2 
state by downregulation of proinflammatory cytokines and iNOS expression, and by 
upregulation of typical M2 markers, such as arginase. This was mediated by binding 
of gal-1 to core 2 O-glycans decorating CD45 on microglial cells, resulting in 
retention of this glycoprotein on the plasma membrane and augmenting its 
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phosphatase activity. Further, gal-1 indirectly decreased neuronal loss through 
mechanisms involving p38MAPK-, CREB-, and NF-B-dependent signaling 
pathways, which are activated upstream of the neurotoxic molecules tumor necrosis 
factor (TNF) and nitric oxide (NO) in the microglia (Starossom et al., 2012). The 
finding, that gal-1 shifts the neurodegenerative activation state of microglia into a 
neuroprotective state could play an important role for neuroprotective effects in vivo.  
Collectively, there is evidence in the literature that both, the oxidized and the reduced 
form of gal-1, provide beneficial effects on neural cells. 
In the model system of glutamate-induced apoptosis in HT-22 cells recombinant 
mouse gal-1 attenuated glutamate toxicity. In addition, the neuroprotective effect of 
CM was reduced by a specific antibody. The fact, that the reduction of the 
neuroprotective effect was not seen in all experiments can be due to inefficiency of 
the antibody. Further, it is not known, whether the inhibition by the antibody is 
competitive or reversible. Since an unspecific antibody did not affect the 
neuroprotective effects of CM, these experiments clearly demonstrated that gal-1 
contributed to the neuroprotective effect of CM. 
So far, there is only one study published demonstrating a contribution of gal-1 to 
neuroprotective effects observed after stem cell transplantation. Adult common 
marmosets were treated with human NSCs that were transfected by lentivirus with 
gal-1 nine days after contusive cervical SCI. The Gal-NSC-grafted animals showed a 
better performance on all the behavioral tests compared with the other control groups 
including their spontaneous motor activity, bar grip power, and performance on a 
treadmill test (Yamane et al., 2010). This clearly demonstrates the potential of gal-1 
to provide beneficial effects after transplantation into the CNS in models of neuronal 
injury. However, very few is reported about the possible mechanisms behind this 
neuroprotective potential. There are several studies reporting that gal-1 influences 
the secretion and the receptors of growth factors that can mediate neuroprotection, 
for example, via the Akt signaling pathway. Former experiments in our laboratory 
demonstrated that NPC CM also leads to activation of Akt and Erk 1/2 in primary 
cortical neurons, which could suggest the involvement of growth factors (Neunteibl, 
Dolga, personal communication). 
Hsieh et al. reported that gal-1 activates VEGFR-2 signaling by an direct interaction 
with the neuronal receptor neuropilin-1 (Hsieh et al., 2008). This mechanism is in line 
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with findings showing that transplanted stem cells mediate neuroprotective effects 
after stroke, such as recovery, inflammation, and vascular repair by secretion of 
VEGF (Horie et al., 2011). VEGF can be secreted and act in very low concentrations 
(pg/ml; Cho et al., 2012) so that it is conceivable that it is under the detection limit the 
MALDI-TOF measurements. Another interesting aspect in this context is that VEGF 
has been demonstrated to be heat stable when heating at 65°C for 5 minutes 
(Ferrara and Henzel, 1989) which is also found for the investigated CM in this study. 
Whether VEGFR stimulation or VEGF-mediated neuroprotective plays a role in the 
HT-22 cell model remains to be unknown. However, since VEGF is expected to 
mediate neuroprotective effects via the PI3K/Akt signaling pathway (Kilic et al., 2006) 
also this factor would presumably be an additional compound for the CM-mediated 
neuroprotection in HT-22 cells, if at all, since inhibition of PI3K marginally affected 
the neuroprotective potency of CM only as already described. 
Another possible mechanism to provide neuroprotection by gal-1 is the induction of 
BDNF synthesis in the target cells. For example, Gal-1 enhanced BDNF synthesis in 
astrocytes which improved the functional outcome in rats following ischemia (Qu et 
al., 2010). However, BDNF was not able to provide neuroprotective effects in the 
applied HT-22 cell system leading to the conclusion, that gal-1 does not mediate 
neuroprotection of CM by stimulation of BDNF synthesis and release. This is in 
accordance with former reports showing that HT-22 cells do not express functional 
TrkB receptors and even after viral infection TrkB expressing HT-22 cells cannot be 
rescued from oxidative glutamate toxicity by BDNF but only from serum deprived cell 
death (Rössler et al., 2004). In primary cortical neurons BDNF is described to provide 
neuroprotection from glutamate-induced toxicity as well as from serum withdrawal 
(Hashimoto et al., 2002;Poser et al., 2003). Thus, BDNF production could still be a 
possible mechanism contributing to protective effects of gal-1 in CM in primary 
cortical neurons. 
The data of this study suggest that gal-1 secreted by dying NPCs is able to contribute 
to the neuroprotective effect mediated by NPC CM, however, comparable to prdx-1 it 
may only play a minor role in the complex CM mixture.  
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4.3.3.3. Further possible neuroprotective components in NPC CM 
In addition to prdxs and gal-1 there were also other proteins identified in NPC CM, 
which may provide neuroprotective effects. 
Further possible candidate proteins for neuroprotection are members of the HSP 
family. The HSPs are separated into subfamilies according to their molecular weight. 
Under physiological conditions, HSPs are expressed at low levels, and they are 
induced by cellular stress, such as increased temperature, radiation, exposure to 
chemicals, oxidative stress, and various other pathological stimuli. Furthermore, they 
act as chaperone proteins and prevent protein misfolding and aggregation. In 
addition, it has been shown that recombinant HSPs can function as cytokines to 
induce production of proinflammatory cytokines and promote dendritic cell maturation 
(Romi et al., 2011;Wang et al., 2002).   
The HSPs identified in NPC CM in this thesis were HSP 60, 70, and 90. There are 
several studies indicating that HSPs, especially HSP 70, provide neuroprotective 
effects in various models of neurodegenerative diseases and acute brain injury. For 
example, Liebelt et al. demonstrated that exercise preconditioning on a treadmill for 
several weeks before the onset of stroke in rats induced neuroprotection, which 
coincided with a significant upregulation of HSP 70 and p-Erk 1/2. These results were 
further associated with downregulated expression levels of Bax and AIF, while levels 
of Bcl-xL were upregulated in response to stroke after exercise (Liebelt et al., 2010).  
Also in animal models of ALS HSP 70 is shown to be involved in neuroprotective 
mechanisms. For example, intraperitoneal injected recombinant human HSP 70 into 
G93A mutant SOD1 mice was effective at increasing lifespan, delaying symptom 
onset, preserving motor function, and prolonging motoneuronal survival (Gifondorwa 
et al., 2007).  
Further, HSPs were shown to induce the production of IL-6 and TNF  and increase 
the phagocytosis and clearance of Aβ peptides in rat microglia. The mechanism of 
these activations by exogenous HSPs involved the NF-κB and p38MAPK pathways 
mediated by Toll-like receptor 4 activation. Thus, HSPs may serve a neuroprotective 
role by facilitating Aβ clearance and cytokine production (Kakimura et al., 2002). In 
another study Klucken et al. demonstrated that overexpression of HSP 70 reduced 
accumulation and toxicity of alpha-Synuclein, and also the alpha-Synuclein fibrillar 
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assembly was prevented by HSP 70 in mice (Huang et al., 2006;Klucken et al., 
2004). 
These examples clearly indicate that HSPs, especially HSP 70, have high potential to 
protect neural cells by intracellular as well as extracellular mechanisms. It has been 
demonstrated that HSP 70 can be released from several cells and taken up by other 
cells in a biologically active form, for example, in a model of human T98G glioma 
cells and differentiated LA-N-5 neuroblastoma cells as model for glia to neurons cell-
cell communication (Guzhova et al., 2001;Hightower and Guidon, Jr., 1989;Tytell et 
al., 1986). In the present study, HSP 70 was identified in several MALDI-TOF 
analyses of NPC CM and, thus, it may contribute to the protective effects. However, 
all HSPs identified in CM have a higher molecular weight than 50 kDa while the main 
protective effects of CM were detected with fractions containing proteins at molecular 
weights between 10 and 50 kDa. An additional contributing effect of HSPs is, 
however, conceivable since separation by the cut off filters is not very stringent. In 
addition, it should be kept in mind that the investigation of separated CM fractions 
can also lead to misinterpretations since it is also conceivable that the potency of 
some compounds is strongly dependent on cofactors and interactions with other 
proteins. The separation of these interaction partners may lead to the abolishment of 
neuroprotective events since cofactors, such as identified in the 3 kDa cut off filtrate, 
get lost. Furthermore, the separation of CM is mostly associated with dilution effects 
as in the experiments performed by column gel filtration or adsorption effects when 
using size exclusion filters to fractionate the mixture.  
 
In addition, MALDI-TOF analyses of NPC CM identified the eukaryotic elongation 
factors (eEF) 1 and 2. During elongation eEF 1 catalyzes the aminoacylated-transfer 
RNA delivery step, whereas eEF 2 acts as the translocase, allowing the ribosome to 
move down the mRNA one codon at a time (Sasikumar et al., 2012). 
Marin et al. demonstrated that glutamate leads to a calcium-dependent 
phosphorylation of eEF 2 and they suggested that the resulting depression of protein 
translation represents a self-protecting mechanism against glutamate-induced 
neurotoxicity (Marin et al., 1997). Moreover, the kinase for eEF 2 regulates dendritic 
spine stability and synaptic structure by modulating dendritic BNDF synthesis 
(Verpelli et al., 2010), which may be a relevant mechanism for the neuroprotective 
effect of CM in primary cortical neurons. 
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The data of this study clearly demonstrated that there were several different 
modulators of cell survival in the mixture of CM, and additive effects of prdxs, gal-1 
and also HSP 70 are very likely. Presumably, the interaction of several protein 
factors results in the highly potent neuroprotective composition of NPC CM. This 
hypothesis is further supported by the fact that neuronal loss and neurodegeneration 
in brain diseases are also not due to one single mechanism mediating neural cell 
death, but to multiple different mechanisms, including oxygen deficits, free radicals, 
products of lipid degradation, disrupted ionic homeostasis (e.g. calcium), altered 
neurotransmitter release (e.g. glutamate) and receptor function, inflammatory and 
immune changes, and apoptosis (Faden and Stoica, 2007;Yakovlev and Faden, 
2004). Therefore, a therapy that combines synergistic effects of potent 
neuroprotectants with different modes of action directed against the main 
pathological mechanisms involved in neuronal cell death promises much higher 
therapeutic effects than drugs directed toward a single pathophysiological 
mechanism. Of course, such single targets can also inhibit cell death by reducing the 
barrier of factors that has to be overcome for cell death, or by prolonging the time 
window until executing damage, which can be used for regeneration. However, a 
combination therapy promises much more efficiency, and may lower risks for adverse 
effects as compared with prolonged high-dose therapy. One example for the higher 
efficiency of a combination therapy compared to the single application of the 
substances is the study of Culmsee et al., that demonstrates that combination 
therapy of the NMDA receptor antagonist memantine and the 2-adrenoceptor 
agonist clenbuterol not only resulted in a further reduction of brain damage as 
compared with effects of the single components but also significantly extended the 
therapeutic window in a mouse model of permanent focal cerebral ischemia 
(Culmsee et al., 2004). Thus, CM promises to be a very efficient option for the 
treatment of neurological deficits. 
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4.3.4. Clinical implications of CM 
The data of this thesis indicate that CM from dying NPCs may offer a highly potent 
therapeutic option for the treatment of diseases that are characterized by neural loss 
and degeneration.  
There are several points that make CM an attractive alternative to direct 
stem/progenitor cell transplantation. Stem/progenitor cells are relatively easy to 
isolate and to expand, and thus, large amounts of CM can be produced easily in a 
short time. The activity of CM was found in this study to be improved by heating at 
60°C. This process results not only in a higher efficacy of CM but also in high 
stability. NPC CM in this thesis was shown to mediate neuroprotection even after 7 
days storage at 37°C without any loss of its potency. Due to this fact also continuous 
infusion of CM is possible which may increase the therapeutic benefit. For example, 
a continuous infusion of CM from human adipose stem cells was demonstrated to 
significantly improve functional and structural recovery in rats after MCAO (Cho et al., 
2012).  
Further advantages of CM compared to stem cell therapy are the setting of control 
standards and quality issues. CM could be standardized, e.g. to one protein that is 
identified to mediate neuroprotection. However, before such control standards can be 
introduced the exact composition of CM has to be clarified.  
Since the exact mixture in CM is not yet known it is also conceivable that CM 
contains considerable amounts of toxic or counteracting substances. Therefore, CM 
needs to be examined for such potentially harmful factors, which then could be 
eliminated to further optimize CM for therapeutic applications. One possibility to get 
rid of such toxic substances could be the heating process at 60°C. Such toxic 
substances, that can be eliminated more easily from CM than from stem cells, could 
also include carcinogen components. An outgrowth of transformed cells in human 
MSC cultures (Scheibe et al., 2012;Wang et al., 2005) and similar characteristics in 
both stem cells and cancer stem cells (Ratajczak, 2005) have been reported. Thus, 
the risk of tumorigenicity induced by stem cell transplantation and also CM has to be 
studied very thoroughly. To date, there is one report of a human brain tumor derived 
from stem cell therapy. A 9-year old boy with ataxia telangiectasia was treated with 
intracerebellar and intrathecal injections of human fetal NSCs. Four years after the 
first injection a multifocal brain tumor of nonhost origin was diagnosed suggesting 
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that it was derived from the transplanted NSCs (Amariglio et al., 2009). The risk of 
tumor formation as a late effect of stem cell therapy is not only topic of discussion 
after transplantation into the brain but also discussed in other fields. For example, an 
increased risk for secondary tumor formation has been described for patients after 
allogenic hematopoietic stem cell transplantation (Gallagher and Forrest, 2007) and 
also iPS cells that are a promising tool for future stem cell therapy are known to have 
the potential for tumorigenicity, and thus, the generation of tumor-free iPSCs reaches 
more and more interest (Lin and Ying, 2013;Zhao et al., 2012). For that reason, it is 
highly important to ensure the safety of stem/progenitor cell transplantation, to 
identify risk factors, and to develop alternative therapy methods, such as the 
application of stem/progenitor cell CM that may overcome risks and limitations of 
classical stem cell therapy.  
Another remaining question is the optimum route of delivery for CM. It has to be 
tested whether CM has to be applied directly into the brain or if also a peripheral 
application is possible. Several studies showed beneficial effects of intravenous 
injection of stem cells. For example, Chen et al. demonstrated that intravenously 
administered MSCs mediated recovery of somatosensory behavior and Neurological 
Severity Score in a rat model of stroke. Morphological analysis of the tissue indicated 
that MSCs are more likely to enter into damaged brain than into contralateral 
nonischemic brain (Chen et al., 2001). Another study from Jackson et al. directly 
compared different stem cell types and different routes of application, such as 
intracerebral or intravenous applications. Both BMSCs and epidermal neural crest 
stem cells (eNCSCs) were transplanted into the corpus callosum of rats lateral to an 
LPS inflammatory lesion or were injected intravenously. Both stem cell types showed 
significant homing potential to sites of inflammatory brain injury after intracerebral as 
well as after intravenous transplantation. However, only 8 % of the intravenously 
injected stem cells migrated to the lesion whereas more than 10 times of this number 
of stem cells reached the lesion site after intracranial administration (Jackson et al., 
2010). The mechanisms responsible for stem cell migration into the brain after i.v. 
application are not yet fully understood. Inflammatory substances, such as IL-1, 
TNF, and IL-6 originating from degenerating tissue may provide chemoattractant 
signals for stem cells, and the movement could be controlled in part through changes 
in expression of cell surface adhesion molecules. Further, disruption of the BBB may 
also facilitate selective entry of stem cells into brain lesion (Chen et al., 2001;Jackson 
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et al., 2010).  
It would be necessary to investigate whether the observations of stem cell migration 
are also transferable for the substances providing neuroprotection in CM from 
stem/progenitor cells, or if the whole cells are needed to serve as a kind of shuttle for 
the neuroprotection-mediating compounds after intravenous injection.  
Further, it is also necessary to develop an efficient and gently method to concentrate 
CM to guarantee an uncomplicated and efficient dosage for individual patients. 
Of course, the neuroprotective benefit of CM as well as the safety, the reproducible 
generation, and the exact application of CM have to be tested extensively in vivo 
models before transferring the concept of CM application to clinical trials. 
 
The data from this thesis indicate the benefit of NPC CM resulting from cell lysis 
during cell death. This implies the potential use of cell lysates instead of CM, since 
lysates are much easier generated than CM from dying cells. However, standardizing 
and controlling such a lysate, e.g. for the content of proteases, is also a major 
challenge. Furthermore, the lysate could not be activated by heat reliable, which is a 
great advantage of NPC CM. In addition, NPC lysate was less stable compared to 
NPC CM when stored at 37°C, and thus, cell lysates are unlikely suitable for 
continuous infusion or long-time storage. 
 
Collectively, the results of this thesis indicate that CM from dying NPCs could be a 
viable and promising tool for the treatment of neurodegenerative insults, which could 
bypass several technical and clinical limitations of stem/progenitor cell 
transplantation. 
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5. Summary 
Neuronal preconditioning describes a phenomenon that affords robust brain 
tolerance against neurodegenerative insults. This adaptive cytoprotection is a 
fundamental capability of living cells, allowing them to survive exposure to potentially 
recurrent stressors. The research of the molecular and cellular signaling during this 
self-protecting process is an important tool to develop novel strategies for the 
treatment of diseases that are characterized by neuronal cell death, which causes 
progressive loss of brain tissue and function after acute brain injury and in chronic 
neurodegenerative diseases.  
The major aim of this study was to investigate preconditioning effects in a model of 
neuronal cell death on the molecular and cellular level. This issue was addressed in 
immortalized mouse hippocampal HT-22 neurons exposed to glutamate toxicity, 
which selectively induces oxidative stress through glutathione depletion. 
The first part of the present study investigates, whether the neuroprotective effect 
mediated by the depletion of the pro-apoptotic protein AIF is attributed to 
mitochondrial preconditioning. AIF is a mitochondrial protein that mediates caspase-
independent cell death after translocation into the nucleus by chromatin 
condensation and large-scale DNA fragmentation. The findings of this study 
demonstrate that AIF gene silencing protects mitochondrial function and integrity in a 
paradigm of lethal oxidative stress in the used neural cell line. Depletion of AIF 
preserved mitochondrial morphology, mitochondrial membrane potential, and ATP 
levels after induction of oxidative stress in HT-22 cells, and this mitoprotective effect 
also significantly attenuated the secondary increase in lipid peroxidation which was 
associated with mitochondrial damage and cell death in this model system. 
Furthermore, AIF depletion was associated with reduced complex I expression 
levels, and similar to protective effects achieved by low doses of the complex I 
inhibitor rotenone. These results suggest for the first time that AIF silencing provides 
protection against oxidative cell death at the level of mitochondria by preconditioning 
and not at the level of apoptotic DNA damage in the nucleus. 
The second part of this thesis investigated conditioned medium (CM), which was 
generated by neural progenitor cells (NPCs) that undergo starvation-induced 
apoptosis after growth factor withdrawal. It is well established that transplantation of 
stem/progenitor cells to the brain improve abnormal motor behavior and memory 
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function in a broad spectrum of neurodegenerative diseases and after acute brain 
injury. However, stem cell-based therapy still holds many risks and unresolved issues 
regarding the mode of action and the optimal application. The validation of a CM from 
dying NPCs reflects the conditions after stem/progenitor cell injection since only very 
few cells survive after the transplantation. The findings of the present study clearly 
demonstrate that CM provides very potent, long-lasting, and stable neuroprotective 
effects that can even be further increased by heat activation. The data also indicate 
that cell lysis is essential for the generation of protective properties. Thus, the release 
of neuroprotective substances during the cell death of stem/progenitor cells seems to 
be a kind of cellular communication that protects neighboring cells and other tissues. 
Interestingly, a variety of proteins were identified as potential candidates that 
mediated the neuroprotective effect of CM, such as prdx-1 and gal-1. Further, the 
contribution of a low molecular weight cofactor was found. Thus, the results of these 
investigations are the basis for the development of a highly potent, standardized 
composition for the therapy of neurodegenerative diseases and acute brain injury. 
In summary, the data from this thesis highlight the neuroprotective potential of 
preconditioning effects for the regulation of cell survival after neurodegenerative 
insults. In addition, they indicate the importance of understanding the underlying 
mechanisms to develop new strategies for the therapy of neurodegenerative 
diseases. 
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6. Zusammenfassung 
Neuronale Präkonditionierung beschreibt ein Phänomen, bei dem es durch potentiell 
toxische Reize zu einer Toleranzentwicklung gegenüber neurodegenerativen 
Prozessen im Gehirn kommt. Diese Anpassungsfähigkeit der Zellen ist essentiell, um 
gegen spätere Stresseinwirkungen besser geschützt zu sein. Für die Entwicklung 
neuer Strategien bei der Behandlung von Erkrankungen, die durch neuronalen 
Zelltod und dem daraus resultierenden Verlust von funktionsfähigem Hirngewebe 
gekennzeichnet sind, ist es von größter Bedeutung, diesen Selbstschutz-
mechanismus auf molekularer und zellulärer Ebene zu erforschen.  
Das Ziel dieser Arbeit bestand darin, Effekte der Präkonditionierung sowohl auf 
molekularer Ebene, als auch auf zellulärer Ebene in einem Modell des neuronalen 
Zelltods zu untersuchen. Hierzu wurde eine neuronale hippocampale Zelllinie (HT-22 
Zellen) verwendet, die dadurch gekennzeichnet ist, dass eine Schädigung mit 
Glutamat zu einem kontinuierlichen Abfall der intrazellulären Glutathionspiegel führt 
und somit oxidativen Stress induziert. 
Der erste Teil der vorliegenden Arbeit beschäftigt sich mit der Fragestellung, ob ein 
durch AIF-Depletion vermittelter neuroprotektiver Effekt auf mitochondriale 
Präkonditionierung zurück zu führen ist. Das pro-apoptotische Protein AIF ist ein 
mitochondriales Protein, das Caspase-unabhängigen Zelltod vermitteln kann. Die 
Ergebnisse dieser Arbeit zeigen, dass eine Herunterregulierung von AIF im 
vorliegenden Modell sowohl die Funktionen als auch die Integrität der Mitochondrien 
schützt. Eine verringerte Expression von AIF bewahrte die mitochondriale 
Morphologie, das mitochondriale Membranpotential und die ATP-Spiegel der Zellen 
unter der Einwirkung von oxidativem Stress. Darüber hinaus verzögerte sich auch 
der späte Anstieg an Lipidperoxiden, der im Allgemeinen mit einer Schädigung der 
Mitochondrien und anschließendem Zelltod in diesem Zellmodell einher geht. Des 
Weiteren führte eine AIF-Depletion zu einer verringerten Expression des Komplex I 
der Atmungskette. Der Komplex I-Inhibitor Rotenon erzielte in niedriger Dosierung 
ähnlich protektive Effekte im untersuchten Zellsystem.  
Diese Untersuchungen zeigten erstmalig, dass AIF-Depletion aufgrund 
mitochondrialer Präkonditionierungseffekte zum Schutz der Zelle gegen oxidativen 
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Stress führt und nicht, wie bislang angenommen auf einer verringerten DNA-
Schädigung im Zellkern beruht. 
Der zweite Teil der Arbeit beschäftigt sich mit der Untersuchung von konditioniertem 
Medium (CM), das nach Wachstumsfaktorentzug aus sterbenden neuralen 
Vorläuferzellen (NPCs) gewonnen wurde. Die Transplantation von Stammzellen und 
Vorläuferzellen ins Gehirn kann sowohl die motorischen Funktionen, als auch die 
Gedächtnisfunktion in einer Vielzahl von neurodegenerativen Erkrankungen, sowie 
nach Schädel-Hirn-Trauma und Schlaganfall verbessern. Jedoch beinhaltet die 
Stammzell-basierte Therapie noch sehr viele Risiken und offene Fragen bezüglich 
ihrer Wirkweise und der optimalen Anwendung. Die Entwicklung eines CMs von 
sterbenden NPCs spiegelt sehr gut die Bedingungen nach der Transplantation von 
Stammzellen wieder, da nur wenige Zellen diese Transplantation überleben und die 
meisten Zellen, während sie sterben, eine Vielzahl von Faktoren freisetzen. Die 
Ergebnisse der vorliegenden Studie zeigten, dass CM einen starken und lang 
andauernden neuroprotektiven Effekt vermittelt. Dieser Effekt konnte durch 
Hitzebehandlung des CMs noch verstärkt werden. Darüber hinaus zeigten die Daten, 
dass eine Lyse der NPCs notwendig ist, um einen protektiven Effekt zu erzielen. 
Vermutlich handelt es sich bei der beobachteten Protektion um Schutzsignale der 
sterbenden Zellen für die benachbarten Zellen und umliegendes Gewebe. 
Interessanterweise wurde eine Vielzahl von Proteinen im CM identifiziert, die für die 
Neuroprotektion verantwortlich zu sein scheinen, darunter auch Peroxiredoxin-1 und 
Galectin-1. Zusätzlich wurde die Beteiligung eines niedermolekularen Cofaktors an 
der Vermittlung des neuroprotektiven Effekts nachgewiesen. Die Ergebnisse dieser 
Untersuchungen bilden somit die Grundlage für die Entwicklung eines äußert 
potenten und standardisierbaren CMs, das für eine therapeutische Anwendung bei 
neurodegenerativen Erkrankungen, sowie anderen zerebralen Schädigungen 
vorstellbar ist. 
Zusammenfassend zeigt diese Arbeit, wie effektiv Präkonditionierungseffekte für das 
Überleben neuronaler Zellen bei neurodegenerativen Ereignissen sind. Für die 
Entwicklung neuer Therapieoptionen ist es von größter Bedeutung, die zugrunde 
liegenden Mechanismen der protektiven Effekte durch molekulare und zelluläre 
Präkonditionierung zu entschlüsseln. 
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7. Abbreviations 
ACA     Asphyxial cardiac arrest 
AD     Alzheimer’s disease 
AIF     Apoptosis inducing factor  
ALS     Amyotrophic lateral sclerosis 
AICAR 5-Amino-1-β-D-ribofuranosyl-imidazole-4-
carboxamide 
AMP Adenosine monophosphate 
AMPK 5' Adenosine monophosphate-activated protein 
kinase 
ANOVA     Analysis of variance 
Apaf-1    Apoptosis protease-activating factor-1  
ASK-1    Apoptosis signal-regulating kinase 1  
ATP     Adenosinetriphosphate 
ATP 5A    ATP synthase  
BBB     Blood brain barrier 
BCA     Bicinchonic acid 
Bcl-2      B-cell lymphoma-2 
BDNF     Brain-derived neurotrophic factor 
bFGF     basic Fibroblast growth factor 
BMSC    Bone mesenchymal stem cells 
BSA     Bovine serum albumin  
BODIPY  4,4-Difluoro-5-(4- phenyl-1,3-butadienyl)-4-bora 
3a,4a-diaza-sindacene-3-undecanoic acid 
CAD     Caspase-activated deoxyribonuclease 
CCCP     Carbonyl cyanide 3-chlorophenylhydrazone 
CHX     Cycloheximide 
CM     Conditioned medium 
CNS     Central nervous system 
CRD     Carbohydrate-recognition domain 
Cx43     Connexin 43 
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Cyt C     Cytochrome C     
DAPI     4',6-Diamidino-2-phenylindole 
DMEM     Dulbecco's Modified Eagle Medium 
DMSO    Dimethyl sulfoxide 
DNA      Desoxyribonucleic acid 
DTT     D,L-Dithiotreitol 
EBSS     Earle's Balanced Salt Solution 
EDTA     Ethylenediamine-tetra-acetic acid 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’- 
tetraacetic acid 
eEF 2     eukaryotic Elongation factor 2 
EGF     Endothelian growth factor 
EMA     European Medicines Agency 
eNCSCs    Epidermal neural crest stem cells 
Erk     Extracellular signal-regulated kinase 
ESC     Embryonic stem cell 
FACS     Fluorescence-activated cell sorting 
FasL      Fas-ligand 
FCS      Fetal calf serum 
FDA     Food and Drug Administration 
FGF     Fibroblast growth factor 
FOXO3    Forkhead box O3 
Gal-1     Galectin-1 
Glut     Glutamate 
Gpx 4     Glutathion peroxidase 4 
GSH      Glutathione 
IL     Interleukin 
iNOS     inducible nitric oxide synthase 
iPSC     induced pluripotent stem cell 
HD     Huntington’s disease 
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HIF-1     Hypoxia-inducible factor 1 
H2O2     Hydrogen peroxide 
Hq     Harlequin 
HRP     Horseradish peroxidase 
HSP     Heat shock protein 
LIF     Leukaemic inhibitory factor 
12/15 LOX    12/15 Lipoxygenase 
LPS     Lipopolysaccharide 
LY 294002    2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
MAPK     Mitogen-activated protein kinase 
MEF     Mouse embryonic fibroblast 
miRNA    microRNA 
mitoKATP Mitochondrial adenosine triphosphate-dependent 
potassium 
MLS     Mitochondrial location sequences 
MMP     Mitochondrial membrane potential 
MnSOD    Manganese superoxide dismutase 
MPTP     1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MSC     Mesenchymal stem cell 
MTCO 1    Mitochondrially encoded cytochrome c oxidase 1 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
NAD+ Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide 
NaOH     Sodium hydroxide 
NDUFA-8 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 8 
NEAA     Non-essential amino acids 
NPC     Neural progenitor cell 
Nrf-2     Nuclear factor (erythroid-derived 2)-like 2  
NSC     Neural stem cell 
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NF-κB     Nuclear factor κB 
NO     Nitric oxide 
OGD     Oxygen-glucose deprivation 
Omi/HtrA2     High temperature requirement protein A2 
PAR     Poly(ADP-ribose) 
PARP-1    Poly(ADP-ribose)polymerase 1 
PBS     Phosphate buffered saline 
PCD     Programmed cell death 
PD     Parkinson’s disease 
PFA     Paraformaldehyde 
PI3K     Phosphoinositide-3-kinase 
PKC     Protein kinase C 
PLA 2     Phospholipase A 2 
Prdx     Peroxiredoxin 
PVDF     Polyvinylidenfluorid 
Q     Ubiquinone 
QH2     Ubiquinol 
Q-VD-OPH N-(2-Quinolyl)valyl-aspartyl-(2,6-difluorophenoxy) 
methyl ketone  
RGC Retinal ganglion cell  
ROR Receptor-related orphan receptor  
ROS     Reactive oxygen species 
SCI     Spinal cord injury 
Scr     Scrambled 
SDHB     Succinate dehydrogenase complex, subunit B 
SDS     Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SGZ subgranular zone 
SMAC/DIABLO  Second mitochondria – derived activator of 
caspase/direct IAP binding protein with low pI 
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SVZ subventricular zone 
TBE Tris/borate/EDTA 
TBI     Traumatic brain injury 
tBid      truncated Bid 
TBST     Tris-buffered solution with Tween 20 
TEMED     Tetramethylenethylendiamin 
TMRE     Tetramethylrhodamin ethal ester 
TNF     Tumor necrosis factor 
Trolox 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic 
acid 
UCP 2    Uncoupling protein 2 
UQCRC 2    Ubiquinol-cytochrome c reductase core protein 2 
VEGF     Vascular endothelial growth factor 
xCT     glutamine-cystine antiporter 
XIAP     X-chromosomal linked inhibitor of apoptosis 
ZMP     AICAR-monophosphate 
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8. Attachment 
  Accession Number 
Peptide 
Count 
Total 
Ion 
Score Blast 
n
  
1 
P000022070|10481..18563
|X150812|MAUS_026728 11 678 vimentin 3 
2 
P000025562|10126..15853
|X171365|MAUS_011752 11 692 phosphoglycerate mutase 1 3 
3 
P000050959|11039..12925
|X170662|MAUS_029580 10 823 actin, cytoplasmic 1  3 
4 
P000024841|10204..71927
|X167120|MAUS_047126 9 556 clathrin heavy chain 1  2 
5 
P000021382|7754..13998|
X146990|MAUS_004980 9 612 
heterogeneous nuclear 
ribonucleoproteins A2/B1 isoform 2  3 
6 
P000049905|13972..15652
|X126642|MAUS_023944 7 445 Hsp90ab1 protein  3 
7 
P000021080|10090..41734
|X145184|MAUS_020849 7 565 14-3-3 protein epsilon 2 
8 
P000051665|14256..15439
|X186510|MAUS_034994 6 392 Eef2 protein 2 
9 
P000025352|10111..18938
|X170045|MAUS_004891 6 354 nestin  3 
10 
P000024506|10001..56355
|X165166|MAUS_020917 6 310 ATP-citrate synthase isoform 2  1 
11 
P000049063|10208..11951
|X127700|MAUS_017390 5 412 fructose-bisphosphate aldolase C  3 
12 
P000025266|10359..12260
|X169662|MAUS_059970 5 354 heat shock-related 70 kDa protein 2  3 
13 
P000024794|10233..14024
|X166888|MAUS_026864 5 255 
78 kDa glucose-regulated protein 
precursor 2 
14 
P000018018|10907..19558
|X126344|MAUS_025980 4 372 
60 kDa heat shock protein, 
mitochondrial 2 
15 
P000026091|10145..33559
|X174409|MAUS_051391 4 368 14-3-3 protein gamma 3 
16 
P000050150|11259..26246
|X150241|MAUS_025153 4 266 fatty acid synthase, isoform CRA_a  2 
17 
P000049393|10068..10738
|X173202|MAUS_020736 4 234 5',3'-nucleotidase, cytosolic  2 
18 
P000049887|10141..13142
|X127442|MAUS_023456 4 176 triosephosphate isomerase  3 
19 
P000049100|10156..11861
|X144739|MAUS_018293 3 256 profilin 1  2 
20 
P000052491|10112..53449
|X174110|MAUS_052397 3 186 ezrin 1 
21 
P000028168|10167..37010
|X186979|MAUS_021218 3 157 unnamed protein product** 2 
22 
P000021200|10058..20134
|X145952|MAUS_062380 3 126 tubulin beta-3 chain 2 
23 
P000027169|10057..20834
|X181030|MAUS_022234 3 397 mKIAA0098 protein  2 
24 
P000048462|9927..34091|
X146372|MAUS_001924 3 267 
ubiquitin-like modifier-activating 
enzyme 1 isoform 1 
 
2 
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25 
P000022728|10265..48819
|X154656|MAUS_020361 3 227 mKIAA4025 protein  2 
26 
P000025576|10054..10446
|X171437|MAUS_036964 3 226 histone H2A.1  3 
27 
P000024051|10098..78052
|X162659|MAUS_054808 3 211 alpha-actinin-4  1 
28 
P000023811|18093..23788
|X161063|MAUS_055762 3 202 
elongation factor 1-delta isoform b 
and a  1 
29 
P000051382|23866..49452
|X171377|MAUS_032050 3 191 radixin isoform b and a  2 
30 
P000020729|12290..20903
|X143030|MAUS_071644 3 189 Eef1g protein  2 
31 
P000018185|10070..21870
|X127342|MAUS_025613 3 171 mKIAA0002 protein  2 
32 
P000027703|10218..41795
3|X184343|MAUS_001424 3 170 
staphylococcal nuclease domain-
containing protein 1  2 
33 
P000017842|10105..15686
|X125163|MAUS_020372 3 164 unnamed protein product*** 1 
34 
P000023670|9343..21805|
X160286|MAUS_034024 3 159 T-complex protein 1 subunit beta 1 
35 
P000049906|12179..13076
|X126644|MAUS_023944 3 158 unnamed protein product* 3 
36 
P000020214|10028..37827
|X139742|MAUS_036427 3 124 glucose-6-phosphate isomerase  2 
37 
P000022446|10050..26205
|X152953|MAUS_030007 3 110 T-complex protein 1 subunit eta  1 
38 
P000023525|11427..21677
|X159460|MAUS_019432 3 116 spliceosome RNA helicase Ddx39b  2 
39 
P000017827|18606..32227
|X125077|MAUS_032294 2 230 pyruvate kinase isozymes M1/M2  3 
40 
P000022563|10037..14605
|X153648|MAUS_022884 2 226 
eukaryotic initiation factor 4A-II 
isoform c  2 
41 
P000019273|11820..23658
|X134237|MAUS_028691 2 132 peroxiredoxin-1  3 
42 
P000023813|18093..23788
|X161064|MAUS_055762 2 114 Eef1d protein 1 
43 
P000052885|10071..13417
|X174586|MAUS_068220 2 123 galectin-1 3 
44 
P000022841|10671..15229
|X155501|MAUS_060600 2 215 beta-enolase isoform 1 3 
45 
P000026814|10162..22559
|X178937|MAUS_007739 2 202 T-complex protein 1 subunit delta  1 
46 
P000021882|10657..14323
|X149735|MAUS_012848 2 201 40S ribosomal protein S5  1 
47 
P000022358|12325..18862
|X152492|MAUS_037601 2 151 nucleoside diphosphate kinase A 2 
48 
P000018051|10145..13565
|X126574|MAUS_027342 2 139 proliferating cell nuclear antigen 2 
49 
P000023615|10568..16711
|X160009|MAUS_005566 2 135 tripartite motif protein 28 1 
50 
P000018324|10012..45563
|X128172|MAUS_030662 2 120 importin-5 1 
51 
P000049450|19814..52139
|X141334|MAUS_020929 2 116 
116 kDa U5 small nuclear 
ribonucleoprotein component 
isoform b and a 1 
Attachment   139 
 
 
 
52 
P000051363|13015..31287
|X128933|MAUS_031960 2 116 
alanyl-tRNA synthetase, isoform 
CRA_a  2 
53 
P000023351|10064..25998
|X158430|MAUS_024359 2 111 stress-70 protein, mitochondrial  2 
54 
P000050193|10116..14645
|X133351|MAUS_025403 2 111 
serine hydroxymethyltransferase, 
mitochondrial  2 
55 
P000051168|10572..27299
|X124954|MAUS_030824 2 100 nucleobindin-1 isoform 2 1 
56 
P000051666|12663..13178
|X186511|MAUS_034994 2 86 Eef2 protein 2 
57 
P000025173|16286..28220
|X169131|MAUS_030934 2 75 
ornithine aminotransferase, 
mitochondrial precursor  1 
58 
P000028300|15849..29542
|X187842|MAUS_020608 2 60 unnamed protein product **** 1 
59 
P000052058|54375..85324
|X137072|MAUS_040136 2 56 Abcc8 protein  1 
60 
P000052788|11093..11751
|X133760|MAUS_062929 2 106 cofilin-2  2 
61 
P000020979|13650..14999
|X144561|MAUS_045427 2 98 
heterogeneous nuclear 
ribonucleoprotein H2  1 
62 
P000024530|11780..19301
|X165293|MAUS_063229 2 85 
L-lactate dehydrogenase A chain 
isoform 1 3 
63 
P000050306|10059..12827
|X138058|MAUS_026202 1 84 tubulin alpha-4A chain  2 
64 
P000022341|4987..19276|
X152343|MAUS_020321 1 81 malate dehydrogenase, cytoplasmic  2 
65 
P000027044|11348..15940
|X180333|MAUS_031134 1 70 RNA binding motif protein, X-linked  1 
66 
P000048610|10070..11949
|X180376|MAUS_003814 1 67 unnamed protein product # 2 
67 
P000051603|10079..19680
|X160287|MAUS_034024 1 49 T-complex protein 1 subunit beta  2 
68 
P000027728|11792..17011
|X184472|MAUS_033124 1 46 autophagy-related protein 9A  1 
69 
P000018585|18297..36323
|X129808|MAUS_029767 1 45 calumenin isoform 2 precursor 2 
70 
P000052150|14007..14518
|X184135|MAUS_041070 1 202 
eukaryotic translation initiation 
factor 5A, isoform CRA_j  2 
71 
P000027720|10001..29781
|X184437|MAUS_028478 1 143 clathrin light chain A isoform a 2 
72 
P000049171|10105..14953
|X156572|MAUS_019179 1 142 
malate dehydrogenase 2, NAD 
(mitochondrial), isoform CRA_a  2 
73 
P000018256|10051..19446
|X127751|MAUS_026701 1 133 peroxiredoxin-6  1 
74 
P000021612|10095..17089
5|X148246|MAUS_059248 1 116 septin-9 isoform a  1 
75 
P000050901|31261..37899
|X160534|MAUS_029309 1 103 SPARC-like protein 1 precursor  1 
76 
P000019044|10067..70923
|X132733|MAUS_031996 1 92 
amyloid beta (A4) precursor-like 
protein 2, isoform CRA_a  1 
77 
P000050653|40956..49939
|X144926|MAUS_028426 1 90 
RAD23b homolog (S. cerevisiae), 
isoform CRA_b 1 
78 
P000048814|21370..23494
|X149919|MAUS_007564 1 80 
Protein phosphatase 2 (formerly 
2A), regulatory subunit A (PR 65), 
alpha isoform  1 
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79 
P000023849|138851..1973
46|X161353|MAUS_01522 1 80 
microtubule-associated protein 2 
isoform 1  1 
80 
P000022723|10082..34315
|X154628|MAUS_027193 1 76 apoptosis inhibitor 5  1 
81 
P000024990|10032..32892
|X168014|MAUS_027694 1 73 
ubiquitin-conjugating enzyme E2 
variant 1  1 
82 
P000024886|10079..25200
|X167431|MAUS_025487 1 73 unnamed protein product ## 1 
83 
P000022098|10031..14375
|X150947|MAUS_030744 1 72 40S ribosomal protein S3  1 
84 
P000018086|10493..16824
|X126792|MAUS_027613 1 72 
eukaryotic translation initiation 
factor 6  1 
85 
P000020876|16150..26184
|X143958|MAUS_003131 1 68 
Platelet-activating factor 
acetylhydrolase, isoform 1b, alpha2 
subunit  2 
86 
P000050727|10552..36224
|X151778|MAUS_028693 1 68 
nuclear autoantigenic sperm protein 
isoform 2  1 
87 
P000019422|94063..11892
6|X135040|MAUS_037921 1 64 Ddx60 protein 1 
88 
P000023062|23421..35730
|X156697|MAUS_028656 1 63 
CAP, adenylate cyclase-associated 
protein 1 (yeast), isoform CRA_a 1 
89 
P000028379|13763..29650
|X188281|MAUS_025950 1 62 
isocitrate dehydrogenase [NADP] 
cytoplasmic  1 
90 
P000028261|13795..26507
|X187628|MAUS_001416 1 62 unnamed protein product ###  2 
91 
P000019757|31491..33092
|X137005|MAUS_017466 1 58 differential display clone 8  1 
92 
P000026583|7873..12543|
X177454|MAUS_042730 1 57 
transcription elongation factor B 
polypeptide 1 isoform a  1 
93 
P000020021|8921..14148|
X138532|MAUS_026817 1 56 
adenylate kinase isoenzyme 1 
isoform 1 and 2  1 
94 
P000024905|11351..27007
|X167554|MAUS_032966 1 55 FK506 binding protein 1a  1 
95 
P000027584|10018..14299
|X183530|MAUS_026926 1 55 
peptidase (mitochondrial 
processing) alpha  1 
96 
P000026144|21788..28437
|X174683|MAUS_024601 1 52 unnamed protein, Isoc2a protein  1 
97 
P000023329|11444..22540
|X158255|MAUS_028964 1 52 protein DJ-1  1 
98 
P000025490|10227..43905
|X170939|MAUS_028577 1 50 
phospholipase A-2-activating 
protein 1 
99 
P000026153|32053..40277
|X174766|MAUS_008206 1 47 
LAG1 longevity assurance homolog 
4  1 
10
0 
P000018440|11141..27236
|X128960|MAUS_029716 1 47 
transferrin receptor 2, isoform 
CRA_d  1 
10
1 
P000018700|10266..54945
|X130521|MAUS_020698 1 46 chaperonin subunit 6b (zeta)  1 
10
2 
P000020601|10034..14008
|X142106|MAUS_031807 1 95 6-phosphogluconolactonase  1 
10
3 
P000052151|12644..14518
|X184127|MAUS_041070 1 61 
eukaryotic translation initiation 
factor 5A, isoform CRA_j  1 
10
4 
P000024559|10621..14464
|X165482|MAUS_005161 1 54 peroxiredoxin-2  1 
10
5 
P000051643|46982..14755
1|X153454|MAUS_034573 1 54 
tyrosine-protein phosphatase non-
receptor type 13 3 
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Attachment 1: MALDI-TOF analysis of CM, 10 kDa concentrate.  
Proteins with a total ion score > 45 are listed; n = number of experiments containing the 
named protein out of three independent experiments, two runs each.  
*pubmed data base also found heat-shock protein hsp86 and heat-shock protein hsp84 as 
significant alignment 
** pubmed data base also found  guanosine diphosphate (GDP) dissociation inhibitor 2, 
isoform CRA_b 
*** pubmed database also found G protein beta subunit like as significant alignment 
**** pubmed database also found Smc6 protein as significant alignment 
# pubmed database also found calreticulin precursor as significant alignment 
## pubmed database also found 26S proteasome non-ATPase regulatory subunit 13 as 
significant alignment 
### pubmed database also found T-complex protein 1 subunit gamma as significant 
alignment. 
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 Accession Number 
Peptide 
Count 
Total 
Ion 
Score Blast n 
1 
P000049887|10141..13142
|X127442|MAUS_023456 11 893 triosephosphate isomerase  2 
2 
P000021382|7754..13998|
X146990|MAUS_004980 9 702 
heterogeneous nuclear 
ribonucleoproteins A2/B1 isoform 2  2 
3 
P000025352|10111..18938
|X170045|MAUS_004891 7 755 nestin 2 
4 
P000021019|10156..12512
|X144737|MAUS_018293 6 726 profilin-1  1 
5 
P000052885|10071..13417
|X174586|MAUS_068220 6 565 galectin-1 2 
6 
P000026632|10064..18153
|X177687|MAUS_027559 5 324 carbonic anhydrase 3  1 
7 
P000026934|10089..37671
|X179615|MAUS_039323 4 269 
insulin-like growth factor-binding 
protein 2 precursor  2 
8 
P000025562|10126..15853
|X171365|MAUS_011752 4 245 
phosphoglycerate mutase 1, 
unnamed protein product 1 
9 
P000023042|10105..21577
|X156567|MAUS_019179 3 359 
malate dehydrogenase, mitochondrial 
precursor  1 
10 
P000018256|10051..19446
|X127751|MAUS_026701 3 214 peroxiredoxin-6 1 
11 
P000028443|16065..25048
|X188757|MAUS_028692 3 111 alcohol dehydrogenase [NADP+] 1 
12 
P000052788|11093..11751
|X133760|MAUS_062929 2 165 cofilin-2  2 
13 
P000020601|10034..14008
|X142106|MAUS_031807 2 103 6-phosphogluconolactonase 2 
14 
P000026451|11180..12320
|X176611|MAUS_025132 2 86 rho GDP-dissociation inhibitor 1  2 
15 
P000025619|10186..29074
|X171634|MAUS_007656 2 79 
cAMP-regulated phosphoprotein 19 
isoform 1  1 
16 
P000024559|10621..14464
|X165482|MAUS_005161 2 60 peroxiredoxin-2  1 
17 
P000026744|10033..11265
|X178434|MAUS_036504 2 225 
14 kDa phosphohistidine 
phosphatase  1 
18 
P000027044|11348..15940
|X180333|MAUS_031134 2 207 RNA binding motif protein, X-linked  1 
19 
P000019273|11820..23658
|X134237|MAUS_028691 2 182 peroxiredoxin-1  2 
20 
P000020729|12290..20903
|X143030|MAUS_071644 2 170 Eef1g protein  1 
21 
P000052151|12644..14518
|X184127|MAUS_041070 2 168 
eukaryotic translation initiation factor 
5A, isoform CRA_j  1 
22 
P000022127|20166..42003
|X151103|MAUS_019961 2 160 
lamina-associated polypeptide 2 
isoform delta  1 
23 
P000028168|10167..37010
|X186979|MAUS_021218 2 147 
guanosine diphosphate (GDP) 
dissociation inhibitor 2, isoform 
CRA_b and c  1 
24 
P000020999|10119..26981
|X144660|MAUS_036371 2 131 
plasminogen activator inhibitor 1 
RNA-binding protein isoform 3 1 
25 
P000022070|10481..18563
|X150812|MAUS_026728 2 120 vimentin, unnamed protein 1 
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26 
P000026522|10089..36769
|X177075|MAUS_028567 2 107 
thioredoxin domain-containing protein 
12 precursor  1 
27 
P000020979|13650..14999
|X144561|MAUS_045427 2 104 
heterogeneous nuclear 
ribonucleoprotein H2  1 
28 
P000049816|10037..11120
|X153661|MAUS_022884 1 96 
eukaryotic translation initiation factor 
4A2, isoform CRA_e  1 
29 
P000022841|10671..15229
|X155501|MAUS_060600 1 76 
enolase 3, beta muscle, isoform 
CRA_a  1 
30 
P000022628|10124..21100
|X154058|MAUS_030663 1 64 small acidic protein  1 
31 
P000021143|15292..17032
|X145559|MAUS_030057 1 46 
cellular nucleic acid binding protein, 
isoform CRA_d  1 
32 
P000025266|10359..12260
|X169662|MAUS_059970 1 46 heat shock-related 70 kDa protein 2  1 
33 
P000026252|10001..22211
|X175425|MAUS_005354 1 118 thioredoxin, mitochondrial precursor  1 
34 
P000028454|11635..18736
|X188794|MAUS_041459 1 113 unnamed protein product ## 1 
35 
P000019800|10092..14855
|X137236|MAUS_004035 1 106 glutathione S-transferase Mu 7  1 
36 
P000023849|138851..1973
46|X161353|MAUS_01522
2 1 103 
microtubule-associated protein 2 
isoform 1  2 
37 
P000023755|25947..39844
|X160758|MAUS_018583 1 98 
ras GTPase-activating protein-
binding protein 1  1 
38 
P000050754|10031..24753
|X121146|MAUS_028792 1 97 unnamed protein ### 1 
39 
P000049274|17720..19987
|X153496|MAUS_020265 1 95 unnamed protein product* 1 
40 
P000023615|10568..16711
|X160009|MAUS_005566 1 93 tripartite motif protein 28 1 
41 
P000027139|10177..22272
|X180900|MAUS_017421 1 92 zinc finger protein 207 isoform 3  1 
42 
P000049950|10013..26131
|X160634|MAUS_024165 1 76 
hematological and neurological 
expressed 1-like protein 1 
43 
P000024242|23317..45487
|X163695|MAUS_040028 1 76 ELAV-like protein 1 1 
44 
P000018497|10091..11013
|X129298|MAUS_028843 1 71 
SH3 domain-binding glutamic acid-
rich-like protein 3  1 
45 
P000048657|14481..31915
|X149553|MAUS_004789 1 70 
dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydroge 1 
46 
P000017842|10105..15686
|X125163|MAUS_020372 1 69 unnamed protein product** 1 
47 
P000048624|10030..27024
|X142457|MAUS_004207 1 66 
sulfated glycoprotein 1 isoform E 
preproprotein  1 
48 
P000048921|16130..18081
|X172408|MAUS_013698 1 63 
astrocytic phosphoprotein PEA-15 
isoform 2  1 
49 
P000022341|4987..19276|
X152343|MAUS_020321 1 57 malate dehydrogenase, cytoplasmic  1 
50 
P000020713|33915..59863
|X142921|MAUS_026867 1 48 
GTPase-activating protein and VPS9 
domain-containing protein 1  1 
51 
P000017718|10358..13038
|X124382|MAUS_029328 1 49 
Heterogeneous nuclear 
ribonucleoprotein D-like 1 
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52 
P000048998|10001..59254
|X149970|MAUS_015647 1 46 laminin subunit alpha-5 precursor  1 
53 
P000021881|10243..14334
|X149727|MAUS_026694 1 45 unnamed protein product*** 1 
 
Attachment 2: MADLI-TOF analysis from CM containing proteins between 10 and 
50 kDA.  
Proteins with a total ion score > 45 are listed. n = number of experiments containing the 
named protein out of two independent experiments, two runs each.  
##  pubmed database also found TAR DNA-binding protein 43 isoform 1 as significant 
alignment 
### pubmed database also found adenylate kinase 2, mitochondrial isoform b as significant 
alignment 
* pubmed database also found small ubiquitin-related modifier 3 precursor as significant 
alignment 
** pubmed database also found G protein beta subunit like as significant alignment 
*** pubmed database also found methyltransferase-like protein 13 as significant alignment. 
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 Accession Number 
Peptide 
Count 
Total 
Ion 
Score Blast 
1 
P000022070|10481..18563
|X150812|MAUS_026728 24 2142 vimentin, unnamed protein 
2 
P000025352|10111..18938
|X170045|MAUS_004891 13 1494 nestin  
3 
P000021382|7754..13998|
X146990|MAUS_004980 13 1299 
heterogeneous nuclear 
ribonucleoproteins A2/B1 isoform 2  
4 
P000018018|10907..19558
|X126344|MAUS_025980 5 746 
60 kDa heat shock protein, 
mitochondrial  
6 
P000021080|10090..41734
|X145184|MAUS_020849 5 487 unnamed protein product 
5 
P000049063|10208..11951
|X127700|MAUS_017390 4 511 fructose-bisphosphate aldolase C  
7 
P000019273|11820..23658
|X134237|MAUS_028691 4 435 peroxiredoxin-1  
8 
P000051665|14256..15439
|X186510|MAUS_034994 4 402 Eef2 protein  
9 
P000025266|10359..12260
|X169662|MAUS_059970 4 373 heat shock-related 70 kDa protein 2  
10 
P000022358|12325..18862
|X152492|MAUS_037601 3 352 nucleoside diphosphate kinase A  
11 
P000024559|10621..14464
|X165482|MAUS_005161 3 347 peroxiredoxin-2  
12 
P000049887|10141..13142
|X127442|MAUS_023456 3 304 triosephosphate isomerase  
16 
P000026091|10145..33559
|X174409|MAUS_051391 3 189 14-3-3 protein gamma  
24 
P000020999|10119..26981
|X144660|MAUS_036371 3 162 
plasminogen activator inhibitor 1 RNA-
binding protein isoform 3 
13 
P000052150|14007..14518
|X184135|MAUS_041070 2 268 
eukaryotic translation initiation factor 
5A, isoform CRA_j 
14 
P000026451|11180..12320
|X176611|MAUS_025132 2 218 rho GDP-dissociation inhibitor 1  
15 
P000050901|31261..37899
|X160534|MAUS_029309 2 212 SPARC-like protein 1 precursor  
19 
P000023849|138851..1973
46|X161353|MAUS_01522
2 2 167 
microtubule-associated protein 2 
isoform 1 
20 
P000018561|11055..12743
|X129678|MAUS_031972 2 167 actin 
21 
P000018609|10131..29603
|X129995|MAUS_032366 2 164 tropomyosin alpha-1 chain isoform 5  
22 
P000050192|10767..14471
|X158955|MAUS_025381 2 164 protein canopy homolog 2 precursor  
23 
P000024794|10233..14024
|X166888|MAUS_026864 2 163 
78 kDa glucose-regulated protein 
precursor  
25 
P000023351|10064..25998
|X158430|MAUS_024359 2 162 stress-70 protein, mitochondrial 
26 
P000052885|10071..13417
|X174586|MAUS_068220 2 154 galectin-1  
31 
P000020601|10034..14008
|X142106|MAUS_031807 2 111 6-phosphogluconolactonase 
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40 
P000020539|15102..16662
|X141828|MAUS_026547 2 66 transgelin-2  
41 
P000022244|31246..60587
|X151691|MAUS_019894 2 66 
sodium-dependent neutral amino acid 
transporter B(0)AT2 
17 
P000018256|10051..19446
|X127751|MAUS_026701 1 181 peroxiredoxin-6  
18 
P000027720|10001..29781
|X184437|MAUS_028478 1 175 clathrin light chain A isoform a  
27 
P000049100|10156..11861
|X144739|MAUS_018293 1 151 profilin 1  
28 
P000048410|12191..48337
|X168533|MAUS_001120 1 150 
poly(rC) binding protein 3, isoform 
CRA_b  
29 
P000049705|84568..90210
|X126712|MAUS_022443 1 131 Myh9 protein  
30 
P000026252|10001..22211
|X175425|MAUS_005354 1 121 thioredoxin, mitochondrial precursor  
32 
P000027044|11348..15940
|X180333|MAUS_031134 1 108 RNA binding motif protein, X-linked 
33 
P000023329|11444..22540
|X158255|MAUS_028964 1 105 protein DJ-1  
34 
P000050754|10031..24753
|X121146|MAUS_028792 1 97 Unnamed protein*** 
35 
P000048979|10078..13203
|X153786|MAUS_015092 1 94 
endothelial differentiation-related factor 
1  
36 
P000052754|16001..20459
|X186796|MAUS_062014 1 90 glia maturation factor-beta  
37 
P000049395|10113..23779
|X141606|MAUS_020737 1 76 
hematological and neurological 
expressed 1 protein  
38 
P000051643|46982..14755
1|X153454|MAUS_034573 1 69 
tyrosine-protein phosphatase non-
receptor type 13  
39 
P000050653|40956..49939
|X144926|MAUS_028426 1 67 
RAD23b homolog (S. cerevisiae), 
isoform CRA_b  
42 
P000018585|18297..36323
|X129808|MAUS_029767 1 65 calumenin isoform 2  
43 
P000022645|10044..16863
1|X154135|MAUS_027722 1 58 
spermatogenesis-associated protein 5 
isoform 2  
44 
P000049274|17720..19987
|X153496|MAUS_020265 1 63 Unnamed protein product* 
45 
P000026522|10089..36769
|X177075|MAUS_028567 1 62 
thioredoxin domain-containing protein 
12 precursor  
46 
P000024981|10082..33538
|X167954|MAUS_024740 1 61 DNA damage-binding protein 1  
47 
P000048921|16130..18081
|X172408|MAUS_013698 1 57 
astrocytic phosphoprotein PEA-15 
isoform 2  
48 
P000018229|10016..21244
|X127553|MAUS_071533 1 54 unnamed protein** 
49 
P000018477|12311..67294
|X129159|MAUS_009614 1 52 
sarcosine dehydrogenase, 
mitochondrial precursor  
50 
P000028244|12672..22236
|X187481|MAUS_056917 1 51 
signal-induced proliferation-associated 
protein 1  
51 
P000018497|10091..11013
|X129298|MAUS_028843 1 49 
SH3 domain-binding glutamic acid-rich-
like protein 3  
52 
P000017718|10358..13038
|X124382|MAUS_029328 1 49 
Heterogeneous nuclear 
ribonucleoprotein D-like 
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53 
P000022531|12780..15567
|X153420|MAUS_046879 1 46 
immunity-related GTPase family M 
protein 1 
54 
P000027951|10175..25032
|X185764|MAUS_022683 1 49 Pla2g10 protein  
 
Attachment 3: MALDI-TOF analysis from CM after heating at 60°C.  
Proteins with a total ion score > 45 are listed. Data are given from one experiment with two 
runs.  
* pubmed database also found mCG1036415 as significant alignment 
** pubmed database also found small ubiquitin-related modifier 3 precursor as significant 
alignment 
*** pubmed database also found  adenylate kinase 2 as significant alignment, mitochondrial 
isoform b as significant alignment 
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  Accession Number 
Peptide 
Count 
Total 
Ion 
Score Blast 
1 
P000050959|11039..12925
|X170662|MAUS_029580 3 138 A-X actin 
2 
P000023042|10105..21577
|X156567|MAUS_019179 2 124 
malate dehydrogenase, mitochondrial 
precursor  
3 
P000049063|10208..11951
|X127700|MAUS_017390 2 120 fructose-bisphosphate aldolase C 
4 
P000017827|18606..32227
|X125077|MAUS_032294 2 111 pyruvate kinase isozymes M1/M2  
5 
P000025173|16286..28220
|X169131|MAUS_030934 2 90 
ornithine aminotransferase, 
mitochondrial precursor  
6 
P000050193|10116..14645
|X133351|MAUS_025403 2 90 
serine hydroxymethyltransferase, 
mitochondrial  
7 
P000021382|7754..13998|
X146990|MAUS_004980 2 70 
heterogeneous nuclear 
ribonucleoproteins A2/B1 isoform 2  
8 
P000025352|10111..18938
|X170045|MAUS_004891 1 99 nestin  
9 
P000018256|10051..19446
|X127751|MAUS_026701 1 76 peroxiredoxin-6  
10 
P000025576|10054..10446
|X171437|MAUS_036964 1 68 histone H2A.1  
11 
P000019800|10092..14855
|X137236|MAUS_004035 1 56 glutathione S-transferase Mu 7 
12 
P000023351|10064..25998
|X158430|MAUS_024359 1 51 kynureninase 
13 
P000017842|10105..15686
|X125163|MAUS_020372 1 49 unnamed protein product*** 
14 
P000021200|10058..20134
|X145952|MAUS_062380 1 47 tubulin beta-3 chain 
15 
P000019600|10041..39229
|X136112|MAUS_039853 1 45 tripartite motif-containing protein 14 
16 
P000021143|15292..17032
|X145559|MAUS_030057 1 46 
cellular nucleic acid binding protein, 
isoform CRA_d 
17 
P000049100|10156..11861
|X144739|MAUS_018293 1 46 profilin 1 
 
Attachment 4: MALDI-TOF analysis of NPC lysate.  
Proteins with a total ion score > 45 are listed Data are given from one experiment with two 
runs. 
 ***pubmed database also found G protein beta subunit like as significant alignment. 
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 Accession Number 
Peptide 
Count 
Total 
Ion 
Score Blast n 
1 
P000021382|7754..13998|
X146990|MAUS_004980 5 409 
heterogeneous nuclear 
ribonucleoproteins A2/B1 isoform 2  3 
2 
P000019273|11820..23658
|X134237|MAUS_028691 4 421 peroxiredoxin-1  3 
3 
P000050959|11039..12925
|X170662|MAUS_029580 4 243 actin, cytoplasmic 1  2 
4 
P000022070|10481..18563
|X150812|MAUS_026728 4 311 vimentin 3 
5 
P000018561|11055..12743
|X129678|MAUS_031972 3 159 actin 1 
6 
P000021074|13694..16995
|X145089|MAUS_070436 2 173 serpin H1 precursor  1 
7 
P000025266|10359..12260
|X169662|MAUS_059970 2 115 heat shock-related 70 kDa protein 2  1 
8 
P000022841|10671..15229
|X155501|MAUS_060600 2 65 
enolase 3, beta muscle, isoform 
CRA_a  1 
9 
P000049887|10141..13142
|X127442|MAUS_023456 2 72 triosephosphate isomerase 1 
10 
P000052788|11093..11751
|X133760|MAUS_062929 1 83 cofilin-2  2 
11 
P000025577|5121..21089|
X171447|MAUS_041126 1 72 
eukaryotic translation initiation factor 
5A, isoform CRA_j  2 
12 
P000052151|12644..14518
|X184127|MAUS_041070 1 64 
eukaryotic translation initiation factor 
5A, isoform CRA_j  1 
13 
P000050043|10137..29012
|X177775|MAUS_024640 1 60 
phosphoserine aminotransferase 
isoform 1  1 
14 
P000017827|18606..32227
|X125077|MAUS_032294 1 45 pyruvate kinase isozymes M1/M2  1 
15 
P000019759|10417..61808
|X137002|MAUS_017466 1 79 TIMP-2  1 
16 
P000027720|10001..29781
|X184437|MAUS_028478 1 55 clathrin light chain A isoform a  1 
17 
P000052885|10071..13417
|X174586|MAUS_068220 1 60 galectin-1  2 
18 
P000051665|14256..15439
|X186510|MAUS_034994 1 53 Eef2 protein  1 
19 
P000018203|10303..23041
|X127436|MAUS_022658 1 116 transgelin-3  1 
20 
P000024530|11780..19301
|X165293|MAUS_063229 1 95 
L-lactate dehydrogenase A chain 
isoform 1  2 
21 
P000023813|18093..23788
|X161064|MAUS_055762 1 75 Eef1d protein  1 
22 
P000019023|10120..25648
|X132628|MAUS_022241 1 49 
threonyl-tRNA synthetase, 
cytoplasmic  1 
 
Attachment 5: MALDI-TOF analysis of HT-22-CM.   
Proteins with a total ion score > 45 are listed; n = number of experiments containing the 
named protein out of three independent experiments, two runs each. 
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  Accession Number 
Peptide 
Count 
Total 
Ion 
Scor
e Blast 
1 
P000022070|10481..18563|X1508
12|MAUS_026728 3 133 vimentin  
2 
P000018561|11055..12743|X1296
78|MAUS_031972 2 123 actin, alpha skeletal muscle  
3 
P000050981|12265..13493|X1846
58|MAUS_029718 1 85 
procollagen C-endopeptidase 
enhancer 1  
4 
P000020887|30213..69016|X1439
91|MAUS_064080 1 68 fibulin-2 isoform b  
5 
P000025538|10024..26993|X1712
20|MAUS_026005 1 45 ribulose-phosphate 3-epimerase  
6 
P000025852|10118..18033|X1728
82|MAUS_024650 1 45 solute carrier family 22 member 6  
 
Attachment 6: MALDI-TOF analysis of SNL-CM.  
Proteins with a total ion score > 45 are listed. Data are given from one experiment with two 
runs.
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